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Summary
The Epithelial Membrane Antigen(EMA) is known to be 
strongly expressed by the majority of adenocarcinomas including 
those of the breast, ovary and colon and also weakly by a variety of 
normal glandular tissues. This antigen has not, however, been 
investigated specifically in colorectal cancer. This thesis investigates 
the clinical applications in colorectal cancer of a monoclonal 
antibody(MAb), labelled ICR2 after the Institute of Cancer Research, 
Sutton, Surrey, which recognises EMA.
The expression of EMA in histological sections was explored by 
immunohistochemical techniques using human paraffin embedded 
tissues and the indirect immunoperoxidase staining method. The 
majority of primary colorectal cancers and metastases were found to 
strongly express the antigen whereas EMA was rarely expressed by 
normal colon and by adenomatous polyps only at sites of severe 
dysplasia. A further study compared the expression of EMA with 
Carcinoembryonic Antigen (CEA) in tissues from a consecutive series of 
patients undergoing resection for a colorectal cancer. EMA expression 
was found to be more restricted than CEA in that fewer primary and 
metastatic cancers expressed the antigen but more specific in that 
EMA, unlike CEA, was not expressed by normal colon nor benign 
adenomatous polyps. When the antigen expression of the cancers was 
graded and compared with standard pathological variables the 
expression of CEA was shown to be greater than EMA in most cancers 
and that CEA expression of cancers increased from proximal to distal 
in the colon.
Immunohistochemistry has been suggested as a means of 
detecting microscopic tumour deposits which may be overlooked
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by routine staining methods. This was investigated in a series of 
lymph nodes from patients undergoing resection of a colorectal cancer 
using MAb's targeting both EMA and CEA and the indirect 
immunoperoxidase staining method. The results, however, did not 
suggest this to be a clinically useful technique.
Having demonstrated the presence of EMA in colorectal cancer 
sections a study was carried out to determine whether this antigen is 
present in the circulation of cancer patients, and if so whether it might 
be used as a tumour marker. A radioimmunoassay (RIA) using the 
MAb ICR2 was used to measure EMA in serum from healthy controls 
and patients with breast and colorectal cancer. All serum samples 
showed evidence of circulating antigen and the levels in patients with 
breast or colon cancer were not significantly different from controls.
To allow the MAb ICR2 to be used for the detection of colorectal 
cancer in patients the antibody was labelled with the gamma emitting 
radionuclide 1 ^  Indium ( ^ I n )  and its in-vitro stability analysed. 
Previous studies have demonstrated that the major limitation to the 
detection of gastro-intestinal cancers using ^ I n  labelled MAb's is 
the uptake of radioactivity by the liver. This problem was investigated 
prior to clinical studies by the use of an in-vitro model consisting of 
freshly isolated hepatocytes and the EMA expressing tumour cell line 
MCF7. Various reagents were analysed for their ability to reduce the 
uptake of radioactivity by the hepatocytes without affecting tumour 
cell uptake when * * ^ In-ICR2 was applied to both cell groups. The 
synthetic metal chelating agent diethylene-triamine-pentacetic acid 
(DTPA) was found to significantly reduce the hepatocyte uptake 
without affecting the tumour uptake of radioactivity when incubated 
with the cells or added to the radiolabelled antibody either at the time 
of or prior to its application to the cells. The effect of incubating DTPA
12.
with the radiolabelled antibody was dependent on the concentration of 
DTPA and the period of incubation with the radiolabelled antibody.
An imaging study was carried out in patients with known or 
suspected colorectal cancer using the l^ I n  labelled MAb ICR2. A 
control group was compared with a group whose injectate was treated 
with DTPA and a group whose injectate was treated with DTPA and 
who recieved unlabelled MAb prior to ^  ^ In-ICR2 administration in 
an attempt to reduce the radiolabelled antibody forming circulating 
immune complex. The images were independently interpreted by a 
clinician with knowledge of the clinical details and investigations and 
completely blind by a nuclear medicine specialist provided with no 
clinical information. Imaging with  ^1 ^ In-ICR2 was found to be a 
sensitive method of detecting primary cancers and detected metastatic 
lymph node deposits pre-operatively. False positive images, however, 
were produced with inflammatory lesions and dysplastic benign 
polyps and liver metastases could not be detected.
The imaging results were not significantly different in the three 
groups of patients outlined above. Analysis of the biodistribution of 
11 lln-ICR2 in these groups of colorectal cancer patients has also 
shown there to be no significant difference in the percentage of the 
injected dose taken up in the tumour tissue or in the ratio of activity 
in the tumour to that of normal colon. The uptake of activity in the 
tumour was, however, shown to be related to the antigen expression of 
the cancer and also the level of circulating antigen. Chelation of the 
11 lln-ICR2 with DTPA prior to its administration reduced the urinary 
excretion of radioactivity but did not reduce the liver uptake of 
radioactivity. Unlabelled MAb administration produced a minimal 
reduction in the level of circulating immune complex.
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In addition to carrying out external imaging of the colorectal 
cancer patients following ^4n-IC R 2 administation the use of a 
radiation detecting probe for the localisation of metastases at the time 
of operation was also investigated. This technique, first described in 
1984, should theoretically allow smaller lesions to be detected than by 
external imaging. The majority of patients with cancer had higher 
counts recorded over the tumour than over normal colon whereas 
those with benign lesions showed no preferential uptake. Counting 
oyer the lymph nodes in the large bowel mesentery could differentiate 
glands containing cancer deposits from those which did not by the 
uptake of radioactivity relative to normal colon.
The limitations of intra-operative probing following 
radiolabelled MAb administration have not previously been 
investigated. A model of the clinical situation was therefore 
established using hollow spheres filled with a radioactive solution to 
represent 'tumour' deposits placed within a tank containing a mildly 
radioactive solution to represent the background radioactivity of 
normal tissues. By altering the size of 'tumours’ and the ratio of 
radioactivity in 'tumour' to that of background the ability was 
investigated of the two currently available forms of radiation detector 
to locate the 'tumour' deposit within the background radioactivity 
using a statistical criteria of detectability. This study demonstrated 
that for the reliable detection of small tumour deposits using an 
intra-operative probe a high tumour to background ratio is required, 
but that this is within the range of values which have been reported 
from patient studies.
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1.1. DIAGNOSIS AND TREATMENT OF COLORECTAL CANCER
Colorectal cancer is the second most common cause of 
death from malignant disease, with over 18,000 deaths 
annually in the United Kingdom> (■*■). Despite improvements 
in the standard of patient care the mortality from this 
condition has not improved significantly over the last 
two decades( ,  with a mean five year survival 
generally less than 50% The stage of the disease
at presentation is the most important factor affecting 
survival, patients with cancers confined to the bowel 
mucosa having greater than 90% 5 year survival, those 
with invasion of the muscular coat 50-80% and 
approximately 30% when regional lymph nodes are 
involved(^•7'®).
1.1.i Screening and early detection
Unfortunately only about 1 in 20 people presenting 
with colorectal cancer will have mucosal lesions and 
hence a good prognosis(^ ). The relationship between the 
presence of localised disease and a good prognosis has 
focused attention on the importance of the early 
detection of colorectal cancer and the management of 
pre-malignant lesions such as adenomatous polyps(9-11)# 
Sigmoidoscopy may be used as a method of screening for 
colorectal cancer and in 1978 Gilbertson reported the 
findings of proctosigmoidoscopy on asymptomatic 
patients over 45 years of age(^). The initial 
procedure discovered 27 cancers in 21,150 patients and
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on annual follow up (mean 5.4 examinations / patient) a 
further 13 cancers. By removing all adenomatous polyps 
the expected incidence of colorectal cancer in this 
defined population was decreased by 90% over the period 
1948-1976. Although these results would suggest a 
beneficial effect of screening by sigmoidoscopy, this 
may not be an acceptable method of screening for many 
asymptomatic patients. With symptomatic patients, 
however, the use of endoscopy and improvements in 
radiological techniques appear to have increased the 
number of patients being diagnosed with early 
disease^ ^ ).
An alternative, non-invasive approach to the early 
detection of colorectal cancer is the use of population 
screening with faecal occult blood testing(14-16). 
major drawbacks to this form of screening study are 
that the patient compliance is generally poor, the 
detection rate and test sensitivity low and a long 
follow up period is required to prove a survival 
advantage. Despite these problems occult blood 
screening has been shown to increase the number of 
early stage cancers detected and should therefore 
improve the prognosis (17,18) #
1.1.ii) Surgical treatment
Surgery remains the best treatment option for 
patients with colorectal cancer. Although the operative 
technique employed is often controversial little 
evidence exists that any particular method carries a
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more favourable prognosis. In 1908 Moynihan suggested 
high ligation of the inferior mesenteric vessels to be 
an important factor in preventing the recurrence of 
rectosigmoid carcinoma(^ ). This was not supported, 
however, by the study of Pezim and Nicholls(^) which 
analysed the 5 year survival of 1370 patients 
undergoing surgery for cancers of the rectum and 
rectosigmoid at St Marks Hospital. No difference was 
found between those having ligation above and those 
having ligation below the left colic vessels. The 
importance of a radical removal of regional lymphatics 
has also been questioned, with no benefit being shown 
in a group of patients undergoing extended abdominal- 
iliac lymphadenectomy as opposed to conventional 
resection(^1).
A no-touch operative technique in which the 
supplying and draining blood vessels are divided 
prior to mobilising the tumour has been advocated by 
Turnbull( 2^) to limit the known dissemination of tumour 
cells at the time of operation(^ ) and reduce the risk 
of recurrence. However, in Turnbull's study the 
survival results were compared between one surgeon 
practising, and a group of surgeons who were not 
practising the no-touch technique, and the patients 
were not randomised. In a prospective controlled trial 
the no-touch isolation technique decreased the number 
and delayed the development of liver metastases but 
with no improvement in survival (^ ). The importance of
22.
operative technique to the results of surgery for 
rectal cancer was emphasised in the study by Heald 
reported in 1986 in which the local recurrence rate of 
4% and long term survival of 80% was attributed to the 
careful dissection of the mesorectum (^ 5). This study 
was, however, uncontrolled and therefore open to 
misinterpretation.
1.1.iii) Adjuvant therapy
Because of the advanced nature of the disease at 
presentation surgery is curative in less than half of 
those treated (^ ). In order to improve the results 
obtained adjuvant therapies have been investigated.
In 1959 Stearns reported the results of the use of 
pre-operative radiotherapy for rectal carcinomas (^6). 
Giving 1000-2000 rads in 10 daily fractions resulted in 
both a better 5 and 10 year survival in treated over 
untreated patients although the study was not 
randomised. A similar dosage regime was used by 
Roswit in a prospective controlled randomised study 
reported in 1975^7) which suggested that radiotherapy 
reduced the incidence of Dukes stage C lesions. This 
finding has subsequently been supported by the MRC 
working party on adjuvant radiotherapy( )  who studied 
824 patients with operable rectal cancer. This 
randomised multicentre study compared surgery alone, 
surgery and a single pre-operative 500 rad fraction of 
radiotherapy and surgery following 2000 rads in 10 
daily fractions. Although the patients given the higher
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radiotherapy dose had fewer Dukes C tumours and their 
tumours were significantly smaller the 5 year follow up 
has shown no difference in recurrence rate nor survival 
benefit.
Despite the many studies carried out on adjuvant 
chemotherapy few have shown any evidence of improvement 
in the prognosis for patients with colorectal cancer. A 
large randomised study carried out by the 
Gastrointestinal study group in the U.S.A. compared 
chemotherapy, immunotherapy and a combination of both 
with a control group (2^). The chemotherapy group 
receiving 5-fluorouracil(5FU) and semustine, the 
immunotherapy group receiving a methanol extract of the 
Bacillus Calmette Guerin(BCG), and the combination of 
both therapies showed no survival advantage over the 
control group. Systemic chemotherapy, however, delivers 
a relatively small drug concentration to the liver 
which is the main site of colorectal cancer metastases. 
For this reason considerable interest has surrounded 
the use of adjuvant regional therapy. In 1985 the 
results of a randomised controlled trial of adjuvant 
portal vein 5FU were reported (3Q). Patients with no 
evidence of liver metastases were randomised to receive 
either lg daily of 5FU into the portal vein over the 
first 7 post-op days or no adjuvant treatment.
Fewer liver metastases developed in the treatment 
group and the Dukes B patients showed an improved 
survival. Encouraging results have also been obtained 
in the use of adjuvant systemic 5FU in combination with
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the immune stimulant Levamisole which has been shown to 
reduce the period of post-operative
immunosuppression (31). Comparing groups of patients 
receiving 5FU alone, 5FU with Levamisole and a control 
group showed death from tumour recurrence on 5 year 
follow up to be 44%, 32% and 52% respectively.
This represented a significant survival advantage to 
those patients receiving 5 FU and levamisole (^2).
Also of significant interest in the adjuvant 
treatment of colorectal cancer was the study on the 
anti-mitotic drug Razoxane reported in 1986 (^3). & 5 
year follow up of 272 randomised patients showed a 
prolonged time to recurrence in the Dukes C patients 
receiving Razoxane. Unfortunately the side effect of 
the development of acute leukaemia in three of these 
patients would seem to prohibit further evaluation of 
this drug.
l.l.iv) Staging and the detection of recurrence
Adjuvant radiotherapy and chemotherapy seem to 
have benefitted only a small percentage of patients 
undergoing surgery for colorectal cancer.
One of the reasons for the poor results of 
treatment may be incorrect staging and hence 
inappropriate or inadequate management of the primary 
cancers. Routine staging of patients with colorectal 
cancer will be based on a clinical examination, 
sigmoidoscopy or colonoscopy, a barium series, chest X- 
ray, liver function test and either a radioisotope or
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ultrasound scan of the liver. Newer technology may 
improve the results of pre-operative staging. 
Computerised axial tomography(CT) has been shown to be 
better than either ultrasound or radionuclide imaging 
in the detection of liver metastases( )  and can detect 
occult metastases in up to 24% of patients (35). 
liver may also be examined intra-operatively using an 
ultrasound probe which is capable of detecting 
metastases less than 0.5cm in diameter (36).
With rectal cancers the involvement of lymph nodes 
in the mesorectum as well as direct lateral spread have 
been shown to be important factors in prognosis and 
hence are important aspects of pre-operative staging 
(25,37)^ Although some would claim that accurate 
staging of rectal cancers may be achieved clinically 
(38) other alternatives include CT scanning and 
endoluminal ultrasound. In a study comparing these 
techniques with clinical examination the closest 
approximation to operative and pathological findings 
was achieved by endoluminal ultrasound. All 
these techniques provided useful information on 
direct disease spread but none reliably discriminated 
involved from uninvolved lymph nodes (39)#
Approximately 50% of patients undergoing resection 
for a colorectal cancer will die of disease 
recurrence (5*6). By the time diagnosis of recurrence is 
made the majority have disseminated disease and will 
not benefit from any operative intervention. Local 
disease was found in 27% of patients with recurrence at
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post mortem but diagnosed in 55% of patients in a 
prospective clinical study, the difference being 
attributed to the clinical under-staging of 
disease . (^ ®). Methods for the early detection of 
recurrent disease are clearly required. Wangsteen 
proposed the concept of "second-look" surgery in an 
attempt to detect early locally recurrent disease and 
reported that 17% of patients undergoing second look 
surgery could be returned to a disease free 
state (^ ^ ^ ). Although the concept may be appealing, in 
reality many patients with either no recurrence or 
recurrence beyond resection would be required to 
undergo surgery for the questionable benefit of a few. 
The use of circulating tumour markers as a guide for 
those patients likely to have recurrent disease and 
hence to benefit from a second look laparotomy has 
therefore been intensively investigated (^3,44)^
Raised levels of circulating tumour markers, however, 
are usually associated with significant disease bulk 
and are insensitive for the detection of locally 
recurrent disease.
It is apparent that improvements are needed in the 
staging of primary cancers, their initial management 
including adjuvant therapy, methods for diagnosing 
disease recurrence and new treatment modalities. The 
discovery of tumour antigens, substances expressed 
principally on cancerous tissue, has opened the door to 
a new approach to the investigation and treatment of 
patients with colorectal cancer by the use of
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polyclonal and more recently monoclonal antibodies to 
these tumour associated antigens. Almost every aspect 
of present management may be influenced with 
immunological methods of cancer screening, the use of 
radiolabelled antibodies for improved staging of 
primary cancers and detecting recurrences by external 
imaging as well as the intra-operative localisation of 
tumour deposits using radiation detectors. In addition 
further circulating tumour markers may be detected by 
antibodies allowing improved methods of diagnosis and 
follow up. The present stage in the clinical use of 
antibodies in colorectal cancer is reviewed in section
1.3.
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1.2. THE DEVELOPMENT OF ANTIBODIES TO TUMOUR ANTIGENS
In 1953 Foley published the results of work 
carried out on the "antigenic properties of 
methycholanthrene-induced tumours in mice of strain of 
origin" (^). jn these studies Foley demonstrated that 
methycholanthrene induced tumours transplanted between 
syngeneic (highly inbred) mice could be rejected under 
appropriately controlled circumstances. Since these 
tumours were transplanted between genetically identical 
animals the rejection could only be due to an 
immunological response to a newly developed antigen on 
the surface of the tumour during neoplastic 
transformation. This formed the first conclusive 
evidence of antigens forming on chemically induced 
tumours which were termed tumor-specific 
transplantation antigens as tumour rejection was used 
as the reaction to detect their presence.
Although tumour antigens have now been defined on 
a variety of human tumour tissues none, apart from the 
idiotype to the surface Ig found on some B cell 
lymphomas(^ ), have been found to be entirely specific 
for cancer. Many tumour antigens represent only 
quantitative or qualitative differences from naturally 
occurring tissue or serum components and are considered 
tumour antigens only in that they are sought by 
antibody probes. Examples of such antigens are the 
paraproteins associated with multiple myeloma, the 
pathological elevations of human chorionic
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gonadotrophin (HCG) in patients with choriocarcinoma 
and prostatic acid phosphatase in patients with 
carcinoma of the prostate. True tumour antigens are 
substances which appear de novo during tumour growth 
and include specific tumour antigens and the larger 
group of oncofoetal substances (carcinoembryonic 
antigen (CEA), alpha foetoprotein (AFP), haemoglobin F 
and some enzymes).
Production of polyclonal antisera
The first reports on the use of antibodies in the 
treatment of cancer were those of Hericourt and Richet 
in 1 8 9 5 who prepared antisera to a human osteogenic 
sarcoma in an ass and two dogs and used it in the 
treatment of two patients, one with a fibrosarcoma of 
the chest wall and the other a gastric cancer. The 
initial results stimulated a more extensive study of 50 
patients with cancer who similarly were felt to have 
benefitted from treatment whereas those given normal 
serum obtained no similar response ). Antisera 
raised against tumour tissue contain many clones of 
antibodies(polyclonal). Although many attempts to use 
polyclonal sera in therapy have been made since this 
time no convincing evidence of a therapeutic potential 
has been established. The presence within this mixture 
of antibodies against tumour tissue was demonstrated in 
1954 by the radioactive labelling of polyclonal 
antisera with subsequent specific localisation of 
activity in tumour tissue (^).
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It was subsequently demonstrated that not only could 
radiolabelled antibodies localise in tumour tissue but 
that a therapeutic dose of radioactivity could be 
delivered (^).The obvious disadvantage of polyclonal 
antisera is the diverse nature of the target antigens, 
only some clones of antibodies being related to tumour 
tissue. This problem was initially tackled by removal 
of the cross reacting antibodies by injection into a 
second animal(51). Results were greatly improved when 
the target antigen could be isolated, such as with CEA, 
and affinity purification of the polyclonal antisera 
was introduced(52).
Production of monoclonal antibodies
An antigen usually has several determinants, or 
epitopes, which can stimulate the conversion of a B 
lymphocyte into a plasma cell. Immune responses 
therefore result in the production of polyclonal 
antibodies. If individual plasma cells were selected 
and cloned antibodies with a single defined specificity 
could be obtained, but unfortunately plasma cells do 
not survive in tissue culture. In 1975 Kohler and 
Milstein published their work on the production of 
monoclonal antibodies by the fusion of sensitised 
lymphocytes and a myeloma cell line . (53)# This resulted 
in the ability to produce a plentiful supply of pure 
antibody recognising a single epitope of any specific 
antigen and has had a monumental impact on the use of 
antibodies as both diagnostic and therapeutic tools.
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1.3. THE USE OF ANTIBODIES IN COLORECTAL CANCER
New applications for the use of monoclonal 
antibodies in clinical medicine are being investigated 
at a staggering rate. In the field of colorectal cancer 
the main areas being explored at present include the 
following ;
1.3.i) Serology
1.3.i.a) Circulating tumour antigens
Tumour markers are substances secreted into the 
circulation by malignant tumours and which may be used 
to assess the presence, stage or progress of disease. 
The nature of these markers varies greatly, some being 
recognisable products of normal cell metabolism and 
others having no known biological function. Normal 
products of cellular metabolism which may be produced 
in excessive amounts in malignancy include the enzyme 
acid phosphatase whose level in the serum has proven of 
value in the management of prostatic carcinoma( )  and 
beta HCG, a hormone useful in the monitoring of germ 
cell carcinomas (^ 5). perhaps the largest group of both 
established and potential tumour markers are 
glycoproteins, expressed by normal foetal tissues but 
not significantly in adult tissues unless neoplasia 
arises ; the onco-foetal antigens. Included in this 
group are AFP and CEA, which have been shown to be 
useful clinical markers of hepatocellular carcinomas 
and gastrointestinal cancers respectively Many
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other tumour associated antigens have been described. 
The majority are not oncofoetal in nature but are 
simply expressed more strongly by malignancies than 
normal tissues. Some are glycoproteins although the 
vast majority of "new" tumour markers are 
carbohydrates, such as CA125^®) found in ovarian 
cancer and CA 19—9 ( )  in colonic and pancreatic 
cancer.
Other circulating markers of malignancy which have 
been investigated in patients with colorectal cancer 
include levels of immune complexes (60,61) ancj 
secretory immunoglobulins IgA and IgM (62,63)^  Levels 
of immune complex were elevated in a high percentage of 
patients with benign polyps and equated poorly with 
tumour bulk whilst secretory immunoglobulin was 
significantly raised only when liver metastases were 
present.
1.3.1.b) Carcinoembryonic antigen levels in colorectal 
cancer
It is now almost twenty years since CEA was first 
suggested as a serum marker in colorectal cancer. Since 
this time investigators have looked at many different 
applications of the serum CEA level including its use 
in diagnosis, staging and detecting recurrent 
colorectal cancer. Others have used CEA levels as a 
basis for second look laparotomy and to monitor patient 
response to chemotherapy.
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The majority of patients with colorectal cancer 
have an elevated level of CEA pre-operatively. The 
degree of elevation will depend on the arbitrary cut­
off level which is taken as "abnormal". In a series of 
518 patients with gastro-intestinal neoplasms studied 
by Cooper et al in 1979 (*^), 78% of patients with 
colorectal cancer had a level greater than 2.5ng/ml. In 
this series, however, 56% of patients with other 
malignancies and almost 50% of those with benign 
disease had similarly elevated levels. This would not 
suggest a useful role for CEA levels in the screening 
for colorectal cancers. A correlation is generally 
found between the stage of the disease at presentation 
and the CEA level, patients with extensive disease 
being more likely to have elevated levels (65). Although 
previously reported not to correlate with resectability
(66) the pre-operative CEA level has been shown on 
stastistical analysis to correlate with tumour fixity
(67)^ pre-operative CEA level has also been shown
to have a prognostic value, a pre-operative level 
greater than 2.5ng/ml being associated with an 
increased risk of subsequent local recurrence or of 
later metastatic disease (68). ■
Although the use of CEA levels for the diagnosis 
or staging of colorectal cancer has proven to be 
disappointing it may have a role in the detection of 
recurrent disease following resection. Mach 
demonstrated that following curative resections
CEA levels return to normal and that failure to do so 
was suggestive of residual disease (69). Longer follow 
up of this series of patients, however, revealed a 
group who had moderately raised and fluctuating levels 
of CEA but had no evidence of recurrent disease. This 
group did not include patients with conditions known to 
be associated with elevations in circulating CEA such 
as heavy cigarette smokers and those with liver disease 
(70). Despite these difficulties a group of patients 
could be defined in whom a rise in CEA levels preceded 
the recurrence of clinically obvious disease and who 
may therefore have benefitted from interventional 
treatment. The reported "lag time" was 2-26 months. 
Although other authors have supported the concept of a 
useful lag in the time between CEA levels becoming 
elevated and the recurrence of clinically 
detectable disease (71/72) opposite situation was
found by Finlay (73)/ wh0 demonstrated hepatic 
metastases by CT scanning a considerable period of time 
before the serum CEA level became elevated. Whether the 
finding of asymptomatic recurrent disease by elevations 
of post-operative CEA levels and subsequent treatment 
will affect the prognosis remains to be established in 
long term prospective studies. Despite this some 
surgeons have based a second-look operation on a 
persistently elevated level (43,74-76)# Although 
refinements in CEA determination eg. the frequency of 
serial sampling, slope analysis and CEA nomograms may 
increase the certainty with which recurrent disease is
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diagnosed the beneficial effect of second look surgery 
remains to be determined.
Treatment based on elevation of CEA levels is 
likely to be most beneficial when recurrent disease is 
minimal and not detectable by conventional means. On 
this premise Hine and Dykes(77) prospectively 
randomised patients, who were asymptomatic 
but had persistently raised CEA levels following 
resection for colorectal cancer, for either 
chemotherapy or no specific treatment. A course of 5FU 
and methyl CCNU produced no significant difference 
between treated and untreated groups as regards disease 
free interval and survival. The CEA levels in these 
patients did, however, show an inflection at the time 
of chemotherapy.
The majority of patients with disseminated 
colorectal cancer will have elevated CEA levels, the 
absolute number depending on the cut off level 
selected as normal. Elevated levels of CEA have been 
used as a means of monitoring tumour bulk and hence the 
response of individual patients to chemotherapy. 
Although patients in remission have been found to have 
reducing levels of circulating CEA and those with 
progressing disease exhibit rising levels, the 
correlation is poor in the majority of patients 
(78,79)# Serum levels of CEA have also been shown to 
correlate poorly with radiological evidence of tumour 
regression (®0).
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1.3.1.C) Other tumour markers in colorectal cancer
The gastrointestinal cancer antigen (GICA) is 
recognised by a monoclonal antibody CA19-9, raised in 
the mouse to a human colorectal carcinoma cell line 
SW1116 ( ) .  Initially the antigen was believed 
to be specific to the sera of patients with colorectal 
cancer and to be onco-foetal in origin. Since this
time, however, antibody CA19-9 has been.shown by 
immunocytochemistry to bind to both pancreatic and 
gastric tumours (®3) an(j elevated antigen levels in 
serum are to be found associated with these 
malignancies rather than with colorectal cancers (®^). 
The specificity of the CA19-9 test for diagnosing 
malignancy is high with less than 2% of normal people 
having elevated levels but its sensitivity is lower 
than that of CEA for colorectal cancers. An alternative 
role for GICA in the diagnosis and investigation of 
pancreatic carcinoma appears to be more promising at 
present (85-87)# Prospective studies are awaited to 
determine the value of serial CA 19-9 estimations in 
the routine follow up of patients following resection 
of a colorectal cancer.
Other carbohydrate molecules may be useful as 
potential tumour markers. For example Stage Specific 
Embryonic Antigen-1 (SSEA-1) and the Lewisx antigen 
have been detected in colorectal cancer tissues 
using Fluorescein labelled monoclonal antibodies (®®)' 
and by RIA in the serum of patients with colorectal 
cancer. Low levels, however, may be present
in the serum and tissues of normal individuals and in 
those with non neoplastic diseases (89). Elevated serum 
levels of secretory immunoglobulins have been reported 
in some patients with colorectal cancers, and may 
signify the presence of metastatic disease (62,63) ^ 
Circulating immune complexes have also been monitored 
in patients with colorectal cancers and following a 
curative resection or in normal controls the levels of 
immune complex are minimal. In advanced disease, 
however, the serum levels of immune complex vary and 
correlate poorly with tumour b u l k ( '81).
Although individually these other markers may not be 
as clinically useful as CEA they may have a role in the 
management of patients with colorectal cancer if 
they can be combined into a prognostic index which 
accurately predicts those patients likely to develop 
recurrence and hence may benefit from adjuvant therapy.
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1.3.ii) Immunohistochemistry
The role of circulating CEA and other tumour 
markers has been investigated intensively in patients 
with colorectal cancer because of their potential use 
for detecting recurrent disease. The expression of 
tumour antigens in excised colorectal tissues has yet 
to establish a definite clinical role. Several 
important applications are, however, being 
investigated. In 1984 Heyderman recommended the use of 
a panel of monoclonal antibodies to epithelial membrane 
antigen (EMA), CEA and prostatic acid phosphatase to 
aid in the histological determination of the tissue of 
origin of poorly differentiated carcinomas (90). of more 
obvious clinical benefit is the use of 
immunohistochemistry for the detection of 
micrometastases. In colorectal cancer two main studies 
have been carried out. In 1984 Crowson reported that 4% 
of patients with colorectal cancer will have 
micrometastases in regional lymph nodes which may be 
detected using anti-CEA MAb's (91). This contrasts with 
a recent study suggesting that 25% of patients with 
colorectal cancer have micrometastases detectable by 
immunohistochemistry (^ ). The clinical significance of 
these findings is great as this may allow improved 
staging for patients with colorectal cancer and may 
indicate a patient group who would benefit from 
adjuvant therapy.
Another important aspect of the 
immunohistochemical detection of tumour antigens is
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their use as prognostic markers. The antigen 
expression of primary cancers may be categorised with 
standard pathological variables to produce better 
prognostic indicators in large bowel cancer. This may 
help in the selection of patients for adjuvant 
therapy. (93'94).
The immunohistochemical staining of tumour 
biopsies for a range of tumour antigens may also 
provide a means of determining the optimum antibody for 
use in any individual patient for either tumour imaging 
with radiolabelled antibodies or for drug, radionuclide 
or toxin conjugated antibody therapy.
1.3.iii) Radioimmunolocalisation of colorectal cancers 
1.3.iii.a) External imaging
Radio-immunolocalisation (RIL) is a term coined for 
the technique of localising tumours following the 
administration of radiolabelled antibodies, usually by 
imaging with an external gamma camera. Its success is 
dependent on the use of an antibody which is 
specifically or selectively taken up by tumour tissue 
being combined with a radioactive isotope with a 
satisfactory half life and energy of emissions.
Localisation experiments using animals with 
CEA expressing tumour xenografts implanted 
subcutaneously have shown that radio-iodinated anti-CEA 
antibodies can successfully localise these tumours 
(52,95,96)# Qn basis Qf these experiments 
Goldenberg administered hyperimmune goat anti-CEA
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antiserum radio-labelled with -LJ-Li to 18 patients with 
diverse carcinomas (9 )^. External gamma camera images 
were obtained at intervals following administration of 
the radio-labelled antibody. The images obtained were 
found to be obscured by the blood pool activity of the 
radionuclide but this problem could be partly overcome 
by computerised subtraction following the 
administration of Technetium oxide ( " mTcC>4”) and 99mTc 
labelled human serum albumin. Of four patients with 
advanced colorectal cancers three had positive images 
of the primary tumour and the secondary deposits were 
identified in all. In the decade since these initial 
studies were reported by Goldenberg significant changes 
have taken place in the antibodies used for imaging, 
the radiolabel and the imaging techniques.
Antibody used in imaging
Early tumour localisation in animal xenografts was 
carried out using IgG fractions of anti-CEA serum.
This serum was produced by the repeated innoculation of 
CEA derived from colorectal tumours into a host animal 
and the subsequent seperation of the IgG fraction (93). 
Such antisera contained many antibody species and was 
therefore subject to significant cross reactivity.
To reduce this problem antisera were absorbed with 
human red blood cells and a variety of human tissues 
(liver, lung, spleen, kidney) conjugated to a gel 
matrix (Sepharose 4B). Further purification was 
achieved by affinity chromatography in which an isolate
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of a specific antigen is used to separate specific 
antibodies from a mixture (antigen immuno- 
absorbent) (9 ^.).
Although this allowed a significant improvement in 
purity of the antibody the most noticeable advance in 
antibody production was the development of hybridoma 
technology by Kohler and Milstein in 1975 (^3). By the 
fusion of lymphocytes sensitised by CEA with a myeloma 
cell line a continuous culture of cells producing 
monoclonal anti-CEA antibodies could be established.
The results achieved by affinity purified anti-CEA 
antisera in the localisation of colorectal cancers(9 
l®4)f however, have been similar on a numerical basis 
to monoclonal anti-CEA (105,106). Most studies, 
however, have been neither controlled nor had any 
quantification of tumour uptake of radio-labelled 
antibody. Of the few studies which have quantified 
uptake the ratios of activity in the tumour to normal 
colon were found to range from 2 s  1 (107) to 8.6 s 1  
(106)# These values may not be directly comparable, 
however, due to differences in the dose of antibody 
and radio-label administered and the interval between 
administration and tissue sampling.
Although anti-CEA antibodies have been the most 
widely used in the radio-immunolocalisation of 
colorectal cancers other groups have investigated the 
use of monoclonal antibodies to other tumour associated 
antigens. Monoclonal antibody 791T/36 was originally 
raised using cultured osteogenic sarcoma cells as
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immunogen and has been shown to localise osteogenic 
sarcoma xenografts(I®3) and human malignant bone 
tumours (I®9). It was also found to react with 
colorectal cancer cell lines (H®) and 
has been used to localise human colorectal cancers
Other antibodies which have been used for 
the localisation of colorectal cancers have included 
17-1A (II3) and 19-9 (H®) which were raised to 
colorectal cancer cell lines. Monoclonal antibody YPC 
2/12.1, raised to a membrane extract of a colorectal 
cancer, has been reported as being useful in tumour 
localisation (117) , but this was subsequently disputed 
(118).
Radionuclides used in tumour imaging
The most widely used radionuclides for the imaging
1 3 1of colorectal cancers in patients are Iodine 1 3 1 I)
1 1 1 1 3 1and Indium 111(■L-LJ-In) . XJXi was the first radioisotope
to be used, being covalently bound to the antibody
molecule by either the Iodogen method (H^) or the
Chloramine T method (12®). There are, however, major
1 31drawbacks to the use of XJXi as a radionuclide for
1 31imaging. Firstly XJXi has a relatively long half-life
of 8 days and tends to persist in the intravascular
compartment. This results in a high background activity
and the need to employ computerised subtraction
techniques using a second radionuclide (97,111,121)^
Such techniques may, however, result in the production
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of false positive images (122-124)# administration
of radioiodine also requires the pre-administration of 
inactive iodine prior to scanning to block the uptake 
of radioactivity in the thyroid gland. Other drawbacks 
include the high energy gamma emissions of l^lj which 
are unsatisfactory for imaging techniques and the 
production of unwanted beta emissions. These
111
difficulties have led some groups to use -LJ-J-In as the 
radionuclide of choice (102,105,106,114,125) _ The lllln
is attached to the protein molecule by the use of a
chelating agent as originally described by Krejcarek et
al in 1977(12 )^ and later modified by Hnatowich (127-
129). Ulin has the advantage of a shorter half life of
2.8 days, medium energy gamma emissions, no beta
emissions and does not require subtraction techniques
illto allow tumour localisation. J-J-xIn labelled antibodies 
are, however, taken up by the liver, spleen and bone 
marrow independent of the antigen to which they have 
been raised and this may seriously prohibit the 
localisation of metastatic deposits (l3 )^.
Imaging techniques in radioimmunolocalisation
The standard technique for gathering information 
following the administration of labelled tumour 
associated monoclonal antibodies is planar imaging 
using a gamma camera. From the outset of antibody 
imaging difficulties arose with imaging due to the high 
background activity and low tumour uptake of 
radiolabelled antibody.
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With iodinated antibodies this was largely due to 
persisting activity in the blood pool. Methods were 
therefore introduced for reducing this background 
activity by administering a second radionuclide and 
by techniques for computer subtraction of images (^7). 
Considerable controversy persists as to the optimum 
method of background subtraction and whether false 
positive images are produced (122,123,124,131,132). In
an attempt to avoid the difficulties inherent in dual
radio-nuclide subtraction techniques interest has
illturned to the use of J"LAIn linked to the monoclonal 
antibody by a metal chelating agent. Regardless of the 
radionuclide used, however, a low tumour uptake with a 
high background activity produces a planar image which 
is difficult to interpret. One possible solution to the 
problem is to clear the radiolabelled antibody from the 
circulation once tumour localisation has occurred. This 
rather novel solution was reported by Begent et al in 
1982. A goat anti-CEA MAb was used in patients with 
colorectal cancers for localising the lesions. 
Liposomally packaged horse anti-goat antibody was 
subsequently used to clear the blood pool activity. 
Using this technique an improved quality of image was 
reported with three of five patients studied (133)^  
Another method employed in an attempt to improve the 
quality of images produced is to produce cross 
sectional images using single photon emission 
computerised tomography (SPECT), a technique analagous 
to CT scanning.
Originally described in 1963(134) this technique has 
produced an increased sensitivity and specificity in 
some studies (135)  ^ This may, however, be associated 
with the production of false positive images as in 
planar imaging (1^). A further attempt at improving the 
interpretation of immunoscintigraphy involved the 
combination of the information obtained from SPECT with 
that of conventional CT scanning thus improving the 
anatomical localisation of the tumours (1^6). whether 
this is a practical technique for routine imaging 
remains to be established.
One distinct alternative to conventional gamma 
camera imaging techniques is the application of 
positron emission tomography (PET). This technique 
utilises the paired gamma-rays produced from positron- 
electron interaction. The gamma rays are emitted at 
180° to each other and their point of origin can be 
accurately located by two opposed linked detectors. The 
application of PET to antibody imaging has yet to be 
realised.
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1.3.±i±.b) Intra-operative tumour detection
Immunoscintigraphy using an external gamma camera
has as yet a limited clinical application in the
investigation of patients with cancer. Although large
primary tumours which are easily localised by other
modalities may be imaged, the small metastatic or
recurrent deposits are rarely detected. Most
investigators have reported their failure to image
tumours of less than 2cm in diameter, with even poorer
results if the tumour is situated deeply. The
fundamental problem lies with the specificity and
affinity of the radiolabelled MAb's. The uptake of
activity achieved in the tumour tissue is generally
only 0.01-0.001% of the injected dose and tumour to
normal tissue differentials in uptake are 1.3:1 to
8:i(130) This inevitably results in few counts being
emitted from small tumours against a high background
activity in blood and normal tissues. With deep seated
tumours scatter of activity is an additional problem as
is the attenuation caused by the tissues intervening
between tumour and detector. In addition to these
difficulties certain organs may accumulate a large
percentage of the injected radiolabelled antibody
thereby obscuring antibody localised to cancers in
their vicinity. Uptake by the liver is the main problem 
illand may, with ■LJ"LIn labelled antibodies, account for up 
to 30-40% of the injected dose
One solution is to use a gamma detecting probe 
intra-operatively following administration of
radiolabelled MAb to the patient. By reducing the 
distance between the detector and the tumour tissue, 
scatter and tissue attenuation are reduced and the 
number of counts from the tumour will be increased as 
this is inversely related to the square of the distance 
between source and detector. In consequence smaller 
tumour deposits can be detected and at lower tumour 
to normal colon uptake ratios than would be possible by 
external imaging. The potential use in patients with 
primary colorectal cancer would be for detection of 
metastatic deposits outwith the operative field and in 
defining the adequacy of resection margins with 
adherent tumours. In patients with suspected recurrent 
disease such as those with elevated CEA levels 
intraoperative radioimmunolocalisation may allow the 
detection of occult tumour deposits.
Types of radiation detectors
There are two main types of detector which may be 
used for the detection of gamma emissions intra­
operative ly.
Scintillation detectors
The scintillation detector comprises a scintillation 
crystal which produces pulses of visible light on 
interaction with gamma rays and a photomultiplier tube 
(PMT) which converts and amplifies this light signal 
into an electrical pulse suitable for analysis and 
counting.
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Crystalline sodium iodide (Nal) is the most commonly 
used scintillator for nuclear medicine applications, 
the crystal being "doped" with a small proportion of 
Thallium (Nal(Tl)) to allow it to scintillate 
efficiently at room temperatures. An incident gamma-ray 
causes ionisation and excitation of electrons within 
the crystal which emit photons of visible light on 
returning to their original state, the total intensity 
of light being proportional to the energy of the gamma 
ray detected. Nal(Tl) is an efficient detector of gamma 
rays but is fragile, hygroscopic and can be damaged by 
rapid temperature changes.
A photoemissive cathode at the front surface of the 
photomultiplier tube converts the light output to a 
pulse of electrical energy which is then amplified in 
many stages by a chain of further electrodes at 
successively higher voltages, until an output pulse of 
suitable size is produced. This detector system has the 
disadvantage in intra-operative applications that a 
voltage of approximately 1000V is required by the 
PMT which is in close proximity to the patient.
The output signal from the detector system is then 
analysed before display. As the height of the 
electrical output signal varies with the energy of the 
detected gamma ray and this is characteristic to any 
individual radionuclide a pulse height analyser allows 
the selection of a range of gamma energies for 
counting. This is commonly performed by a counter/timer
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or multichannel analyser and is an important feature of 
both scintillation and semiconductor detecting systems 
as it controls the proportion of scattered gamma rays 
detected allowing increased spatial resolution at the 
expense of sensitivity.
Semiconductor detectors
These consist of a crystal of a highly purified 
semiconductor which is sensitive to gamma radiation. 
When a voltage is applied across the crystal face no 
current will flow until an incident gamma ray causes 
ionisation. The resulting charge pulse is then 
collected at the electrodes, its size being 
proportional to the energy of the detected gamma ray. 
This signal is then fed to a preamplifier, an amplifier 
and then a counter/timer for display.
The semiconductors Silicon and Germanium have low 
sensitivities and require to be operated at liquid 
nitrogen temperatures. More recently developed 
semiconductors such as Gallium arsenide, Cadmium 
telluride and Mercuric iodide, however, are more 
efficient at detecting gamma rays and may be operated 
at room temperature. Of these CdTe is the most suitable 
material which is commercially available. The operative 
probes produced with this material are compact and 
operate at low voltage allowing them to be portable 
when powered by batteries. The disadvantages are that 
the small crystals of CdTe which have been produced are 
less sensitive gamma detectors than Nal(Tl) and the
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detector systems are more expensive.
Clinical studies utilising intra-operative radiation 
detecting probes
Gamma radiation detecting probes have been put to a 
variety of clinical uses in the field of nuclear 
medicine and novel applications continue to be 
described. It is now over 15 years since the first 
clinical studies were carried out with semiconductor 
detectors(-^7'-^8) whereas the design and clinical 
application of an intra-operative scintillation counter 
(Csl/Tl) had already been described by Morris et al in 
1971 for use in patients with thyroid cancer. After a 
substantial (therapeutic) dose of 90mCi of •LJAi 
sufficient radionuclide was found to accumulate in an 
area of previously unresected tumour which appeared 
macroscopically normal tissue to allow its detection 
with the gamma detecting probe(GDP) and subsequent 
surgical resection. An activity of 5microcuries was 
claimed to localise in a metastasis of 3mm 
diameter(^9). The detection of osteoid osteomas has 
provided another application. This rare bone tumour, 
which mainly affects young adults, may be difficult to 
detect radiologically but it avidly takes up 99mTc 
polyphosphate. This fact has been exploited in these 
patients, by the pre-operative administration of 99mTc 
monophosphate or polyphosphate. The adequacy of 
surgical resection can then be examined by mobile 
scintillation cameras (-^O) or intra-operative
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scintillation probes(140-145). similarly Harvey et al 
have administered 99mTc methylene diphosphonate (MDP) 
and used a scintillation probe to localise the optimum 
site for bone or soft tissue biopsies (146).
The use of a semiconductor GDP for the 
localisation of radiolabelled MAb was demonstrated 
recently by Aitken and his colleagues (147)^ They 
established xenografts of the CEA secreting HX12 tumour 
in the flank of nude mice and subsequently injected 
them with a polyclonal antiserum to CEA labelled with 
1^11. Using a CdTe probe to count over the tumour 
bearing or the contralateral thigh they showed 
preferential localisation of radio-activity in the 
tumour by 24hrs and maximal uptake at 72hrs. At 72 
hours the ratio of counts over the tumour to that of 
the normal thigh were 1.80+/-0.43 : 1 (mean +/-S.D.).
In this report the probe was also used in a patient 
with a rectal carcinoma who had been injected with 
1.9mCi of 131j anti-CEA 3 days previously. Very low 
count rates were achieved in vivo (100-150 counts/min) 
and the ratio between tumour and normal colon was only 
1.21 si. When tissue from the resected specimen was 
assessed in a gamma well counter the tumour s normal 
rato was considerably higher at 3.2:1. Further patient 
studies were carried out by the same group using the
1 q I
CdTe probe and labelled polyclonal anti-CEA. In
this report patients with both primary and recurrent 
colorectal cancers were investigated (3-48 mean
tumour count to that of normal colon found intra-
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operatively was 3.97:1 in patients with primary cancers 
and 4.18:1 in recurrent cancers, with all tumours 
showing higher counts than that of normal tissue. The 
ratio of counts found in vivo, however, were not 
compared to those assessed by gamma well counting of 
the excised specimens. No clinical benefit of intra­
operative probing was established in these patients. In 
1986 the same group reported the results of an 
additional study using the CdTe probe. On this 
occasion the F(ab')2 fragments or whole MAb 17-1A was 
labelled with the longer lived radionuclide 125j (half 
life of 60 days). Of the 18 patients with colorectal 
cancer that were studied 5 had primary tumours and 13
had r e c u r r e n c e s  (-*-49) # mean operative tumour to
normal tissue count was 3.4:1 for whole antibody and 
2.3:1 for the F(ab')2 fragments. In 3 of the 18 
patients (17%) intra-operative probing using the GDP 
assisted the surgeon in localising tumour tissue. In 
this study a comparison of the results obtained by 
gamma well counting of tumour and normal colon from the 
resected specimen was made with intra-operative probing 
and a ratio of 8.67+/-4.5 : 1 as opposed to 3.46+/-1.9 
: 1 was obtained. The number of counts obtained intra- 
operatively and the statistical significance accorded 
to these counts was not, however, mentioned.
A different antigen (Tag 72) was targeted in 
colorectal cancer patients using the same intra­
operative detector in the report by Sickle- 
Santanello et al in 1987 ^he Tag 72 antigen is
Variable Constant
region region
Figure 1.1. The structure of IgG and its fragments
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expressed by the majority of colorectal cancers and was 
targeted with the ^ 5 j labelled MAb B72.3. In this 
investigation the probe counts obtained over the tumour 
to that of normal colon ranged from 1.5:1 to 22:1 with 
a median of 11:1 but these figures were not compared 
with those of gamma well counted biopsies. Six of the 
31 patients with recurrent cancer underwent probe 
directed biopsies which avoided liver resection in two, 
changed the operative approach in two and established 
subclinical lymph node recurrences in two others.
Whilst this would suggest a useful application of this 
technique three false positive localisations were 
obtained in this group of patients ; one in an 
ischaemic ulcer, a second with an adhesive band and a 
third with a site on the anterior abdominal wall.
In addition to continuing their assessment of a CdTe 
probe for intra-operative detection of radiolabelled 
monoclonal antibodies in patients with colorectal 
cancer Martin and his colleagues have carried out 
further work in nude mice bearing xenografts of a CEA 
secreting human colon carcinoma(^1). The CdTe probe 
was found to be more efficient at counting ^^5j than 
131i labelled antibody. The uptake of activity in 
tumours was also found to be greater when a combination 
of monoclonal and polyclonal antibody was used than if 
either was used alone.
Although there has been a recent upsurge of interest 
in the use of CdTe detectors for localising iodinated 
antibodies in patients other uses have been suggested
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and explored. Ubhi et al(1984) have reported the 
localisation of a mediastinal parathyroid adenoma by 
intra-operative probing following the administration of 
^^Thallium Chloride (152) an(j the localisation of 
99mTc_MDP to osteoid osteoma has been monitored using 
either a Nal or Cd Te detector (1^5)  ^ In the latter 
study the CdTe system was found to be more durable, 
reliable and sensitive than the Nal system. This, 
however, contrasts with the findings of Harcke et al 
in which the sensitivity of the CdTe probe was found 
to be 2-5% of that of the Nal(153)#
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1.3.±v) Therapeutic aspects of monoclonal antibodies
The development of hybridoma technology by Kohler 
and Milstein in 1975(^5) paved the way for the 
therapeutic applications of MAb's by allowing the 
production of quantities of antibodies sufficient for 
clinical application. Despite the ability to produce 
adequate amounts of specific MAb's several problems 
require to be resolved before the therapeutic 
application of MAb's is realised. Firstly the 
expression of an antigen by the tumour tissue is 
essential for the targeting of therapy. The 
heterogeneity of antigen expression, however, may 
result in some patients being unresponsive to treatment 
whereas in others non antigen-expressing clones of 
tumour cells may be selected for survival and result in 
tumour recurrence (^ 54)^  In addition to difference in 
antigen expression by cancers, normal human tissues may 
also express either the target antigen or a similar 
structure resulting in significant cross reactivity.
The site and nature of the antigen itself is also of 
some importance. Although oncogenes have been detected 
in many cancers and MAb's raised to the proteins for 
which the oncogenes code may appear to be a logical 
advance for therapy this may have no useful application 
unless the protein is an accessible constituent of the 
cell membrane. Such cell membrane antigens may, 
however, be secreted and form a circulating complex 
with the MAb-therapy conjugate.
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Moreover the potential of the targeted MAb may be 
thwarted by its removal by the reticulo-endothelial 
system, the instability of the complex, a lack of 
sensitivity of target tissues to the therapeutic agent 
or simply the access of a large molecule to the poorly 
vascularised tissue found at the core of solid tumour. 
Despite these potential problems a vast effort has been 
expended over the last ten years to define agents which 
may be conjugated to monoclonal antibodies and assessed 
for the selective destruction of cancer tissues. A 
brief overview is given here of some of the agents 
which have been considered for targeted therapy, their 
in vitro characteristics, and where possible the 
results of clinical studies. Four main groups of agents 
may be considered:
a) Antibodies alone
b) Antibody-drug conjugates
c) Antibody-radionuclide conjugates
d) Antibody-toxin conjugates
Antibodies against the epithelial membrane antigen are 
being investigated for use in the latter three 
applications and particular emphasis will be placed on 
these studies.
57.
1.3.iv.a) Therapeutic aspects of monoclonal antibodies
Monoclonal antibody inhibition of the growth of a 
tumour cell line expressing the corresponding antigen 
in an in-vitro model has been shown with a variety of 
antibodies and tumour cell lines'(^55,156) as wen  as 
growth inhibition of tumour xenografts in nude 
mice (^5^). Patient studies, however, have been less 
promising. In 1982 Sears et al reported the results of 
a phase 1 trial of monoclonal antibody in the treatment 
of patients with metastatic gastro-intestinal 
tumours (-^8) pour patients were given 15-200mg of 
purified MAb 17-1A (-*-^ 7)^  All patients developed a 
human anti-mouse antibody (HAMA) response (Chapter 5) 
and one patient had an anaphylactic response to the 
fourth antibody injection. Only one patient was 
reported as showing tumour regression on serial CT 
scanning of liver metastases and this patient had 
received antibody coated leucocytes intra-arterially 
into the hepatic artery in addition to the intravenous 
administration of antibody. A further report on passive 
immunotherapy using the same antibody was published by 
the same group in 1984 (-^9). a total of 20 patients 
were studied who had gastro-intestinal carcinomas with 
metastases. They received between 15 and lOOOmg of 
antibody per patient in addition to conventional 
therapy consisting of a combination of surgery, 
chemotherapy and radiotherapy. Patients receiving lower 
dosages (<366mg) of antibody developed
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an HAMA response whereas those receiving larger 
antibody dosages (>366mg) did not. Three of the group 
given passive immunotherapy were disease free 10,13 and 
22 months following treatment. The design of this study 
with multiple modalities of treatment prohibits any 
useful conclusions to be made regarding any possible 
role for passive immunotherapy with monoclonal 
antibodies raised against a tumour associated antigen 
and this question therefore remains unanswered.
1.3.±v.b) Antibody-drug conjugates
The production of a composite molecule consisting 
of a cytotoxic drug and a tumour associated antibody 
for the treatment of cancer is a very appealing 
concept. The specificity of the antibody would allow 
tumour cells to be localised and subsequently destroyed 
by the chemo-therapeutic agent while preventing the 
damage to rapidly dividing tissues, notably the bone 
marrow, which is the major drawback to systemic 
chemotherapy. Investigation into this treatment 
modality has taken place for some thirty years (-*-^0), 
initially with polyclonal antisera and more recently 
with monoclonal antibodies. The earliest reports 
(160,161) concerned the use of methotrexate although 
many other cytotoxic agents have been used since 
including chlorambucil (162)^ adriamycin (163)^ 
melphalan (164)^ vindesine (165) and bleomycin (166) # 
The essential prerequisite for any antibody-drug 
conjugate is that preparation maintains both the
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cytotoxic capability of the drug and the immuno- 
reactivity of the antibody. Even assuming that this is 
achieved considerable controversy remains over whether 
sufficient cytotoxic agent could be delivered to the 
tumour tissue. In an attempt to increase the delivery 
of the drug to tumour tissues many groups have been 
investigating the potential of using a drug carrier 
molecule which, once formed, is conjugated to the 
antibody. Carriers which have been investigated have 
included the albumins (I67), agglutinins (168)f 
polyaspartate (169) and carboxymethycellulose (I7®). 
Antibody-drug conjugates have been shown to be both 
toxic and selective for tumour cell lines expressing 
the appropriate antigen( 171-174) an(j have aiso been 
shown to localise in and suppress the growth of 
xenografts in nude mice (175,176)# To date no major 
therapeutic trials have been carried out in patients 
using antibody-drug conjugates. The biodistibution of 
these conjugates has been assessed, however, in
I *3 I
patients with an ° I-labelled vindesine-anti CEA 
conjugate (I77) and l^I-labelled 791T/36 MTX 
conjugate (l7 )^. in the foamier study localisation on 
external imaging was achieved in only five of eight 
patients and the tissue uptake of activity was not 
measured. In the latter study the median uptake of 
activity was 2.9:1 as against normal tissues. Further 
investigation of the biodistribution in humans of 
antibody-drug conjugates are required along with a
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method of directly assessing the drug uptake in the 
target tissues.
1.3.±v.c) Antibody targeted radionuclides
Evidence is accumulating from a variety of studies 
on different tumours and a number of different 
monoclonal antibodies that heterogeneity exists in the 
expression of all tumour associated antigens. For this 
reason targeted radionuclides may have an advantage 
over targeted drugs or toxins in that selecting a 
radionuclide with the appropriate emissions may allow 
the destruction of both the neighbouring non antigen 
expressing cell as well as the antigen expressing cell 
to which the carrier antibody is adherent.
Immunocompromised animals with tumour xenografts 
have been used to assess the therapeutic efficacy of 
radiolabelled monoclonal antibodies. Using such models 
1311 labelled antibody has been shown to inhibit tumour 
xenograft growth to a greater extent than antibody 
alone (1^9) and similarly labelled specific antibody 
has shown greater inhibition of tumour growth than 
similar doses of non specific antibody (1®0). In these 
animal models, however, the tumour uptake of radio­
labelled antibody as a percentage of the injected dose 
is many times greater than that achieved in patient 
studies. For example in a study on the therapeutic use
1 0 1
of I labelled anti-thy 1.1 monoclonal antibody 6.5% 
of the injected dose accumulated per gram of tumour
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tissue in a lymphoma xenograft in nude mice (1®1), 
compared with the localisation achieved in patients 
which is rarely greater than 0.001% of the injected 
dose per gram (130)^  dosimetry found in animal 
models cannot, therefore, be extrapolated to patient 
studies.
A theoretical calculation of the dosimetry in humans 
was carried out by Vaughan et al in 1987 Using
data on the biodistribution of radiolabelled antibodies 
obtained from imaging studies they constructed a 
mathematical model of the radiation dose to various 
tissues associated with the administration of 
sufficient 131j or 90yittrium (®®Y) to destroy a solid 
tumour. They concluded that at least a ten-fold 
increase in tumour uptake of the radiolabelled antibody 
would be required to combine tumour destruction with a 
survivable whole body irradiation. This study presents 
a plausible estimation of the effects that systemic 
therapy using radiolabelled antibodies would have using 
current techniques. Similar conclusions on the 
inadvisability of systemic treatment with radiolabelled 
antibodies have been produced by other researchers 
(183)# Despite this, radiolabelled antibodies have been 
used systemically for the treatment of metastatic 
melanoma (l®^), hepatoma (1®5) ancj cerebral glioma 
(186). interpretation of these studies is unfortunately 
complicated by their lack of controls and multiple 
concomitant therapies.
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A logical solution to the dosimetry problem using 
radiolabelled antibodies is treatment on a loco- 
regional basis. This provides a high concentration 
directly to the tumour surface whilst avoiding the 
dose-limiting effects of systemic therapy. This 
modality of treatment has been used intra-pleurally and 
intra-pericardially for malignant serous effusions 
(187/188) ancj intra-peritoneally for metastatic ovarian 
c a r c i n o m a ,(188), Although of benefit in preventing the 
re-accumulation of malignant serous effusions the 
efficacy against bulky tumour was negligible. More 
recently studies have been carried out with a variety 
of monoclonal antibodies labelled with 13lj and used in 
the treatment of cerebral tumours by intra-thecal 
administration, (188). Preliminary reports have shown 
evidence of tumour regression as assessed both on 
clinical grounds and CT findings whilst producing 
minimal side effects to this group of patients with a 
very poor prognosis.
The vast majority of patients with cancer, 
however, have solid tumour masses which are not 
amenable to regional therapy. Successful treatment of 
these patients using radio-labelled antibodies will 
require a significantly improved antibody uptake 
by tumour tissues or a satisfactory method of 
protecting radio-sensitive normal tissues.
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1.3.iv.d) Antibody-toxin conjugates
A group of potent toxins derived from plants, of 
which the most widely known is Ricin, are capable of 
causing cell death at very low concentrations by the 
inhibition of protein synthesis at the level of the 60s 
subunit of intra-cellular ribosomes. Such toxins 
consist of two distinct subunits termed A and B. The B 
subunit is principally responsible for the binding of 
the toxin to the cell surface and the internalisation 
of the A unit which inhibits protein synthesis. 
Conjugates formed from tumour associated monoclonal 
antibodies and toxins have obvious appeal for the 
treatment of cancer and such compounds have been 
investigated for almost twenty years (181,192)^ 
Unfortunately such antibody-toxin conjugates have not 
been found to have the expected antigen specificity due 
to the non specific binding of the ricin B chain to 
cell membranes. This binding appears to be related to 
sugar residues present on the B chain and may be 
inhibited by high local lactose concentrations (183) or 
by newer methods of antibody-toxin conjugation (184) #
An alternative to inhibiting the non-specific binding 
of the B chain is to utilise the A chain alone 
conjugated to antibody. Unfortunately removal of the B 
chain although reducing the non specific uptake 
sometimes decreases the toxicity of the conjugate.
Ricin A chains are catabolised within intracellular 
lysosomes and the toxicity of the A chains may be 
implemented in vitro by the presence of high
concentrations of ammonium chloride which alters the 
intra-lysosomal pH (185)  ^Antibody-ricin A chain 
conjugates have been shown to selectively inhibit the 
growth of, and kill, cells expressing the appropriate 
antigen in vitro (186,197)^ patient studies have mainly 
involved the treatment of acute leukaemics. In these 
patients marrow transplantation may be the sole method 
of allowing adequate drug therapy to be carried out. 
Autologous grafting may, however, re-introduce 
malignant stem cells to the host or allow the 
development of graft versus host disease; To circumvent 
these problems antibodies directed against cell surface 
markers on the tumour cells or expressed on normal 
mature T cells may be conjugated to ricin A chains and 
used ex vivo to purge the marrow prior to 
reimplantation (198,199)#
Further advances in the use of antibody toxin 
conjugates are likely to involve the avoidance of non­
specific binding of the B sub-units of whole toxin and 
the potentiation of the effects of A chains by 
inhibiting lysosomal breakdown. As in all aspects of 
monoclonal antibodies in therapy greater antibody 
specificity would allow more toxic substances to be 
safely administered.
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1.4. EPITHELIAL MEMBRANE ANTIGEN
In section 1.3 the current and potential uses of 
MAb's in colorectal cancer have been outlined. These 
antibodies have generally been raised either to CEA or 
a colorectal cancer cell line. An alternative target 
antigen which has not previously been assessed in 
colorectal cancer is the epithelial membrane antigen.
1.4.1) Discovery
Normal lactating breast tissue secretes lipid 
which is packaged in membrane bound globules. The 
membrane of the milk fat globule is derived from the 
luminal surface of the cell during its passage from the 
cytoplasm to the mammary acinus. Extracts produced by 
the defatting of human milk consist largely of the milk 
fat globule membrane.(MFGM) which has been found to be 
a powerful immunogen. In 1977 Ceriani et al(^®®) 
described an antiserum which had been produced to 
defatted human cream and which was felt to be specific 
for an antigen expressed by the mammary membrane. A 
similar method of antisera preparation was used by 
Heyderman et al in 1979(^01)r emulsified membrane 
extracts in complete Freunds adjuvant being injected 
into rabbits at monthly intervals. High titre antisera 
were obtained 2 weeks after the fourth injection. 
Immunocytochemical staining was carried out on a 
variety of normal and neoplastic tissues using the 
antisera produced. Contrary to the findings of
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Ceriani et al these antisera did not react solely with 
mammary tissues. The antigenic determinant being 
recognised was expressed on the luminal membrane of 
lactating, benign and malignant mammary tissues and in 
poorly differentiated carcinomas both cytoplasmic and 
luminal expression was present.
Normal tissues showing a positive staining reaction 
included the salivary gland, pancreas, stomach, 
bronchial mucus glands, bile ducts, endometrial and 
cervical glands, decidual glands and sebaceous glands. 
Of note was the positive staining of the distal 
collecting tubules of the kidney and the negative 
staining of the glomeruli and proximal tubules. Normal 
tissues of interest due to their negative reaction 
included the colon and ileum and the cellular elements 
of normal marrow and lymphoid tissues. Heyderman et al 
also investigated the immunocytochemical staining of 
a wide variety of malignant tumours using the same 
antisera. Adenocarcinomas were found to produce a 
strongly positive staining reaction including those of 
the stomach, colon, prostate, uterus, ovary, lung, 
pleura and thyroid. Tumours notable by their negative 
reaction included oat cell carcinomas, seminomas and 
non-Hodgkins lymphomas.
The unique nature of the antigen detected by these 
antisera to MFGM was confirmed by a comparison of 
tissue sections with antisera to CEA, beta oncofetal 
antigen, alpha lactalbumin, ferritin, lactoferrin,
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secretory piece of IgA, muramidase, casein, cyst fluid 
protein and pregnancy specific bl glycoprotein. In no 
case did the distribution of the immunocytochemical 
staining correspond to that of the antisera to MFGM and 
it was therefore concluded that a new antigenic 
determinant had been defined which was designated 
epithelial membrane antigen (EMA).
1.4.ii) Distribution
Many monoclonal antibodies have been raised to 
epithelial membrane antigen(202-207) ancj have allowed 
the further definition of the distribution of EMA in 
normal and neoplastic tissues. The findings of these 
studies using monoclonal antibodies have generally 
confirmed the findings of Heyderman using a polyclonal 
antisera (201)# The EMA expression of most tissues 
appears to be heterogenous and normal tissues which 
express EMA are mainly of glandular origin. Haemopoetic 
and lymphoid tissues were originally believed not to 
express EMA (201) kut .^he antigen has subsequently been 
found on some non-neoplastic plasma cells (206) A wide 
variety of tumours were studied on immunocytochemistry 
using MAb's to EMA by Pinkus and Kurtin in 1985 (207)# 
90% of adenocarcinomas (breast, lung, colon, stomach, 
pancreas, gallbladder, prostate, endocrine, ovary, 
kidney and thyroid) were immunoreactive for EMA, mainly 
with cytoplasmic and apical luminal membrane staining. 
Of interest non-glandular tumours including squamous 
carcinomas, small cell anaplastic and mesotheliomas
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were also EMA positive. A lack of immunoreactivity was 
noted with malignant lymphomas, endocrine neoplasms 
(carcinoid, medullary thyroid carcinomas, 
adrenocortical and phaeochromocytomas), germ cell 
tumours and connective tissue tumours.
The exact chemical composition and structure of 
EMA has yet to be established. Partial purification has 
been carried out, (208) antigenic activity being
associated with a wide range of molecular weights. The 
antigen itself is largely composed of carbohydrate with 
galactose and N-acetyl glucosamine as the two major 
sugars, the protein content of the antigen being low 
and of variable amino acid composition. Inorganic 
material was also found to be a major constituent of 
EMA.
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1.5. CLINICAL APPLICATION OF ANTIBODIES TO EMA
1.5.±) Serological studies on EMA
Although EMA has been shown on immunohistochemistry 
to be expressed by a wide variety of cancers few 
studies have been carried out to determine if 
these patients have elevated serum levels of EMA. 
Studies have, however, been carried out in patients 
with breast and ovarian cancer using MAbfs raised to 
either extracts of the MFGM or membrane enriched 
extracts of breast cancer metastases. In 1984 Burchell 
et al(^^) examined the sera of 30 patients with breast 
cancer and 30 controls using a "sandwich" 
radioimmunoassay employing the MAb's HMFGM 1 and 2. The 
HMFG 1 antigen was found to be elevated in the serum of 
30% of patients with advanced cancer and in 6% of 
healthy controls whereas HMFG2 was elevated in 53% of 
the sera from patients with advanced cancer and in 
16.6% of controls. Interestingly the circulating 
antigen in serum recognised by these MAb's was found to 
be 320kD and 280kD respectively which is lower than the 
molecular weight of the antigen present in milk. This 
suggests that only a portion of the membrane antigen is 
shed. Antibody HMFG2 was also used by Ward for 
investigating patients with epithelial ovarian 
cancers( ) ,  who found that 33% of stage 1 patients 
had elevated levels of EMA compared to 62% of 
patients at stage 2-4. Circulating EMA levels were also 
found to correlate with tumour bulk by analysis of
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serum levels before and after cytoreductive surgery.
In neither of these studies, however, was evidence 
found to suggest that HMFG2 detection of EMA levels was 
sufficiently sensitive for screening procedures or for 
the routine follow-up of patients following surgery for 
either breast or ovarian cancer.
Serological studies using other MAb's raised against 
HMFG or extracts of breast cancer tissue have 
given similar results, namely that patients with 
extensive local or metastatic breast and ovarian 
cancers have elevated levels whereas those with early 
stages of disease have serum levels similar to those of 
normal controls (211-213)^ Ashorn analysed the serum 
levels of HMFG antigen in patients with a variety of 
cancers in addition to those of the ovary and breast.
Of 33 serum samples from patients with colorectal 
cancer only one had a level above the range of 
healthy controls. In patients with extensive breast 
cancer only 35% had elevated levels of circulating EMA 
and of the small number of patients examined with 
localised breast cancer only 22% had had above normal 
levels. A trend was observed, however, and patients 
with progressive disease had rising levels of HMFG 
whereas those where disease was regressing the levels 
were decreasing (213)^
71.
1.5.±±) Immunohistochemical studies on EMA.
The use of antibodies for the detection of tissue 
antigens in fresh or paraffin embedded tissues is now a 
well established technique in histopathology for 
establishing the exact nature of the tissue under 
study. Epithelial membrane antigen (EMA) is well 
preserved in paraffin embedded tissues which therefore 
provide a suitable source of material for study. As EMA 
is expressed by most epithelial tumours and rarely by 
lymphoid neoplasms or sarcomas, an obvious role for EMA 
antibodies is in the differentiation of poorly 
differentiated carcinomas from malignant lymphomas and 
spindle cell sarcomas.
In 1983 Sloane et al(^^) assessed the value of a 
polyclonal antiserum to EMA in solving diagnostic 
problems in tumour histopathology. Of 70 specimens 
examined 48 tumours were stained for the purpose of 
determining their histogenesis. Twenty-two of these 
were positive for EMA expression and twenty 
subsequently proved to be epithelial on follow-up 
studies. In six of these specimens a diagnosis of non- 
epithelial malignancy had been made on conventional 
staining. Although a role remains for the use of MAb's 
to EMA in determining the nature of poorly 
differentiated tumours EMA expression has been found on 
some reactive and neoplastic plasma cells, some non- 
Hodgkins lymphomas and Reed Sternberg cells in cases of 
lymphocyte-predominant Hodgkins disease (206)^
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On the strength of this finding Delsol (206) suggested 
the use of additional anti-epithelial antibodies in 
conjunction with anti-EMA for tumour diagnosis.
EMA antibodies may also have an important role 
when used in conjunction with other tumour markers for 
establishing the site of origin of epithelial tumours. 
In 1984 Heyderman et al (^ 0) carried out an 
immunoperoxidase study using antibodies to EMA, CEA and 
prostatic acid phosphatase in prostatic/ bladder and 
colorectal cancer. Analysing twenty tumours of each 
type all of the colorectal and bladder tumours and 16 
of 20 prostatic tumours were positive for EMA.
All 20 colorectal, 7 of 20 bladder and 5 of 20 
prostatic tumours stained for CEA. Prostatic carcinomas 
alone were positive for prostatic acid phosphatase. It 
was suggested that these markers may therefore be 
useful in establishing the origin of pelvic tumours for 
which the resultant management will be markedly 
different.
Another major role for immunocytochemistry using 
EMA antibodies has been in the detection of 
micrometastases from breast carcinoma (215-220)# 
Staining of marrow aspirates with EMA antibodies by 
immunoflourescence in patients with clinically primary 
breast carcinomas allows the detection of 
micrometastases not apparent on conventional 
haematoxylin and eosin staining. This important finding 
has recently been supported by a follow up study
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showing that those patients with EMA positive marrow 
smears have a poorer prognosis than those that do 
not (221). Micrometastases have also been detected in 
the regional lymph nodes of patients with breast 
carcinoma using anti-EMA MAb's and this may provide a 
useful method of selecting patients for adjuvant 
cytotoxic chemotherapy.. (2 2 2 r 2 2 3)
The malignant nature of serous effusions, either 
pleural or peritoneal, may often be established by the 
cytological analysis of aspirated fluid. Occasionaly, 
however, although malignancy is confirmed or suspected 
the histological nature of the primary tumour cannot be 
established. This may have important implications for 
future management. Antisera to EMA have been shown to 
have an important role in differentiating the nature of 
such effusions (224-226).
1.5.iii) Radioimmunolocalisation
Studies have been carried out on the localisation 
of breast, ovarian and colonic carcinomas using 
antibodies raised to EMA. In 1982 Epenetos et al(^^) 
reported the use of 123j labelled EMA antibodies HMFGM 
1 and HMFGM 2. These antibodies had previously been 
shown to react strongly with the lactating breast and 
epithelial tumours and only weakly with normal tissues 
(204,228,229)# Localisation was attempted in 20 
patients with advanced malignancy, (ovarian(10), 
breast(6), colon(2) and two Krukenberg tumours of
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colonic origin) following the intravenous 
administration of labelled antibody. Positive images 
were obtained, without subtraction techniques, at three 
minutes to 18 hours following injection. Of the 12 
patients with ovarian tumours 15 of the 18 sites of 
tumour localised the radiolabelled MAB. Twelve sites of 
disease were present in the six patients with advanced 
breast carcinoma, nine of which were localised. Of the 
two patients with colonic carcinomas one had a negative 
scan and the other had incomplete scanning. The uptake 
of label was assessed in five patients by whole body 
scanning and expressed as a percentage of the injected 
dose, the mean tumour uptake being 0.6% of the injected 
dose. The site of localisation of the radiolabelled 
antibodies was confirmed by immunoperoxidase staining 
and autoradiography.
Another important study on the localisation of EMA 
antibodies was carried out by Rainsbury in patients 
with breast carcinoma (125,230 using the antibody LICR 
LON M8 (M8) labelled with ^^In, 29 patients with 
breast carcinoma were studied, 7 with primary tumours 
and 22 with metastases. The results of radio­
localisation were compared with those of conventional 
X-rays and methylene diphosphonate (MDP) bone scans. 
Excised tumour specimens had a mean of 6.2 times 
greater uptake of labelled antibody than normal tissues 
but did not produce positive images. Skeletal 
metastases, on the other hand, were localised in all
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sites confirmed by other means. The reasons proposed 
for the imaging of the bony metastases but not the 
primary tumour was an increased EMA expression in 
marrow metastases and an increased access of radio­
labelled antibody due to improved vascularity. Although 
the vascularity of bony metastases may be greater than 
that of soft tissue lesions a suitable explanation for 
a difference in antigenic expression is not apparent.
Antibodies raised against an antigen expressed by 
one type of tumour may react with other types of tumour 
expressing the same antigen. This fact allows a single 
antibody to be used for the radio-localisation of more 
than one tumour type. Antibody 79IT/36 was originally 
raised to an osteogenic sarcoma and has been 
successfully used for the localisation of both 
bony (-*-09) ancj gastro-intestinal tumours (113,114) ^ 
Similarly the MAb M8, raised to EMA (202,203) ancj usecj 
in the imaging of breast carcinomas (230)  ^was found Qn 
immunoperoxidase staining of colorectal cancers (231) 
to react strongly with these tumours as was the MAb
77.1. Both MAb's have been used in the imaging of 
colorectal cancers (232,233)^
Eighteen patients were administered ^^In labelled 
M8 and scanning took place 3-5 days after 
administration. Thirteen of the 18 patients had 
positive scans(65%) and the findings were confirmed at 
operation. Immunocytochemistry on the excised tumours 
was positive in all patients with positive scans.
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Eleven patients had samples of tumour and normal colon 
taken at the time of operation. The ratio of antibody 
in tumour to that of normal colon was 2.56+/-1.27 
(mean+/-S.D.) and the ratio of tumour to blood activity 
was 11.0+/-6.2(mean+/-S.D.)
The monoclonal antibody 77.1, a mouse monoclonal 
antibody of IgG2a class, was originally raised using a 
bladder carcinoma metastasis as immunogen and has anti- 
EMA like properties (234)^llljn labelled 77.1 was 
administered intravenously to 14 patients. One patient 
had two primary tumours and two had recurrent disease. 
Scanning at 3-5 days following antibody administration 
localised ten of the fifteen tumours(64%). Positive 
scanning results correlated with positive 
immunocytochemistry. Analysis of activity in specimens 
resected 6 days after antibody administration revealed 
a mean tumour to normal colon ratio of 1.93 (range 1.0- 
3.26) and a mean tumour to blood ratio of 3.55 (range 
1.6 to 5.07) .
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1.6. Conclusions and purpose of the present study
Many antibodies have been raised to tumour 
associated antigens which are expressed by colorectal 
cancers. Many of these antibodies, however, recognise 
different epitopes of the same antigen molecule and the 
number of colorectal cancer antigens which have been 
defined are relatively few, CEa (^5)^ ca 19-9 17-
1a(155) anci TAG-72 (237) being most intensively 
investigated. In this chapter the many 
applications of antibodies to these antigens have been 
discussed. It is apparent that neither the ideal 
antibody or target antigen has yet been defined.
Several immunohistochemical studies have reported 
the marked difference in the expression of EMA by 
colorectal cancers and normal colon(201,207,238) ancj 
provisional studies using Indium labelled MAb's M8 and 
77.1 has suggested a possible role for anti-EMA MAb's 
in patients with colorectal cancer (232,233)^ ^his 
target antigen has therefore been investigated in 
greater detail. The studies were conducted in the 
following manner ;
An immunohistochemical study of EMA and CEA expression 
in normal colon and colorectal neoplasia.
No previous studies have looked specifically at EMA 
expression in colorectal cancer. Immunohistochemical 
staining of colorectal cancers using the recently 
developed anti-EMA MAb ICR2 was compared with an
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antibody recognising CEA, the best characterised of 
the gastro-intestinal tumour antigens.
The anti-CEA antibody C46 was obtained from Amersham 
International, U.K.. It is a murine IgG which was 
raised to a sub fraction of CEA of high specific 
activity obtained from the liver metastasis of a human 
colorectal carcinoma,(239). was selected due to its 
successful use conjugated to *^^In in imaging human 
colorectal cancers and its high tumour to normal colon 
differential uptake in vivo^®®).
The anti-EMA ICR2 has been recently developed at 
the Institute of Cancer Research, Sutton, Surrey. It is 
of the IgG2a class and was raised in Chester Beatty 
Hooded (CBH) rats using extracts of MFGM as immunogen. 
Lymphocytes sensitised by repeated injections of 
membrane extracts in Freunds adjuvant were fused with 
the rat myeloma Y3 AG 1.2.3. and the resultant 
hybridomas were grown as ascites. The antibody was 
isolated by salt fractionation and ion exchange 
chromatography using Whatman DE52 cellulose. The 
reaction of this antibody with normal human tissues has 
been assessed (J.P. Sloane, personal communication) and 
the pattern of staining has been found to be similar to 
that of the rabbit polyclonal antiserum used for the 
original description of EMA (^ 01).
Preliminary investigation was performed on randomly 
selected paraffin embedded colorectal tissues obtained 
from the Histopathology Department, University College 
Hospital.
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To allow further comparison of CEA and EMA 
expression in colorectal cancers with benign 
adenomatous polyps and normal colon within individual 
patients and correlations with standard histological 
variables, an immunohistochemical study was 
subsequently carried out on tissues from a consecutive 
series of patients undergoing resection of their 
colorectal cancers.
Immunohistochemistry has been employed in the 
detection of micrometastases. Antibodies to CEA 
detected nodal metastases from colorectal 
cancers with considerable variations in reported 
frequency(^ ^ ) while anti-EMA detection of nodal and 
bone marrow deposits has only been investigated in 
breast carcinoma (221,222 )# immunohistological 
assessment with both anti-CEA and anti-EMA, of lymph 
nodes in resected colorectal cancer specimens has 
therefore been investigated.
Circulating EMA levels in patients with breast and 
colorectal cancer.
The serological studies carried out in colorectal 
cancer patients have been outlined in Section 1.3.i) 
and those using anti-EMA antibodies in Section 1.5.i).
From these studies it would appear that only a 
part of the EMA molecule circulates( )  and that 
circulating levels will depend on the epitopes 
recognised by any individual a n t i b o d y ).
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Nevertheless elevated levels have been noted in 
patients with breast and ovarian cancers and rarely in 
patients with colorectal cancer(213). relevant
therefore in investigating the role of EMA expression 
in colorectal cancer and in its potential as an 
antigen for antibody localisation to measure its 
circulating levels using ICR2 in patients with 
colorectal cancer and compare this to patients with 
breast cancer and age matched healthy blood donors.
The liver uptake of labelled MAb
The uptake of radiolabelled antibody in normal
liver tissue is perhaps the greatest limitation to the
use of radiolabelled antibodies for the detection of
gastrointestinal cancers by gamma camera imaging
(Section 1.3.iii). The limited organ dosimetry
available would suggest that between 20% to 40% of 
illinjected -L-LXIn-MAb accumulates in the liver within 24 
hours(230), which obscures any uptake of activity in 
liver metastases or in tumours in the vicinity of the 
liver. The mechanism for this uptake has not been 
established although the activity takes the form of a 
low molecular weight complex within the hepatocytes 
(240,241 pr£or to embarking on patient studies an in- 
vitro model consisting of isolated hepatocytes and the 
EMA expressing cancer cell line MCF7 has been used to 
analyse factors which may reduce the hepatocytes uptake 
whilst maintaining the specific uptake by the tumour 
cell line.
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Colorectal cancer imaging using the anti-EMA. MAb ICR2
Localising colorectal cancers by gamma camera
imaging following the administration of radiolabelled
antibodies has been carried out for the last 10 years.
(Section 1.3.iii). The majority of studies have used
antibodies raised to CEA labelled with 131j(97-101) or
more recently with 106)# studies have
suggested that anti-EMA antibodies are suitable for
imaging colorectal cancers (232,233 )^ use Qf tjie
illanti-EMA ICR2 labelled with In has therefore been 
investigated for colorectal cancer imaging.
Human biodistribution of *^In-ICR2 in colorectal 
cancer patients.
The process whereby a radiolabelled antibody 
localises and allows a successful imaging of a cancer 
is complex, with problems at any intermediate stage 
affecting the eventual result. The majority of studies 
on radioimmunolocalisation, however, have reported very 
limited if any information on the biodistribution of 
radiolabelled antibodies in patient studies. This data 
is essential if improvements in the results of antibody 
imaging are to be achieved. The biodistribution of 
■*-^ I^n-ICR2 was therefore analysed in patients with 
colorectal cancer and the imaging results related to 
circulating antigen, circulating immune complex, 
clearance of activity, tumour uptake of activity and 
the expression of the target antigen in tumour tissue.
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The effect of unlabelled antibody for the reduction of 
circulating immune complex and DTPA in reducing liver 
uptake have been explored. Previous human studies 
investigating cold antibody administration have failed 
to quantify the effect on circulating antigen formation 
and tumour uptake of activity (242,243 Therefore, this 
is also being examined.
Intra-operative tumour detection
Tumour deposits may be detected at the time of 
operation using radiolabelled monoclonal antibodies and 
a portable radiation detector, with smaller deposits 
being detected than by external imaging. The potential 
application of this technique which was first described 
as recently as 1984(-*-^ 7) £s £n deciding the adequacy of 
resection margins and the presence of metastases with 
both primary and recurrent cancers. Previous studies 
have involved a variety of iodinated antibodies and a 
CdTe radiation detector (148-150)^ We have utilised the 
111In-ICR2 administered to patients with colorectal 
cancer for external imaging to evaluate intra-operative 
tumour detection. The limitations of this technique 
have also been assessed using a phantom model and both 
CdTe and Nal detectors.
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2.1. INTRODUCTION
Immunohistochemistry allows the visualisation of 
tumour antigen expression in histological sections. In 
colorectal cancer these techniques have been used, 
mainly with antibodies raised to CEA, to identify the 
tissue of origin of undifferentiated cancers^®), for 
the detection of micrometastases in regional lymph 
nodes(^ ^ ) and as one of the prognostic indices for 
patients undergoing resection of a colorectal 
cancer(93'94).
Antibodies to EMA have been used in 
immunocytochemistry for establishing the epithelial 
nature of undifferentiated tumours(^14), £0r detecting 
breast cancer micrometastases (215-223) an(j £Qr 
determining the nature of serous effusions(224-226). 
The expression of EMA by colorectal cancers has 
previously been noted(90,207,231) kut not adequately 
investigated. In this series of immunohistochemical 
studies the anti-EMA antibody ICR2 has been evaluated 
as a potential agent for the imaging of colorectal 
cancers by assessing its reaction with primary and 
metastatic colorectal cancers, adenomatous polyps and 
normal colon. A comparison has also been carried out 
between the expression of EMA in colorectal cancer and 
CEA, the best characterised of the colorectal cancer 
antigens. To allow a comparison to be made with 
standard histopathological variables the resected 
specimens of a consecutive series of patients with
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colorectal cancer were then studied for their CEA and 
EMA expression.
The presence of metastatic tumour deposits in the 
regional lymph nodes is a major factor in predicting 
the eventual outcome of a particular patient. The 
reported mean five year survival of patients without 
lymph node metastases is nearly 80%, whereas for those 
with metastatic deposits in regional lymph nodes it is 
only 30% The accurate determination of lymph
node involvement is therefore crucial. Routine 
Haematoxylin and Eosin (H&E) examination may not detect 
minute tumour deposits or groups of cells and will 
result in falsely optimistic tumour staging.
Colorectal cancers and their metastases have 
previously been shown to express both CEA and EMA 
Previous studies have used either anti-CEA in 
colorectal cancer(91/92) or anti-EMA in breast 
cancer(215-223) £or detecting micrometastases. 
Controversy exists over the detection rate of 
colorectal micrometastases with reports of metastases 
present in 4-25% of patients (^'^). A larger series of 
patients has therefore been studied to clarify the 
uncertainty in the detection rate of colorectal cancer 
micrometastases and to determine whether it is improved 
by combining anti-CEA or anti-EMA immunohistochemistry 
with H&E staining.
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2.2. MATERIALS AND METHODS
Throughout the studies in this chapter formalin 
fixed and paraffin embedded tissues were used. The 
preliminary studies in section 2.3. used randomly 
selected tissue blocks. Because this did not allow the 
antigen expression to be compared between tissues 
within any individual patient or for the antigen 
expression to be correlated with routine pathological 
variables, studies in sections 2.4. and 2.5. used 
tissues from a consecutive series of patients. From 
blocks of tissue 6um sections were cut for 
immunocytochemistry using an MSE microtome. The 
monoclonal antibodies ICR2 (anti-EMA) and C46 (anti- 
CEA) have been described previously (Section 1.6.)
2.2.i) Indirect immunoperoxidase staining method
The slides were firstly dewaxed by washing three 
times in xylene (1.1.1.trichloroethane) for three 
minutes each time and then, the xylene was removed in 
absolute alcohol (ethyl alcohol) x 3 for three minutes. 
Endogenous peroxidase activity in gastrointestinal 
tissue was blocked by incubating with 0.5% H2O2 / 
methanol for five minutes then the sections were washed 
in tap water for five minutes followed by Tris buffered 
saline (T.B.S.) pH 7.6 for five minutes. Suitably 
diluted MAb (either ICR2 or C46, both lOug/ml) was 
applied to each slide(80ul) and the sections were 
placed in a perspex levelling tray and left for one
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hour. Further washing was then carried out with T.B.S. 
for five minutes prior to 80ul of a 1:100 dilution of 
the second antibody (rabbit anti-rat for ICR2 or rabbit 
anti-mouse for C46, Dakopatts, Sweden) in T.B.S. being 
applied to each section for 30 minutes. After this 
period the slides were again washed for 5 minutes in 
T.B.S. and the sites of bound antibody revealed by 
application of the chromogen 3-3 diaminobenzidine 
tetrahydrochloride (DAB) which was made up as follows : 
lOOmg D.A.B.
200mls TRIS/ HCL buffer pH 7.6
2mls 1% H2O2 =100ul H2O2 (30% w/v) + 2.9mls
distilled water.
Slides were placed in this solution for ten 
minutes then washed in T.B.S. for one minute, running 
water for five minutes and then stained in Mayer's 
Haemalum (BDH chemicals, Poole) for two minutes. After 
placing briefly in running water the slides were 
cleared by dipping briefly in saturated lithium 
carbonate and then washed in tap water for five 
minutes. Sections were then dehydrated by three periods 
of three minutes in absolute ethanol followed by a 
similar period in xylene. Finally the slides were 
mounted in DPX (BDH, Poole, Dorset). Using this 
technique antigen binding sites appear brown and non 
antigen expressing tissues blue.
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2.2.±1) System for grading antigen expression
In the preliminary studies in this chapter (2.3. i
and ii) the antigen expression was simply graded as
either positive if staining was present or negative if
it was not. In the subsequent and more detailed studies
carried out (2.4 and 2.5) immunocytochemical staining
of the tissues was categorised using a system for
grading similar to that of Ellis et al(2^). Using this
system the percentage of cells within the histological
section which express the target antigen is measured by
two independent observers and classified as shown
below. This system for grading antigen expression on
immunocytochemical staining has been shown previously
to be both consistent and reproducible when applied to
breast cancer tissue stained with the MAb NCRC-11(2^ ).
Grade 1 : <25% cell stain
Grade 2 : 25-50% cell stain
Grade 3 : 50-75% cell stain
Grade 4 : >75% cell stain
Controls consisted of sections known to express 
the target antigen (+ve control) and sections where 
either the first antibody or both first and second 
antibodies were omitted (-ve control). These controls 
were included with each batch of immunocytochemistry. 
Where two different antigens were compared in the same 
tissue sections the antibodies were used at the same 
concentration (titre) and the reaction times were 
standardised. The staining pattern was described as 
membraneous where staining was present only at the cell 
membrane and cytoplasmic where the body of the cell
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showed positive staining. In occasional sections with 
both MAb's the connective tissue of the section showed 
faint staining. This was avoided by the application of 
human serum to the sections (1 in 50 dilution in 
phosphate buffered saline (PBS)) before applying the 
first antibody.
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2.3. PRELIMINARY STUDIES ON CEA AND EMA EXPRESSION IN 
COLORECTAL NEOPLASIA AND NORMAL COLON
2.3.±) EMA expression
Immunoperoxidase staining with ICR2 was carried out 
on 17 primary colorectal cancers, 5 lymph node 
metastases, three liver metastases, 9 colonic 
adenomatous polyps and three sections of normal colon. 
The pattern of staining was membraneous and therefore 
more apparent in areas of gland formation within the 
cancers and metastases (Figure 2.1.). ICR2 reacted with 
15 of the 17 primary colonic cancers(88%) and in 6 of 8 
metastases(75%). No staining was noted on normal colon 
and in only one of the nine adenomatous polyps, this 
corresponded with an area of severe dysplasia.(Table 
2.1. )
2.3.±±) Comparison of CEA and EMA expression
Sections of primary colorectal cancers (n=18), 
lymph node metastases (n=6), liver metastases (n=7), 
benign adenomatous polyps (n=14) and normal colon 
(n=17) were prepared and stained as outlined above. 
Consecutively cut sections were used to determine the 
expression of CEA and EMA and the results again 
classified as either positive or negative.
The results presented in Table 2.2. show that CEA 
was expressed by a greater number of primary cancers 
than EMA. Typically both antibodies gave staining of
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the cell membrane which was strongest in areas of gland 
formation( Figures 2.1. and 2.2.). In a few specimens 
the primary tumours were found to give intracellular 
staining either alone or in addition to membraneous 
staining. Metastatic deposits showed a similar pattern 
of expression of both EMA and CEA than the primary 
cancers. CEA was expressed by the majority of 
adenomatous polyps and normal colon sections whereas 
EMA expression was seen only occasionally in normal 
colon and in adenomatous polyps only in areas showing 
severe dysplasia.
Figure 2.1. : The expression of EMA in a colorectal cancer section.
Sites of antigen binding are stained brown (indirect 
immunoperoxidase x 200)
Figure 2.2. : The expression of CEA in the same colorectal cancer 
section. Antigen binding sites are again stained 
brown (indirect immunoperoxidase x 200)
Table 2.1. EMA expression in normal colon and colorectal 
neoplasia
Tissue No. of samples EMA expression 
No. +ve %
Carcinoma 17 15 88
Metastases 8 6 75
Polyps 9 1 11
Normal colon 3 0 0
Table 2.2.: Comparison of CEA and EMA expression in
normal colon and colorectal neoplasia
Staining reaction 
EMA (ICR2) CEA(C46)
Tissue Number No. +ve % No. +ve %
Carcinoma 18 15 83 18 100
Nodal metastases 6 5 83 5 83
Liver metastases 7 5 71 4 57
Polyps 14 1 7 11 79
Normal colon 17 2 12 12 71
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2.4. RELATIONSHIP OF CEA AND EMA EXPRESSION WITH 
HISTOPATHOLOGICAL VARIABLES
Patients
Over a one year period 51 consecutive patients 
undergoing a potentially curative resection of a 
colorectal carcinoma in a single unit were studied. 
There were 26 males and 25 females with a median age of 
68 years (range 26-90).
Specimens
All specimens had been examined conventionally 
with H & E  staining prior to immunohistochemical 
examination, both procedures being carried out by 
independent investigators and the results subsequently 
compared. A total of 52 specimens of primary colorectal 
cancer were studied, one patient having two synchronous 
carcinomas. The expression of CEA and EMA was also 
determined in the adjacent normal colon in 45 resected 
specimens ; in 11 adenomatous polyps found in the 
resected specimens and in a total of 49 lymph node 
metastases present in specimens from 20 patients.
The antigen expression was measured by the indirect 
immunoperoxidase staining method and the staining 
reactions graded as described earlier (2.2.ii).
93.
Results 
Histopathological examination
Six tumours were classified as Dukes stage A, 26 
stage B and 20 stage C. Twenty seven tumours were well 
differentiated, 22 were moderately differentiated and 
three were poorly differentiated. Fifteen of the 
primary tumours were in the right colon (caecum, 
ascending and right transverse), 22 were in the left 
colon (left transverse, descending and sigmoid) and 15 
were in the rectum. The percentage of well and 
moderately differentiated cancers was similar in the 
right (47% and 40%) and left (55% and 41%) colon and in 
the rectum (53% and 47%)(all n.s.). Forty-nine 
metastatic deposits from 20 patients were found on 
examination of 249 lymph nodes. Of the eleven polyps 
six were tubular and five tubulo-villous adenomas.
Immunohistochemical examination 
Primary cancers
The staining pattern was similar for both the 
anti-CEA and anti-EMA antibodies, being membraneous and 
most pronounced in areas of tumour with gland 
formation. A cytoplasmic staining pattern was 
occassionally seen with both antibodies. Some 
heterogeneity of antigen expression between 
different areas within any individual section was noted 
with both antibodies.
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All 52 primary colorectal cancers stained positively 
for CEA whereas 43 of the 52 sections stained 
positively for EMA (83%)(Table 2.3.). The grade of 
immunohistochemical staining of the tumours (Figure
2.3.) was higher with the anti-CEA antibody than anti- 
EMA in 39 (75%), equal in 11 (21%) and less in two 
(4%). Tumours graded 3 and 4 for CEA expression were 
more commmonly well rather than moderately 
differentiated (23 of 27 vs 11 of 22, p< 0.01, test) 
(Figure 2.4.). No correlation was found between the 
staining pattern with anti-EMA and the degree of tumour 
differentiation (Figure 2.5.). Of the eight tumour 
samples with no detectable EMA expression three were 
moderately and five well differentiated.
The grading of CEA expression varied with the site 
of the primary tumour, right sided colonic tumours 
showing less evidence of CEA expression than left 
sided. Six of the 15 right sided lesions were graded 1 
(<25% cell stain) whereas only two of the 37 lesions
9
in the left colon and rectum were graded 1 (p<0.01,X 
test)(Figure 2.6.). Equivalent figures for EMA 
expression were 3 of 15 in the right colon and 6 of 37 
in the left colon and rectum (n.s.)
Lymph nodes
All nodal metastatic deposits showed staining for 
CEA. Forty-five of the 49 metastases from 20 colorectal 
cancer specimens stained positively for EMA (92%), a
Table 2.3.: Comparison of CEA and EMA expression in
tissues from a consecutive series of patients 
undergoing colorectal cancer resection
Tissue Number EMA +ve(%) CEA +ve(%)
Primary cancers 52 43 (83) 52 (100)
Nodal metastases 49 45 (92) 49 (100)
Adenomatous polyps 11 0 (0) 11 (100)
Normal colon 45 0 (0) 29 (64)
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similar proportion of positive staining as was seen in 
the primary tumours from this group(95%).
Adjacent normal colon
A membranous pattern of staining involving the 
luminal surface of the colonic mucosa was found in 29 
of the 45 specimens of normal colon (64%) stained with 
the anti-CEA antibody whereas none of the sections 
showed evidence of EMA expression. There was no 
correlation between CEA expression of normal colon and 
the immunohistochemical grading of the adjacent 
cancers. Of the 29 sections of normal colon expressing 
CEA, 20 of the associated cancers were graded 3 or 4 
for CEA expression (69%), whilst for the 16 sections of 
normal colon which did not express CEA 11 of the 
adjacent cancers were graded 3 or 4 (69%). The group of 
patients with both a colonic carcinoma and adenomatous 
polyp, however, more commmonly expressed CEA in their 
normal colon than those with a carcinoma alone although 
this trend was not significant (8 of 9(89%) vs 21 of 
36(58%), test, n.s.).
Adenomatous polyps
All of the polyps examined showed strong (grade 3- 
4) expression of CEA with a luminal membrane staining 
pattern similar to that of normal colon. None of the 
polyps expressed EMA.
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2.5. CEA AND EMA EXPRESSION IN THE DETECTION OF OCCULT 
LYMPH NODE METASTASES IN PATIENTS WITH COLORECTAL 
CANCER
Patients and tissue sampling
The study was carried out on 47 of the 51 
consecutive patients undergoing resection of colorectal 
carcinoma over a one year period. One patient had two 
synchronous carcinomas resulting in 48 specimens. The 
primary cancers and the regional lymph nodes were 
examined conventionally by an experienced 
histopathologist prior to immunohistochemical 
examination of the lymph nodes. The two procedures were 
carried out independently on sections from the same 
tissue blocks and the results compared.
Stained sections were scanned at low power(xlO) and 
only when areas of CEA or EMA expressing cells were 
localised were these examined at high power(x25) in 
order to examine their cell morphology in more detail.
Results
Histological examination
Of the 48 colorectal cancer specimens four were 
staged as Dukes A, 24 Dukes B and 20 Dukes C, with 25 
showing well, 20 moderate and three poor cell 
differentiation.
A total of 249 lymph nodes were examined by 
conventional light microscopy. There was a median 
number of five per patient (range 2-11)(Figure 2.7.).
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Figure 2.7.: Number of lymph nodes examined per specimen
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No significant correlation was found between the number 
of lymph nodes examined and the site or Dukes stage of 
the primary tumours (Tables 2.4. and 2.5.). Of the 249 
lymph nodes examined by H & E staining, 49 (20%) 
contained tumour deposits and 200 were free of 
metastases(80%).
Immunohistochemical examination
All control sections produced the expected staining 
reaction or the batch of slides were restained. With 
both antibodies occasional plasma cells and macrophages 
within the regional lymph nodes showed evidence of 
positive staining. These were distinguished from 
malignant cells by their morphology.
Using C46, the anti-CEA, all metastases detected by 
H&E staining were shown to express CEA. Of the 200 
lymph nodes reported as normal metastatic tumour was 
found in a single lymph node after immunocytochmical 
examination with anti-CEA, altering one patients Dukes 
staging from B to C.
On immunocytochemical evaluation with anti-EMA all 
but four of the lymph node metastases detected by H&E 
showed a positive staining reaction(92%). None of the 
200 lymph nodes classified as normal on conventional 
light microscopy had occult metastases detected on 
immunohistochemical staining with anti-EMA.
Table 2.4. : Number of lymph nodes examined by tumour site
Site Number of specimens Number of nodes 
Median Range
Right colon 15 5 2-10
Left colon 19 4 2-10
Rectum 14 5 3-11
Table 2 .5.: Dukes staging and the number of nodes examined
Dukes stage Number of specimens Number of nodes
-
Median Range
A 4 3 2-6
B 24 5 2-10
C 20 4 2-11
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2.6. DISCUSSION
In the preliminary study on the reaction of the 
anti-EMA antibody ICR2 with colorectal cancers (2.3.i), 
a similar pattern of staining was found as that 
previously reported with anti-EMA M A b ( ) and with 
polyclonal a n t i s e r u m  (^1)# Although the majority of 
cancer specimens examined expressed the target antigen 
some heterogeneity was noted between different areas 
within any individual specimen, a finding in common 
with other tumour antigens The expression of EMA
by the cancers and not by normal colon suggested a 
possible role for ICR2 as a tumour marker in 
colorectal cancer and led to a comparison with CEA, the 
most widely investigated marker in colorectal 
cancer(2.3.ii). Comparing CEA and EMA in normal colon 
and colorectal neoplasia demonstrated that a higher 
percentage of colorectal cancers expressed CEA than EMA 
but that the pattern of staining and hence the 
distribution of antigen expression in the cancers was 
similar. Of particular interest was the lack of 
specificity of staining of anti-CEA in comparison to 
anti-EMA and the expression of EMA only in adenomatous 
polyps showing dysplasia.
The clinical and pathological variables in the group 
of patients studied in Section 2.4. are fairly 
comparable with those in a large prospective study on 
colorectal c a n c e r ^ ^ ^ ^ ) . Although the age 
distribution was similar the present group had a lower
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male to female ratio (26 of 51 vs 506 of 709, X^=9.3, 
p<0.001) and a greater proportion of cancers that were 
well differentiated (27 of 52 vs 203 of 709, X^=12.4, 
p<0.001) and a lower proportion that were moderately- 
differentiated. (22 of 52 vs 443 of 709, X^=8.2, 
p<0.01) Otherwise there were no significant differences 
in the Dukes staging or the site of the cancers.
The immunohistochemistry results supported the 
findings of the provisional studies by the investigator 
(248) ancj others (90,207) that CEA is expressed by all 
primary colorectal cancers and EMA in over 80%.
The grading system employed in this study allowed 
cancers to be compared by their expression of tumour 
antigens. Although grading systems may be critisised 
for their semi-quantitative nature the system selected 
for use in the present study has been successfully 
applied to the antigenic expression of breast cancers 
(244) an(j been objectively assessed and found to be 
reproducible (^5).
A correlation between CEA expression in colonic 
carcinomas and their degree of differentiation has been 
suggested, but the evidence as to whether CEA 
expression is greater in well or poorly differentiated 
tumours is conflicting(249-252). gradi.ng has shown
CEA expression to be greater in well rather than 
moderately differentiated cancers. CEA expression in 
the present study was also greater in distal than 
proximal colonic cancers, which was not a reflection of
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differences in tumour differentiaton by site. A similar 
increase in CEA expression has been noted previously in 
distal compared to proximal cancers in the 
gastrointestinal tract (235) kut scanty evidence exists 
of similar differences within the length of the colon. 
Normal tissue antigens such as mucins or blood group 
substances may either increase( )  Qr decrease 
(254,255) from proximal to distal. No relationship was 
found in the present study between the EMA expression 
of tumours and either their degree of differentiation 
or site.
CEA was expressed by all primary cancers and all 
nodal metastases. EMA was expressed by fewer cancers 
and a similar number of metastases. This is at variance 
with the findings of a previous study which suggested 
that metastases may have an enhanced expression of 
ema(125).
The pattern of CEA expression found in normal 
colon was similar to that of adenomatous polyps with 
a linear staining of the luminal membranes. These 
results are consistent with other studies showing that 
CEA is a normal product of colonocyte differentiation 
and may be extracted from normal adult colon (256,257)^ 
In this study EMA expression was not found in either 
the normal colon, which in all cases was sampled 
adjacent to the cancer, or in benign adenomatous 
polyps. This conflicts with previous results suggesting 
either a weak positive staining of normal colon for EMA
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(238) or ^ts expression only in normal colon adjacent 
to neoplasia or inflammation(). Such differences may 
be explained by the cross reactivity of polyclonal 
antibodies used in previous studies compared with the 
specificity of the anti-EMA MAb used in the present 
study. Of interest was the increased expression of CEA 
by the adjacent normal colon of patients in whom both a 
benign adenomatous polyp and colorectal cancer were 
present in comparison to those with a carcinoma alone. 
Although not statistically significant this trend may 
reflect a field change in the adjacent normal colon in 
these patients.
The antigenic expression of tumours and their 
metastases is vital information if antibodies to tumour 
associated antigens are to be considered for use in 
radioimmunolocalisation or for the targeting of 
radionuclides, drugs or toxins for therapeutic 
purposes. It is well recognised that tumour antigen 
heterogeneity is the rule rather than the exception 
(154) ancj £n this study heterogeneity of antigen 
expression was again noted with anti-CEA and anti-EMA 
within different portions of a given tumour and between 
primary and secondary tumours.
From this study we may conclude that CEA and EMA 
have a similar pattern of expression in primary 
colorectal cancers and their nodal metastases although 
EMA expression is more restricted than CEA. Normal 
colon and adenomatous polyps express CEA but not EMA.
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This pattern of antigen expression may be of clinical 
significance, MAb's to CEA or EMA could be selected for 
use in imaging or therapy depending on the 
immunocytochemical staining of tumour biopsies.
In the study on the use of anti-CEA as well as 
anti-EMA in the detection of lymph node micrometastases 
the eventual tumour staging was altered in one patient 
by using immunohistochemistry in addition to light 
microscopy for the detection of lymph node metastases. 
This result is similar to that of a previously reported 
study where anti-CEA was used alone in the detection of 
micrometastases(^1). In contrast a recent report, again 
using anti-CEA, showed that metastatic deposits could 
be detected in the regional lymph nodes of up to 25% of 
the colorectal carcinoma patients examined (92) #
The reason for the significantly higher rate of 
detection in the second study is not clear but the 
number of lymph nodes examined may be a crucial factor. 
Neither of these studies, however, appears to have 
employed techniques to facilitate the lymph node 
harvest such as mesenteric fat clearance (258)# 
Similarly the number of sections taken of the lymph 
nodes sampled may be important. In this study a single 
section of each lymph node was examined as is routinely 
practised for H&E microscopy. Sampling a single section 
of each lymph node, however, will result in some small 
metastases being missed independent of the 
staining method used for their detection (259)^
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In the present study some cross reactivity with 
normal plasma cells and macrophages was observed with 
both antibodies, a problem noted by Cutait, and others 
in previous immunocytochemical studies using antibodies 
to CEA and EMA (92,206,260,261 Qare was taken during
the present investigation and that of Cutait and 
colleagues to confer a malignant diagnosis on antigen 
positive cells only if the morphology was that of 
neoplastic cells.
The overall results of the present study would not 
suggest a useful role for carrying out 
immunohistochemistry on lymph node sections as 
routinely assessed by H & E examination. In fact with 
EMA the diagnostic yield was worse than with H & E  
staining. The detection of metastatic deposits may well 
be significantly improved, however, by a) sampling a 
larger number of lymph nodes from each specimen; b) 
examining multiple sections of each node; c) using a 
panel of MAb's including those against other tumour 
associated antigens which have been shown to be 
expressed by colorectal cancers (83,88)^ rphe detection 
of occult tumour deposits in the regional lymph nodes 
by such means in patients previously thought to have 
Dukes stage A or B tumours may explain relapses seen 
following apparently curative resections.
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3.1. INTRODUCTION
Whether or not a tumour associated antigen is shed 
into the circulation has important implications for the 
clinical use of MAb's to that antigen in patients with 
cancer. It may be useful as a circulating tumour marker 
if levels reflect the presence or absence of cancer. 
Conversely it may be a disadvantage for therapeutic use 
or radioimmunolocalisation if immune complexes are 
formed.
The role of circulating tumour markers in colorectal 
cancer has already been summarised (1.3.i). Post­
operative levels of CEA at present is of established 
clinical value in the detection of recurrent colorectal 
cancer (57,71,72)^
Circulating levels of EMA (1.5.i) have been 
investigated principally in patients with ovarian 
(210,213) ancj breast cancer (209,211,212,213) although 
a recent study has included a group of patients with 
colorectal cancer (2-^)# These studies have shown 
detectable levels of antigen in most normal control 
patients and significant elevations only in patients 
with advanced cancer. Of the 33 patients with 
colorectal cancer analysed by Ashorn and colleagues 
(213) oniy one ba(i a level above that of controls. 
Although these studies have not so far established a 
useful clinical role for EMA as a tumour marker the 
circulating antigen detected by the various MAb's 
raised to EMA would appear to be markedly different.
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Ceriani (262) isolated antigens of 46, 70 and 150kD MWt 
whereas Burchell (209) isoiated antigens of 190, 230, 
280 and 320kD. These circulating antigens are 
significantly smaller than the 400kD MWt EMA antigen 
isolated and characterised by Ormerod from human breast 
milk (208). This would suggest that only a portion of 
the EMA molecule is shed from normal or tumour tissue 
into the blood. Monoclonal antibodies which recognise a 
single epitope on the EMA molecule may or may not, 
therefore, recognise all of the fragment which is 
secreted. This may explain the wide variation in the 
reported levels of circulating antigen depending on the 
particular anti-EMA MAb used.
In this study a competitive binding assay employing 
a newly developed rat antibody raised in the rat to 
MFGM has been employed to analyse the serum of patients 
with breast and colorectal cancer as well as a small 
group of other cancers for the presence of circulating 
EMA. The purpose of this investigation is to determine 
whether the antigen recognised by ICR2 is shed into the 
circulation to be of value as a tumour marker or to 
interfere with radioimmunolocalisation.
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3.2. MATERIALS AMD METHODS 
3.2.1) Serum samples
Serum samples obtained from four groups of patients 
were studied. The groups comprised ;
A : 31 patients with colorectal cancer.
B : 52 patients with breast cancer.
C : 43 age matched controls
D : 9 patients with other forms of cancer
(pancreas x 2, gastric x 1, lung x 1, oesophagus x 5).
Samples of serum were taken from patients at 
University College Hospital with colorectal cancer 
prior to undergoing surgery, samples being stored at 
-20°C until the assay was carried out. Sera from 
patients with breast cancer had been snap frozen and 
were obtained from the liquid nitrogen bank of the 
Royal Marsden Hospital, Sutton, Surrey and comprised of 
sera taken from patients since 1974. The control sera 
were obtained from the National Blood Transfusion 
Service and consisted of Hepatitis B surface antigen 
and Human Immunodeficiency Virus (HIV) screened samples 
taken from blood donors spanning a similar age range as 
the cancer patients. The samples were again stored at 
-20°C until used. The age and sex of these patients is 
given in Table 3.1.
3.2. ii) Monoclonal antibody
The monoclonal antibody ICR2 was used throughout 
these studies. It has been described previously(1.6.i)
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3.2.±ii) Radioimmunoassay(RIA) for EMA
A competitive binding R.I.A. was developed to detect 
the EMA antigen in serum using the rat anti-EMA 
monoclonal antibody ICR2. A purified preparation of EMA 
was prepared from human breast milk by the method of 
Ormerod et al,(^®8) the preparation containing 
16.9ug/ml of protein. Microtitre 96 well PVC plates 
were coated with antigen (50ul/well of a 1/400 dilution 
of EMA in P.B.S. at pH 8.0) by incubation overnight at 
4°C, then washed and blocked by addition of 200ul/well 
of P.B.S. with 0.5% bovine serum albumin (PBS-BSA). 
Using a seperate 96 well microtitre plate doubling 
dilutions of duplicate 30ul aliquots of each serum 
sample (centrifuged after thawing to remove debris) 
were prepared and an equal volume (containing 4xl04 cpm 
125i) Qf 125i_iCR2 (labelled by the Iodogen method 
(119) to gj[ve a specific activity of lOuCi/ug) added. 
Aliquots of 50ul of these mixtures were transferred to 
the EMA coated PVC plates, incubated for one hour at 
18-20°C then washed with PBS-BSA. Bound 125i was 
determined by counting individual wells in an Innotron 
Hydragamma 16 well counter.
A standard curve (Figure 3.1.) was prepared using 
doubling dilutions of EMA (starting concentration 
lOug/ml) mixed with equal volumes of ^^I-ICR2 and 
processed as described for the serum samples.
Semilogarithmic plots of percentage maximum counts 
bound versus serum dilutions were prepared and the
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concentration of EMA-like material present in the sera 
was determined from the standard curve for dilutions of 
serum that lay on the straight portion of the semi-log 
plots.
Results
The ranges of serum EMA levels in the four groups of 
patients is shown in Table 3.2. and depicted in Figure
3.2.
The median values of all patient groups was similar 
at 570-655 ng/ml. No significant differences were found 
between these groups using a Mann Whitney U test.
EMA levels > 5000ng/ml were found in five patients, all 
of whom had cancer (oesophagus x 2, lung x 1, colon x 1 
and breast x 1). In the control group the mean levels 
of EMA were found to be similar in males (540+/-380) 
and females (850+/-808)(meant/- S.D.). Five patients in 
the control group had an EMA level >1000ng/ml of whom 4 
were females (80%) whereas 19 of the 38 patients with 
EMA levels < lOOOng/ml were females (50%). This 
difference did not achieve statistical significance (X 
= 1.74). The EMA levels are given for each patient 
within the groups in Appendix 3.1. and for the "other 
cancers" in Table 3.3.
Table 3.1. : Patient details
Patient group Number Age
median(range)
Sex
M F
Colorectal cancer 31 74(51-87) 11 20
Breast cancer 52 59(33-81) 0 52
Controls 43 54(49-64) 21 22
Other cancers 9 72(44-82) 2 7
Table 3.2. : Serum EMA levels (ng/ml)
Controls Colon Ca Breast Ca. Other Ca.
Number 43 31 52 9
Minimum 90 60 210 120
Maximum 3240 8530 13300 67400
Range 3150 8470 13090 67280
Median 570 580 655 580
Mean 714 830 1003 9542
SE * 93 262 249 7312
S.D.** 609 1462 1801 21937
* Standard error of the mean
** Standard deviation
Table 3.3. : EMA levels in other cancers
EMA level (ng/ml)
185
580
220
9720
580
67400
120
1720
5360
Cancer
Pancreas
Pancreas
Stomach
Lung
Oesophagus
Oesophagus
Oesophagus
Oesophagus
Oesophagus
log
 
[E
MA
] 
ng
/m
l 
x 
10
0
1000
100
• • •••
0*
o*
©•
•••
0 controls colon ca. breast ca. other ca.
Figure 3.2. Serum EMA levels
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3.4. DISCUSSION
The normal control population in this study has 
been found to have detectable levels of circulating EMA 
which is in keeping with previous reports (262,209,213 
The range of normal levels, however, of 90-3240ng/ml is 
wider than those previously reported with a greater 
than 30 fold difference within the group. This may 
reflect important differences in the control group 
sampled. In the present study we measured EMA levels in 
serum samples from age matched patients obtained from 
the blood transfusion bank whereas Ceriani^2^2) 
selected 13 healthy subjects, Burchell(2®^) 30 healthy 
women and A s h o r n ( 2 1 ^) 52 healthy female medical 
students. The control group is therefore better matched 
for comparison with the cancer patients although occult 
malignancy cannot be excluded in this age group. An 
additional factor which should be considered is the 
strong expression of EMA by breast and ovarian tissues 
which would suggest that EMA expression may vary within 
the menstrual cycle or alter after the menopause.
Levels of the breast cancer antigen MAM 6 have been 
shown to be elevated during the third trimester of 
pregnancy (2-*-2). in the present investigation no 
significant differences were found between the levels 
of circulating EMA in males and females. In the control 
group, however, a greater number of patients with EMA 
levels >1000ng/ml were females compared to 
patients with levels <1000ng/ml. This difference, 
however, did not achieve statistical significance.
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There was no difference in MAM 6 levels noted between 
males and females in the control group of Hilkens and 
only a small intra-patient variation in samples taken 
over a one year period, (212
Patients with breast cancer were studied as they 
have previously been shown to have elevated HMFG 
antigen levels (209,213,262)^ These studies have mainly 
demonstrated elevated levels only in patients with 
advanced disease(209) whiie those with localised 
primary disease had normal levels (213,262 )^ In .^e 
present study the serum samples from the patients with 
breast cancer were taken at presentation at the 
hospital out-patient clinic and therefore will include 
both patients with primary and those with metastatic 
disease. In view of the similarity in EMA levels 
between the breast cancer patients and the controls it 
was not considered worthwhile to compare EMA levels 
with the stage of disease. Differences reported in the 
levels of circulating EMA between previous studies and 
the present investigation would be most readily 
explained if the majority of breast cancer patients 
in the present study had localised disease. The 
possibility remains, however, that some patients do not 
shed the portion of EMA recognised by ICR2 into the 
circulation.
Another possible cause of discrepancy between the 
present results and those of the previously mentioned 
studies is the methodology for the detection of 
circulating antigen. The methods usually employed
112.
utilise MAb coated plates or beads for capturing the 
suspected antigen in serum which is then detected by 
the use of a labelled second antibody which recognises 
a different epitope (210,211,213,262)  ^ These methods 
differ significantly from that employed in the present 
study in which putative antigen in serum competes with 
antigen in the serum for binding of applied ICR2-^^I. 
Because of differing methodologies employed the results 
of these serum assays may not be strictly comparable.
Despite the demonstration of the presence of EMA on 
the majority of colorectal cancers (Chapter 2) the 
sera from patients with this disease did not differ 
significantly in "EMA" content from those of the 
controls. Other studies have also suggested that 
circulating EMA levels are rarely elevated in patients 
with colorectal cancer eg. Ashorn and colleagues 
found an elevation in only 1 of 33 patients(^ ^ ), 
Hilkens in 4 of 19 (212) ancj jjayes i Qf 49 (211)^ The 
latter group also included 25 patients with liver 
metastases which would suggest that the normal level is 
not due to the removal of antigen from the portal 
circulation by the liver. With CEA Tabuchi has 
demonstrated significantly higher levels in the portal 
vein than in the peripheral circulation and has shown a 
strong correlation between the level and degree of 
venous invasion of the tumour (^63)# similarly the 
measurement of peripheral and portal venous EMA levels 
would be required to establish whether the liver is
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involved in EMA metabolism. It seems likely, however, 
that even when large bulk disease is present the amount 
of EMA shed by colorectal cancers is insufficient to 
affect the overall level in blood produced by other EMA 
expressing tissues (201,207)^
These findings may have important implications on 
the use of radiolabelled MAb's to EMA for the detection 
of colorectal cancer and their metastases by 
immunoscintigraphy (Chapter 5). It would be expected 
that patients with high circulating levels of antigen 
would form immune complexes and reduce the level of 
radiolabelled antibody reaching the cancer. In animal 
models with cancer xenografts secreting CEA this has 
been supported with higher CEA secretion being 
associated with higher clearance of activity by the 
liver and reduced tumour uptake . (264). ^his has been 
contested in patient studies in which satisfactory 
tumour imaging with anti-CEA has been achieved despite 
high circulating CEA levels (^).
The group of other cancers analysed by this assay 
has produced some interesting elevations in EMA levels. 
Four of the 9 patients in this group had EMA levels > 
lOOOng/ml. Of these 4 patients 3 had oesophageal and 
one a bronchial carcinoma. Few reports on the EMA 
levels in either group of patient are available. Ashorn 
in 4 and Hayes in 7 patients with oesophageal cancer 
reported no increase in EMA levels. Further 
investigation of EMA levels in these patient groups
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would be interesting.
In conclusion some patients with breast, colonic and 
other forms of cancer have EMA levels above the normal 
range of healthy controls. The majority, however, have 
levels within this normal range which would suggest 
that EMA is unlikely to be useful as a circulating 
tumour marker.
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4.1. INTRODUCTION TO THE PROBLEM
The greatest limitation to the use of radiolabelled 
monoclonal antibodies for the imaging of cancers and 
their metastases is the level of background radio 
activity. This uptake by normal tissues reduces the 
signal to noise ratio given by the tumour and the 
ability to detect the cancer.
The problem is encountered independent of the 
antibody used(^®) although different radioisotopes 
result in differences in the uptake of activity in 
normal organs (-265,266) ^
With iodinated antibodies their persistence in the 
blood pool rather than in organs is the major problem 
and has required the use of blood pool subtraction 
techniques to clarify the images obtained. This may 
result in false positive images (122,123,131) ancj may 
explain the high incidence of tumour localisation in 
early imaging studies (97). in addition, the rapid 
tissue dehalogenation reduces the activity persisting 
in the target tissues and results in a high urinary 
excretion of the radiolabel. Other sources of 
background radio-activity include the secretion of 
radioiodine by the gastric mucosa and uptake in thyroid 
tissue despite the use of blocking agents.
A satisfactory alternative to radioiodine and at
present the radionuclide of choice for antibody imaging
illis xx In. It has a more suitable energy of emissions 
for gamma camera imaging and forms stable complexes
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with proteins via chelating agents *(126-129A high 
level of non specific uptake, however, has been 
reported in studies carried out with mIn-MAb 
(102,105,106,125 )^ iphe main site of uptake is the liver
and to a lesser extent the spleen, bone marrow and 
testes. This non specific uptake is of particular 
relevance in the imaging of colorectal cancers. The 
most common site of primary neoplasms, namely the 
rectum and sigmoid colon, may be obscured by uptake in 
the bony pelvis. Nodal deposits, with a smaller uptake 
of radiolabel, would anatomically tend to overlie 
midline abdominal structures of the great vessels and 
lumbar spine, both of which have high non-specific 
activities.
By far the major contributor to background activity
illwith In-MAb is the liver. Organ dosimetry
illcalculations in patients following J"L-L In-MAb 
administration would suggest that one third of the 
injected activity may have accumulated in the liver 24 
hours after administration, This accumulation of
activity in normal liver is so considerable that the 
detection of liver metastases following the 
administration of In-MAb is usually based on the in­
filling of cold areas on early scanning images (106) or 
on the use of a tin colloid liver scan for digital 
subtraction (102). ^ his accumulation of activity also 
affects the ability to image extra-hepatic deposits if 
these lie near the liver or within the same imaging 
field and results in the liver being the dose limiting
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ill
factor for the administration of xxxIn labelled MAb's.
The optimum radioisotope for use in antibody- 
imaging (Ulln) is therefore limited by its organ 
uptake, principally into the liver. Two mechanisms have 
been suggested to explain this non-specific 
accumulation. Firstly uptake by the macrophages of the 
reticuloendothelial system and secondly uptake into 
hepatocytes via transferrin receptors.
4.1.i) The reticuloendothelial system (RES)
The main sites of non specific uptake, namely the 
liver, spleen and bone marrow would suggest that the 
main route for the removal of radiolabelled antibodies 
is via the RES and that the removal of the circulating 
IgG is part of the body's natural defence mechanism to 
foreign proteins.
Macrophages of the RES have several receptors which
may recognise and bind the constant region of the Ig
molecule(Fc)(Figure 4.1.). This includes a receptor for
the binding of monomers and complexes of IgG and
another mediating endocytosis of antigen-antibody
complexes. Macrophages have a variety of other
receptors for complement, lymphokines, colony
stimulating factors, insulin, complex carbohydrates
such as asialoglycoproteins and iron containing
proteins. If macrophages are important to the clearance 
111of ■LJ"LIn-MAb from the circulation it seems likely it 
would be mediated via the Fc or carbohydrate receptors.
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Figure 4.1. The structure of IgG and its fragments
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The liver has been shown to be the principal organ 
responsible for the removal of immune complexes from 
the circulation of experimental animals (267,268 )^
The administration of antibodies which recognise and 
bind to an antigen which is secreted into the 
circulation may result in the formation of circulating 
immune complexes which are cleared from the blood by 
the liver via an Fc receptor mediated mechanism. In 
1985 Hagan demonstrated that the concentration of ^-^In 
in the liver following administration of ^-^In labelled 
anti-CEA antibody to mice with CEA secreting xenografts 
increased as the CEA secretory state of their tumours 
rose. Furthermore those with a high CEA secretion had 
decreased uptake of radiolabelled antibody by the 
tumour (264)^  In contrast to the findings of these 
animal experiments Goldenberg(97) reported that in 
patients undergoing imaging of colorectal cancers with 
anti-CEA the imaging of the tumours was satisfactory 
even in the presence of grossly elevated CEA levels.
The hepatic uptake of immune complexes (I.e.) is 
mainly thought to be a function of the hepatic 
macrophages or Kupffer cells which bear a surface 
receptor for the Fc portion of the IgG molecule (269, 
7^0). However, Fc receptors have also been shown to be 
present on the hepatocyte membrane (271) ancj Uptake 
of I.e. by hepatocytes has been demonstrated in immune 
a n i m a l s ^(272)# jn 1984 Sancho and colleagues assessed 
the binding kinetics of monomeric and aggregated IgG to 
Kupffer cells and the hepatocytes of mice. By isolating
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mouse hepatocytes and Kupffer cells following the 
administration of radiolabelled human IgG to mice they 
demonstrated that 60-70% of the liver uptake of 
radioactivity was recovered in hepatocytes. In-vitro 
the maximum number of IgG and aggregated IgG (A-IgG) 
molecules bound per cell was higher with hepatocytes 
(mean 14 x 10^) than on Kupffer cells (mean 2 x 10^) 
although the association rate constant for aggregates 
was higher for Kupffer cells than for hepatocytes 
(273)^ binding site was present on the constant
region (Fc) of the antibody (Figure 4.1.) as 
F(ab')2 fragments (Figure 4.1.) failed to inhibit 
labelled monomeric IgG or A-IgG. The receptor 
also appeared to be specific for IgG as unlabelled 
monomeric IgA did not inhibit the binding of labelled 
IgG or A-IgG.
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4.1.11) INHIBITION OF RETICULOENDOTHELIAL UPTAKE
If binding to Fc receptors is an important mechanism 
for the non specific clearance of MAb's this will have 
some important clinical implications. First it may be 
possible to block non-specific antibody uptake by the 
concomitant administration of either pooled human Ig, 
an antibody of the same isotype or unlabelled 
monoclonal antibody itself. Secondly the use of 
labelled F(ab')2 (Figure 4.1.) fragments which do not 
have an Fc sequence should overcome the problem 
altogether.
4.1.ii.a) The effect of administering pooled IgG
The effect on non-specific uptake of administering 
pooled human Ig before administration of labelled MAb 
was monitored in patients with melanoma by 
Carrasquillo .(243)^  patients were given 7.5g of 
pooled human Ig over the one hour prior to injection of 
^•^In labelled MAb (MAb 9.2.27). Although no 
measurements of tissue uptake using excised tissues 
were carried out the data obtained for plasma clearance 
and for serial imaging was similar to that seen in 
patients given lmg of radiolabelled antibody alone. 
Large amounts of radiolabel continued to accumulate in 
the liver, spleen and bone marrow. Pooled human Ig has 
previously been shown to effectively block Fc receptor 
binding (274) which would suggest that either the dose 
administered (7.5g) was insufficient to block Fc
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receptor binding or that this is not an important 
mechanism in producing non specific uptake of 
radioactivity.
4.1.ii.b) Unlabelled MAb
In another group of patients with malignant melanoma 
Carrasquillo (243) aiso analysed the effects on 
biodistribution of giving unlabelled Ig before the 
administration of labelled antibody. Five patients 
recieved 49mg and one patient 99mg of unlabelled 
antibody prior to administration of lmg of m I n  
labelled antibody. Five control patients recieved lmg 
of labelled antibody alone. No data for tissue uptake 
of radioactivity was presented but when unlabelled 
antibody was co-administered it was found to increase 
the half life in the blood and to reduce the uptake in 
the spleen and bone marrow. More importantly an 
increased number of tumour sites were localised.
The unlabelled antibody, however, did not have a 
significant effect on reducing liver uptake. The 
effects on blood pool distribution by the injection 
of unlabelled antibody or giving higher antibody 
dosages had been noted previously and termed the "mass 
effect" (130). rphe differences observed between the 
uptake in the liver and that of the spleen and bone 
marrow may suggest that the mechanisms of uptake vary 
in the different sites.
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4.1.ii.c) Antibody fragments
Antibody fragments retaining the antigen binding
specificity of the antibody but with loss of the Fc
portion can be produced by proteolysis (Figure 4.1.).
These fragments are either divalent F(ab')2 or
monovalent (Fab') if the disulphide bridge linking the
heavy chains is reduced. It may seem an obvious
solution to the problem of Fc receptor mediated uptake
of MAb's to use these fragments which maintain the
antibody specificity of the parent molecule without an
Fc portion, but their pharmacology is quite different
from that of intact immunoglobulin. While the smaller
size of F(ab')2 and Fab' fragments allow a more rapid
uptake of antibody into the tumour tissue compared to
whole antibody their half life is considerably shorter
(130)  ^ Fab' fragments are excreted rapidly in the urine
and are not, therefore, suitable for imaging. F(ab')2
labelled with -^^In show a rather surprising degree of
accumulation in the liver. Hnatowich^27^) reported a
rapid and persistent accumulation in the liver of
radioactivity amounting to 20% of the injected dose in
illcancer patients administered ■LJ"LIn labelled F(ab')2 
fragments of MAb CA19-9. Similarly Halpern and 
colleagues(^30) noted a persistently high hepatic 
uptake with In labelled F(ab')2 fragments of an 
anti-CEA MAb in patients and no obvious difference 
could be detected between scintiscans obtained with 
fragments or whole antibody. These studies would not
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suggest an important role for the Fc receptor in the 
clearance of ^^In labelled antibody.
4.1.ii.d) Isotype matched antibody
The administration of unlabelled prior to labelled 
antibody in the study of patients with malignant 
melanoma by Carrasquillo() increased the number of 
sites localised by external imaging. This would suggest 
that this procedure either increased uptake in tumour 
tissue or reduced background activity. Whether the pre­
administration of MAb of the same isotype but different 
specificity would have a similar or greater effect has 
not as yet been established.
4.1.iii) The role of the hepatocyte
Transferrin(Tf) is a circulating plasma protein
which has a high binding affinity for both Iron and
Indium. The administration of free 111In to patients
illresults in the immediate formation of In-Tf complex. 
This localises in and may be used clinically for 
detecting sites of malignancy( ) .  Similarly any
r
free Indium present in a preparation of 111In-MAB would 
become bound to plasma Tf and be removed by hepatocytes 
which have high levels of surface receptors for 
Tf (278,279 instability of the MAb-chelate-^-^In 
complex in vivo leading to the generation of free ^^In 
would also result in hepatocyte uptake via Tf 
receptors. This exchange of ^-^In from labelled
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antibody to circulating Tf has been calculated as being 
1.9% of circulating activity in mice with tumour 
xenografts(280) but as high as 9% per day in 
humans (275) _. Factors which may affect the stability of 
the complex and hence the rate of transfer from 
labelled antibody to Tf and liver uptake would include 
the number of chelate molecules bound per antibody 
molecule (^81) ancj the nature of the chelating agent, 
since recently introduced chelating agents show a 
reduction in the liver uptake of activity( ) .
The chelating agents commonly used for attaching
metallic radionuclides to MAb's are derivatives of
ethylenediamine-tetracetic acid (EDTA) and diethylene-
triamine-tetracetic acid(DTPA). These compounds have
illbinding affinities for J-LAIn which are of a similar 
order but slightly higher than that of Tf. Attempts 
have been made to reduce the transcomplexation of In 
by administering additional chelating agents. Goodwin 
(280) demonstrated that the administration of a "chase" 
dose of EDTA following the administration of 
radiolabelled MAb to mice facilitated the urinary 
excretion of activity. A similar study carried out by 
Ward(^^) investigated the effects on the 
biodistribution of ^*^^In-DTPA-M8 and ^Ga-DF0-M8 in 
mice of the chelating agents desferrioxamine (DFO), 
diethylenetriamine pentaacetic acid (DTPA), 
ethylenediamine-di(O-hydroxyphenylacetic acid)(EDHPA) 
and 2,2' dipyridyl(DIPY). All the chelating agents
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except DIPY altered the biodistribution of free ^^In
and ^^Ga but did not affect the tissue uptake of the
labelled antibodies.
Perhaps the most direct evidence of the importance
of hepatocytes to the liver uptake of activity 
illfollowing AAAIn labelled antibody administration was 
provided by Sands and colleagues( ) ,  who injected 
mice with ^^In labelled antibody with or without 
blockade of their reticuloendothelial system (RES) and 
found RES blockade to make no significant difference to 
liver uptake. The studies of Shochat^^) have
illdemonstrated that the activity following AAAln-MAB 
administration forms of a low molecular weight complex 
within the liver.
4.2. A MODEL FOR LIVER UPTAKE OF 111In-MAb
Despite the major clinical problems resulting from
111the liver uptake of AAAIn-MAb it is apparent from the
preceding discussion that the mechanism of uptake has
not been established and methods to reduce liver
accumulation have not as yet been determined. The
studies by Sands, Sancho and Shockat outlined above
would suggest that the low molecular weight complex
which accumulates in the liver following lllln-MAb
administration involves hepatocytes rather than the RES 
(241,240,273 )^
To investigate ways in which the uptake of ^^In-MAB 
by liver parenchymal cells may be reduced an in-vitro
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model has been developed which mimics the localisation
illof an intra-abdominal tumour with A AIn labelled MAb. 
This consists of freshly isolated rat hepatocytes and a 
cultured tumour cell line (MCF7), which expresses the 
specific antigen (EMA) identified by the monoclonal 
antibody ICR2. To these tissue cultures a variety of 
reagents have been applied to assess their efficacy in 
preferentially inhibiting the uptake of ^-^In-MAB.
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4.2.±) Materials and methods
4.2.±.a) Radiolabelled antibody
The rat MAb ICR2 was conjugated to the chelating
agent DTPA using the bicyclic anhydride (ccDTPA)(Sigma,
Poole, Dorset) at a molar ratio of 2:1 based on the
method of Hnatowich . At this ratio the conjugate
retained 90% of the immunoreactivity of unconjugated
ICR2. The antibody was labelled with -^^In (Amersham,
U.K.) by the method of Carrasquillo (243) ancj any 
111unbound •LJ"LIn separated by gel chromatography on
Sephadex G25. Using this method over 95% of the
radioactivity in the protein peak remained protein
bound on thin layer silica gel chromatography following
treatment with excess DTPA (lmmol for 15 minutes). In
all experiments the antibody was reacted with In at
illa ratio of lmg antibody to 2mCi AAInCl3, as used in
illpatient studies. The •LAXIn-ICR2 was applied to the 
cells to give a final concentration of approximately 2 
ug/ml. (Further description of conjugation and 
labelling procedures is given in Appendices 5.1.- 5.4.)
4.2.±.b) Isolation and preparation of cells
Hepatocytes were isolated from the rat liver by 
collagenase perfusion as follows ;
Male Wistar rats weighing less than 35Og were 
selected. The rats were anaesthetised by an 
intramuscular injection of 0.4mls of diazemuls 
(diazepam 10mg/2 mis. Kabivitrum, Uxbridge, U.K.)
followed by 0.4mls of Hypnorm (Fentanyl citrate, 
0.315mg/ml and Fluanisone lOmg/ml, Janssen animal 
health). An incision was made in the midline of the 
abdomen extending along both costal margins to fully 
expose the liver and abdominal organs. The bowel was 
retracted to one side and the portal vein exposed. 
Ligatures were passed round the portal vein and the 
vein was then cannulated (Braunule,18 gauge, B. Braun, 
Melsungen, Germany) the plastic sheath being held in 
place by the ligatures. Once completed the animal was 
killed by exsanguination by division of the inferior 
vena cava. The liver was removed suspended by the 
cannula in the portal vein and transferred to a 
perfusion cabinet which was preheated to 35°C. The 
liver was perfused for 10 minutes with Hanks balanced 
salt solution (at 35°C) before introducing the 
collagenase mixture (Table 4.1.) to which 200umol/l 
calcium chloride was added. After recirculation of this 
mixture through the liver for 20 minutes the liver was 
removed from the perfusion cabinet and "shaken out" to 
dislodge the cells. Any large aggregates of cells were 
divided by sharp dissection and the resultant cell 
mixture was then filtered through a coarse gauze into 
universal containers. The filtered cells were then spun 
in a centrifuge at 400 r.p.m. for two minutes. The 
supernatant was discarded and the cells which had been 
spun to the base of the universal container were 
resuspended in foetal calf serum and respun. The
Table 4.1. Composition of the collagenase perfusate
Collagenase (Type l)(Boeringer, Mannheim) 50mg
DNAase (Type IV) (Sigma) 5mg
RNAase(Type 1-A) (Sigma) 5mg
Soya bean Trypsin inhibitor E (Sigma) lOmg
These are dissolved in 20mls of Hanks balanced salt solution.
Table 4.2. Culture medium
RPMI 1640 (Gibco) 500mls
10% heat inactivated foetal calf serum (FCS) 50mls
Streptomycin (Sigma)(final concentration 50ug/ml) 27.5mg
Penicillin(Sigma) (final concentration 50units/ml) 30mg
Insulin (Sigma)2 x 10'^M 6mg
Under aseptic conditions the FCS was added to the RPMI medium by filtration 
through a 0.22um millipore filter(Millipore S.A., Molsheim, France). Antibiotics 
in the quantities shown above were added and mixed until dissolved.
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procedure of resuspending and spinning the cells and 
discarding the supernatant was then repeated a further 
six times. After the second spin the cells were 
filtered through a fine gauze and from the fourth spin 
onwards the procedure was carried out under aseptic 
conditions. After the final spin the cells were 
transferred to a sterile culture flask (Falcon,
Becton Dickinson) and an aliquot counted to assess cell 
numbers using a haemocytometer slide. After calculating 
the cell numbers, medium was added to the flask to 
produce a final cell concentration of 1 x 10  ^cells / 
ml. One ml of this cell suspension and 2 mis of RPMI 
1640 medium (Gibco, U.K.) containing 10% foetal calf 
serum and antibiotics (Table 4.2.) were plated onto 
sterile collagen coated plates (Falcon, Becton 
Dickenson) and left to adhere over a two hour period.
Experiments were carried out within 24 hours of cell 
isolation, previous experiments having shown > 98% 
viability of the isolated hepatocytes within this time 
period (2®4).
4.2.i.b) Tumour cell line
The human breast cancer cell line MCF7 was used. This 
cell line strongly expresses the EMA antigen recognised 
by the MAb ICR2. It also has good growth 
characteristics and forms a confluent monolayer. The 
cell line was grown in a culture flask in RPMI 1640 
medium which was enriched with 10% foetal calf serum 
and antibiotics (Table 4.2.). When the cells had grown
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to confluence they were removed from the flask by 
trypsinisation, washed three times and then resuspended 
in sufficient medium to allow 2mls of the new cell 
suspension to be aliquoted into each plate. Experiments 
were carried out when the cells had grown to form a 
confluent layer in the plates, approximately 5 days 
from splitting the cells in the flask.
4.2.i.c) Experimental procedure
The rat hepatocytes were isolated and experiments 
carried out when the tumour cells had grown to form a 
confluent monolayer on the plates. Three plates of 
hepatocytes and three of MCF7 cells were used for each 
variable under investigation and as a control in each 
experiment. Prior to use the plates of cells were 
washed repeatedly with RPMI medium (Table 4.2.) to 
remove any dead and non adherent cells and 2mls of 
fresh medium added to all plates.
The MAb ICR2 was labelled with ^-^In (Appendix 5.4.)
at the ratio of lmg ICR2 to approximately 2mCi InCl3,
the labelled activity depending on the time period
between generation of the radioisotope and its use. The 
illICR2-xxxIn was applied to the medium in the plates of 
cells with the amount of labelled antibody applied 
being constant for all plates. The reagents being 
investigated were also added to the medium in the 
plates of cells at variable times and at different 
concentrations or to the labelled antibody prior to its
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application to the cells. After a period of incubation 
at 37°C the supernatant was collected from each plate 
as were four washings of the cells with 2ml aliquots of 
PBS. In view of the rapid accumulation of activity by 
the liver seen in the studies with patients an 
incubation time of two hours was used in the majority 
of experiments. The cells were then removed from the 
plates in 2mls PBS using a rubber policeman and the 
supernatant, washings and cells from each plate counted 
in a gamma well counter (LKB 1282 Compugamma). In order 
to compensate for any variations in the number of 
either hepatocytes or tumour cells per plate the 
protein content from each plate was determined using 
the Folin-Lowry procedure (285) (Appendix 4.1.) and the 
radioactivity bound to the cells was expressed as the 
counts per minute taken up by the cells / mg cell 
protein.
The uptake of activity by the cells was compared 
between groups of at least three plates following 
correction for protein concentration using a students 
t-test.
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4.2.11) Basic properties of the experimental model
Baseline parameters were established for the uptake 
of  ^In-MAb by the hepatocytes and the tumour cell 
line. When the cells were incubated for two hours with
c 1 1 1
approximately 3 x 10° cpm of xxxIn-ICR2 in 2mls of 
medium, 34.3% (+/- S.D. 2.78) of the applied counts 
bound / mg of cell protein with the tumour cell line 
and 3.65% (+/- S.D. 0.67) of the applied counts bound 
/mg cell protein with the hepatocytes (Table 4.3. and 
appendix 4.2.). Incubating the cells with labelled 
antibody at either 4°C or 37°C, showed that hepatocytes 
bound 57% more activity at 37°C than at 4°C while 
binding to the tumour cell line was 123% greater at 
37°C than at 4°C (Table 4.4. and Appendix 4.3.). It was 
concluded from these initial experiments that the 
binding between the labelled antibody and its specific 
receptor on the tumour cell line was considerably 
greater than with the hepatocytes and that an active 
and temperature dependent uptake mechanism was 
involved. A series of experiments were then carried out 
to assess the use of a variety of reagents in 
preferentially reducing the hepatocyte uptake of 
activity by the method described earlier. (4.2.i.c)
Table 4.3. Baseline uptake of ^^^In-ICR2
Cell type Applied 
cpm (xiofy
Cell uptake 
cpm(x 10^)
Protein
(mg/ml)
cpm/mg % uptake /mg
MCF7 3.02(0.17) 26.4(2.5) 0.25(0.03) 1.06 x 106 34.3(2.78)
Heps. 2.93(0.27) 2.1(0.22) 0.20(0) 0.107 xlO6 3.65(0.67)
All results are mean (S.D.) of triplicate determinations (Appendix 4.2.)
Table 4.4. The effect of temperature on cell uptake
Cell uptake of activity 
(% applied counts/plate)
Temperature
4° C 37° C
Hepatocytes 0.28(0.02) 0.44(0.10)
MCF7 5.03(1.13) 11.2(0.79)
Results are mean(S.D.) of three determinations (Appendix 4.3.)
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4.3. RESULTS
4.3.1) Transferrin
To assess the importance of transferrin and the 
transferrin receptor mechanism for uptake of ^^In- 
ICR2, hepatocytes or MCF7 cells were incubated with 
•^■^In-ICR2 in the presence of either saturated or 
unsaturated transferrin, prepared at a final 
concentration of 2g/l (Appendix 4.4.). Foetal calf 
serum (FCS) contains transferrin and was therefore 
replaced by bovine serum albumin (BSA) in these 
experiments.
In the first experiment the influence of the iron 
saturation state of transferrin on the uptake of ^^In- 
ICR2 was assessed with hepatocytes alone. The 
hepatocytes took up approximately 0.1% of the applied 
counts. This value was not significantly altered by the 
addition of either fully saturated or fully unsaturated 
transferrin (ApoTf) at a concentration of 2g/l (Table
4.5. and Appendix 4.5.). For further confirmation that
the transferrin saturation state was not a major
influence on the cell uptake of In-ICR2 the
experiment was repeated using fully unsaturated
transferrin and both hepatocytes and MCF7 cells. Again
no significant differences were found in the uptake of 
illJ"LXIn-ICR2 by the presence of apotransferrin (Table
4.6. and appendix 4.6.).
Table 4.5. Tf saturation and the hepatocyte uptake of Hlln-ICR2
Cell group Applied cpm(x 10^) Counts bound % uptake
Control 3.56(0.40) 359(76) 0.101(0.021)
Saturated Tf 3.69(0.30) 350(49) 0.095(0.017)
ApoTf 3.79(0.15) 363(122) 0.095(0.030)
Results are mean (S.D.) for triplicate determinations. (Appendix 4.5.)
Table 4.6. ApoTf and Hlln-ICR2 uptake by hepatocytes and MCF7
MCF7 Hepatocytes
Control ApoTf Control ApoTf
Applied (cpmxlO^) 2.45(0.01) 2.38(0.07) 2.41(0.04) 2.41(0.05)
Uptake (cpm x 10^) 299.8(32.1) 275(35.6) 5.92(0.64) 5.51(0.92)
% uptake 12.2(1.32) 11.53(1.20) 0.25(0.02) 0.22(0.04)
Results are mean(S.D.) for triplicate determinations (Appendix 4.6.)
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4.3.ii) DTPA
4.3.ii.a) Co-administration of DTPA with ^^^In-ICR2
To assess whether the metal chelating agent DTPA 
may have an effect on the uptake of activity by 
hepatocytes the labelled antibody was applied to 
monolayers of both the MCF7's or hepatocytes, together 
with or without (control) DTPA added to produce a 
final [DTPA] in the tissue culture medium of lOOumolar. 
A reduction of 13% in the uptake of activity on MCF7's 
was found with DTPA compared to the control group(n.s.) 
whereas a significant reduction of 43% was found with 
the hepatocytes (p < 0.01)(Figure 4.2., Table 4.7., 
Appendix 4.7.)
4.3.±i.b) Cell incubation with DTPA
Whether the reduction in hepatocyte uptake seen when 
DTPA was added to 111In-MAb could also be achieved by 
pre-incubating the hepatocytes and MCF7's with DTPA was 
investigated by adding DTPA to the medium of both cell 
types at a final concentration of lOOumolar for 15 
minutes prior to administration of ^^^In-MAb. After the 
two hour incubation period the mean uptake of activity 
was reduced by pretreatment and incubation in the 
presence of DTPA by 12.5% for the MCF7's (n.s.) and 31% 
for the hepatocytes (p=0.02)(Figure 4.3., Table 4.8., 
Appendix 4.8.).
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Table 4.7. Effect of DTPA co-administration
MCF7 
Control DTPA
Hepatocytes 
Control DTPA
Applied (cpm x 10^) 
Uptake (cpm x 10^) 
Uptake (cpm/mg xlO^)
5.40(0.26) 5.60(0.02) 
15.9(0.94) 14.3(0.51) 
4.46(0.37) 3.92(0.51)
5.04(0.86)
7.15(1.01)
1.93(0.27)
5.71(0.14)
4.04(0.70)
1.11(0.16)
Results are mean(S.D.) for triplicate determinations (Appendix 4.7.)
Table 4.8. Cell incubation with DTPA
MCF7 
Control DTPA
Hepatocytes 
Control DTPA
Applied (cpm xlO^) 
Uptake (cpmxlO^) 
Uptake (cpm/mg xlO^)
5.4(0.26) 5.4(0.16) 
15.9(0.94) 14.4(2.47) 
4.46(0.37) 3.90(0.67)
5.04(0.86)
7.15(1.01)
1.93(0.27)
5.67(0.04)
4.91(0.40)
1.33(0.11)
Results are mean (S.D.)for triplicate determinations. (Appendix 4.8.)
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4.3.11.c) Dose response of DTPA added to ^^In-MAB
Having established that DTPA, co-administered with
labelled antibody or pre-incubated with the cell lines,
could produce a reduction in the hepatocyte uptake
of 1-^In-MAb, experiments were carried out to
determine the optimum concentration of DTPA
which produced this effect. Samples of •^ ■*-In-ICR2 were
incubated with a range of concentrations of DTPA from
lOOumolar to lOmmolar for one hour prior to application
to the cells. The control plates of cells were
incubated without chelate. Using a lOOuM [DTPA] ^ I n -
MAb uptake by hepatocytes was reduced by 16% which was
not statistically significant while with ImM and lOmM
[DTPA] binding was reduced by 80% and 83% respectively
(p=0.000). At none of these concentrations of DTPA was 
illthe binding of A AIn-ICR2 to the tumour cell line 
reduced significantly (Figure 4.4., Table 4.9.,
Appendix 4.9.).
4.3.11.d) DTPA incubation time and uptake of ^**Tn-ICR2
The dose response curve (Figure 4.4.) suggested 
that greater than O.lmM [DTPA] was required to produce 
a significant reduction in the hepatocyte uptake. To 
investigate the optimum time for treatment with DTPA 
In-ICR2 was incubated with 0.5mM DTPA for variable 
times before treating the cells. A significant 
reduction was noted at all treatment times with the 
hepatocytes (p<0.05). The binding was reduced by 32% 
after 5 minutes and 45% after 15 minutes. No
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Table 4.9. DTPA concentration and the cell uptake of activity
Cell group Applied 
(cpm x lOfy
Uptake 
(cpm x Kftyplate)
cpm/mg xlO 4
MCF7 control 3.02 (0.17) 26.4 (2.53) 104.5 (3.13)
MCF7 lOOuM DTPA 2.97 (0.09) 23.2 (4.43) 95.0 (9.60)
MCF7 ImMDTPA 2.80 (0.60) 31.2 (2.59) 110.1 (13.14)
MCF7 lOmMDTPA 3.06 (0.16) 26.5 (3.28) 99.2 (5.21)
Heps control 3.10 (0.12) 2.14 (0.21) 10.7 (1.09)
Heps lOOuM DTPA 2.65 (0.23) 1.89 (0.21) 9.01 (0.94)
Heps ImM DTPA 2.95 (0.48) 0.40 (0.06) 2.1 (0.07)
Heps lOmM DTPA 3.07 (0.13) 0.39 (0.05) 1.82 (0.19)
The results are mean (S.D.) of triplicate determinations (Appendix 4.9.)
Table 4.10. DTPA incubation and cell uptake of activity
Cell group Applied 
(cpm x 10^)
Uptake
cpm x 103/plate
cpm/mg xlO 3
MCF7 control 4.96 (0.33) 30.38 (5.52) 79.76 (8.60)
MCF7 5 mins 4.69 (0.17) 27.15 (5.90) 88.09 (8.64)
MCF7 15mins 4.56 (0.01) 24.06 (1.50) 78.58 (4.47)
MCF7 30mins 4.85 (0.10) 28.94 (4.13) 91.34 (4.68)
MCF7 60 mins 4.35 (1.04) 21.64 (1.31) 91.34 (4.68)
Heps control 5.25 (0.14) 6.97 (1.28) 7.27 (1.48)
Heps 5 min 4.76 (0.14) 4.48 (0.24) 4.93 (0.31)
Heps 15 mins 4.52 (0.21) 3.67 (0.28) 4.12 (0.64)
Heps 30 mins 4.75 (0.10) 3.72 (1.04) 3.88 (0.89)
Heps 60 mins 4.62 (0.14) 3.89 (1.46) 4.09 (1.31)
Results are mean (S.D.) of triplicate deteiminations.(Appendix 4.10.)
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significant effect was found by pre-treatment with DTPA
illon the binding of In-ICR2 to the tumour cell line. 
Incubation of ■*'^ I^n-ICR2 with DTPA overnight (18 hours) 
did not reduce further the binding to hepatocytes.
(Figure 4.5., Table 4.10., Appendix 4.10.).
4.3.i±.e) The uptake of free In and ^^In-DTPA
illAny instability of the In-DTPA-MAb complex may
ill illresult in the formation of either free In or xx In- 
DTPA. In order to determine whether the effect of DTPA 
on the uptake of activity by hepatocytes may be related
ill
to the presence of free or chelated xxxIn, the effect
of DTPA was assessed on the uptake of -^^In and ^-^In-
DTPA on hepatocytes and MCF7 cells. Two equal aliquots 
illof 50ul of In acetate were mixed with either 450ul
of ImM DTPA (to form stably bound ^-^In-DTPA) or 450ul
of PBS. After 30 minutes the mixtures were applied to
plates of hepatocytes and MCF7 tumour cells. To
seperate sets of plates DTPA (500uM) was added to the
medium of the cells with the mixtures. The uptake of 
illfree xxxIn was found to be significantly greater than 
111that of In-DTPA for both the hepatocytes and the
tumour cell line. The co-administration of DTPA at the
time of applying activity to the cell lines
significantly reduced the uptake of free In but did
not reduce the uptake of In-DTPA (Table 4.11.,
Apppendix 4.11.). This would suggest that the effect of 
illDTPA on xxxIn-MAb is not related to the presence or 
formation of In-DTPA.
Table 4.11. : Cell uptake of l^ I n  and ^In-D T PA
Cell group Activity Added
DTPA
Applied 
(cpm x 104)
Uptake
(%)
Uptake
cpm/mg
MCF7 U lln No 18.61 (0.13) 0.54 (0.18) 2908 (262)
MCF7 U lln Yes 18.5 (0.25) 0.33 (0.07) 1712 (371)
Heps U lln No 19.1 (1.15) 0.70 (0.17) 2077 (45)
Heps U lln Yes 18.5 (0.19) 0.43 (0.04) 1150 (247)
MCF7 m In-DTPA No 19.5 (0.47) 0.27 (0.05) 1255 (369)
MCF7 i n In-DTPA Yes 18.8 (0.26) 0.32 (0.03) 1866 (748)
Heps m In-DTPA No 18.3 (0.29) 0.21 (0.06) 624 (209)
Heps m In-DTPA Yes 18.8 (0.64) 0.25 (0.01) 713 (66)
Results are mean (S.D.) for triplicate determinations(Appendix 4.11.)
Table 4.12.: A comparison of chelators
Cell group Applied 
(cpm x 10^)
Uptake/ plate 
(cpm x 103)
Uptake/mg 
(cpm x lO )^
MCF7 control 1.38 (0.05) 5.0 (1.8) 18.0 (3.2)
MCF7EDTA 1.32 (0.08) 4.2 (2.3) 16.8 (4.7)
MCF7 DTPA 1.31 (0.04) 5.1 (1.7) 24.0 (10.9)
MCF7 ccDTPA 1.39 (0.08) 5.3 (3.0) 18.4 (5.4)
MCF7 CP040 1.27 (0.05) 4.4 (2.6) 28.2 (13.6)
Heps control 1.35 (0.03) 6.3 (0.9) 9.3 (2.1)
Heps EDTA 1.35 (0.06) 6.0 (0.2) 6.9 (1.2)
Heps DTPA 1.35 (0.06) 4.7 (0.4) 5.4 (0.6)
Heps ccDTPA 1.40 (0.14) 5.2 (1.0) 7.3 (1.9)
Heps CP040 1.57 (0.08) 14.1 (0.10) 17.3 (1.0)
Results are mean (S.D.) for triplicate determinations (Appendix 4.12.)
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4.3.iv) A comparison of chelating agents
A comparison was carried out between four
different chelating agents to assess their relative
illability to inhibit the uptake of In-MAB;
the sodium salt of ethylene-diamine-tetracetic acid
(NaEDTA), the sodium salt of diethylenetriamine
pentacetic acid (NaDTPA), a solution of the bicyclic
anhydride of DTPA (ccDTPA) and an experimental
illbidentate ligand CP040. In-ICR2 was incubated with 
ImM solutions of the chelates for one hour before 
applying the labelled antibody to either MCF7 cells or 
the hepatocytes and incubating for two hours. Sodium 
DTPA produced a significant reduction in the hepatocyte 
uptake of activity whereas CP040 produced a significant 
increase. No significant differences were found in the 
hepatocyte uptake between any of the other chelated 
groups and controls nor between any of the groups of 
tumour cells (Figure 4.6., Table 4.12. , Appendix 
4.12. ) .
4.3.v) The effect of pooled rat Ig
It has been suggested that non-specific antibody 
uptake in patients could be reduced by the 
administration of pooled human immunoglobulin to block 
Fc receptor mediated uptake. In practice this has met 
with little success ( ^ 3). This problem has been 
investigated in this in vitro model using pooled rat 
immunoglobulin. Pooled rat IgG was mixed with ^^In- 
ICR2 at a ratio of 10:1, 50:1, 100:1 and 1000:1 then
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incubated with the tumour cells or the hepatocytes. 
Binding of •^ •*-In-ICR2 to the cells was compared with a 
control group given labelled antibody alone. With the 
tumour cell line no significant differences were noted 
until a 1000 fold excess was applied at which point a 
reduction of 20% was achieved. No inhibition of 
hepatocyte binding was found with any of the 
concentrations of pooled Ig examined (Table 4.13f 
Appendix 4.13). The pooled rat IgG contains a 
substantial amount of rat IgG2a, the same isotype as 
that of the radiolabelled MAb ICR2. The results 
would therefore suggest that binding via the Fc 
receptor or via carbohydrate on the Ig is not a 
major factor to the binding of ICR2 by hepatocytes.
Table 4.13. Pooled rat IgG and the cell uptake of activity
Cell group Pooled Ig Applied
(cpm x 105)
Uptake
(cpm x 10^/plate)
Uptake/mg 
(cpm x 10^)
MCF7 No 9.8 (0.1) 73.1 (2.4) 175 (20)
MCF7 x 10 10.0 (0.3) 75.6 (4.9) 207 (70)
MCF7 x 50 10.2 (0.6) 75.9 (8.8) 186 (37)
MCF7 x 100 10.2 (0.2) 61.6 (3.4) 193 (10)
MCF7 x 1000 9.5 (0.2) 44.3 (3.34) 140 (11)
Heps No 9.1 (0.1) 3.9 (1.4) 6.6 (1.8)
Heps x 10 9.7 (0.1) 6.3 (0.0) 11.1 (1.3)
Heps x50 10.1 (0.2) 5.0 (0.4) 7.3 (0.7)
Heps x 100 11.5 (2.1) 6.0 (1.0) 9.1 (2.4)
Heps x 1000 8.1 (2.0) 3.9 (0.5) 6.4 (0.8)
Results are mean (S.D.) of triplicate determinations (Appendix 4.13)
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4.4. DISCUSSION AND CONCLUSIONS
Transferrin is the most important and prevalent 
circulating metal chelating agent in man. In this study 
therefore the effect of transferrin, both saturated 
with iron and fully unsaturated on the specific and non 
specific uptake of ^^In-MAb was investigated using an 
in vitro model. No significant differences were noted 
between the control group and either the saturated or
unsaturated transferrin groups suggesting that
111 illtranscomplexation of 1AiIn from ■LJ-J-In-MAB to
circulating transferrin is not a major cause of non
specific liver uptake. These results appear to
contrast, however, with studies in both animals and
patients where it has been shown that 2-3% and 9%
respectively of circulating activity may be found
associated with circulating transferrin (280,281)# This
difference may be due to other factors affecting the in
vivo stability such as the pH or the time which the
labelled antibody is in contact with circulating
transferrin.
The chelating agent DTPA has been shown to produce 
significant reductions in the uptake of activity by the 
hepatocytes without significantly reducing tumour cell 
uptake. The uptake of activity, however, was far 
greater with the tumour cell line expressing the target 
antigen than with the hepatocytes and may therefore be 
disguising similar effects of chelates on the tumour 
cell line.
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A reduction in the uptake of activity by the 
hepatocytes was found whether the chelate was added to 
the labelled antibody, co-administered with the 
labelled antibody to the cells or incubated with 
the cells prior to labelled antibody administration. A 
dose-response and time course of hepatocyte uptake with 
DTPA applied to the labelled antibody has also been 
demonstrated. The reductions in uptake of radioactivity 
being apparent with the hepatocytes and not the tumour 
cell line suggests differences in the nature of 
activity taken up specifically by the antigen 
expressing tumour cell line and non specifically by the
ill
hepatocytes. The source of the xxxIn being affected by
ill
the chelating agent is unknown. In bound to MAB via
ccDTPA will not exchange significantly with unbound
illDTPA. Similarly free xxxIn in the antibody preparation 
is unlikely to account for the non specific activity as 
this will be removed with gel chromatography and in 
vivo would readily complex with circulating transferrin 
(275) ^ Large protein molecules may, however, bind 
charged metallic ions non specifically This may
111
result in a failure to remove unchelated xxxIn on gel 
chromatography and its transportation to the liver.
This unstably bound metal may be the target of the 
additional chelating agents in this study.
Further information on the possible mechanism of 
chelates on the liver uptake has been obtained from 
analysis of the cells uptake of free I11!]* and 111In- 
DTPA. Firstly the ratio of uptake of activity in the
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tumour cell line compared to that in the hepatocytes 
was low compared to experiments with labelled antibody 
confirming that the uptake of activity in the tumours 
with labelled antibody is dependent on the antibody- 
antigen interaction. There was also significant 
differences with both the hepatocytes and the tumour
ill ill
cell line in the uptake of free xxxIn and xxxIn-DTPA.
This would suggest that the stably chelated indium
remains extracellular whereas a mechanism exists for
111the intracellular transport of free x In. This is
supported by the reduction in uptake found when DTPA
was added to the group of cells to which free -*-^ In was
applied. No significant changes being found by the
addition of DTPA to the culture medium after
application of the activity would again suggest that 
111
the free xxxIn is rapidly taken up by the cells and is
not therefore available to extracellular chelators.
The reduction in hepatocyte uptake of activity
seen in the present study when DTPA was added to either
the labelled antibody or the cell lines has important
practical applications. This would suggest that in
illpatient studies with xIn labelled monoclonal
antibodies the uptake of activity in the liver may be
reduced whilst preserving tumour uptake by either
administering chelating agents to the patients or
incubating the labelled antibody with chelate. The
potential use of chelating agents for reducing liver 
illuptake of In-MAb must, however, be considered in
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context. Although a significant reduction in hepatocyte
uptake was found only a small percentage of the applied
In-ICR2 bound to hepatocytes. Although this may
initially suggest that hepatocyte uptake is not likely
to be an important factor to the overall uptake of
activity by the liver these differences were based
on an equivalent concentration of cell protein for
hepatocytes and tumour cells. In the clinical
situation, however, the liver is many times larger than
the average primary colonic cancer and the number of
hepatocytes is therefore likely to greatly exceed the
number of tumour cells. Another factor which must be
considered is the cell incubation period which was
short and may overlook a continued uptake of activity.
The very rapid accumulation of liver activity seen in
illpatient studies with In-MAb is largely due to the 
blood pool activity of a large vascular organ rather 
than specific accumulation (see Chapter 6).
The addition of chelates to the injectate has 
previously been carried out by some researchers for the
ill ill
removal of unstably bound In, the xIn-chelate 
complex being readily excreted by the urinary 
tract(2^3). A rational basis for this approach has 
not, however, previously been established. The use of a 
chelating agent following labelled antibody 
administration has also been investigated in animals 
although in the few reported studies a definite role 
has not been established (280,283)^
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With a view to patient studies the optimal 
concentration and incubation period of DTPA with -*-*^ In- 
ICR2 was investigated with the aim of minimising the 
hepatocyte binding of activity using the lowest 
concentration of DTPA and the shortest incubation 
period. This was established at 0.5mM [DTPA] for 15 
minutes producing a 40% reduction in the uptake of 
activity by hepatocytes. Whether the remaining activity 
taken up by the hepatocytes may be removed by other 
chelating agents without affecting tumour uptake 
remains to be established. In an initial study 
comparing EDTA, NaDTPA, ccDTPA and CP040 the greatest 
inhibition of uptake was with Na DTPA. Of interest was 
the significantly increased uptake achieved with the 
bidentate chelate CP040, suggesting that there may be 
cellular uptake of this chelating agent.
Other ways of reducing the uptake of activity in the 
liver have been investigated and important advances 
have been achieved using alternatives to ccDTPA for the 
attachment of ^^In to the antibody molecule, such as 
bifunctional chelating agents(282,286)^
Although hepatocyte uptake is the major factor in 
the accumulation of activity in the liver considerable 
activity accumulates at other sites following ^*^In 
labelled antibody administration some of which is 
associated with the RES. A logical step for the 
reduction of this uptake of activity is the 
administration of pooled gamma globulin which has 
previously been shown to effectively block the Fc
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receptor mechanism (274) ^ Tke results in the few
patient studies, however, have shown little improvement
in the results of imaging obtained (243)  ^ This problem
was investigated in the in vitro model by the
application of a 10-1000 fold excess of pooled rat
illimmunoglobulin along with the xxxIn-MAb to the cell 
lines. A marginal effect being achieved only by 1000 
fold excess of pooled Ig would suggest that this is not 
a practical method of inhibiting the non-specific 
uptake of activity.
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5.1. A REVIEW OF PROBLEMS ASSOCIATED WITH THE
RADIOIMMUNOLOCALISATION OF COLORECTAL CANCERS
Several steps are involved between the production of 
a monoclonal antibody or polyclonal antiserum and its 
successful use for the localisation of cancers. At any 
intermediate stage factors may affect the capacity of 
the labelled antibody to localise and bind to its 
target antigen and thereby result in a failure of 
imaging. Such difficulties may be due to the antibody 
itself, the target antigen, the radiolabel or the 
imaging method employed.
The antibody/antigen interaction
The ideal antibody for tumour imaging would 
recognise an antigen expressed exclusively by the 
tumour tissue. Unfortunately in man the only tumour 
specific antigen which has been discovered to date is 
the idiotype of the surface Ig on some B cell 
lymphomas). The antigens which are targeted in 
tumour imaging are therefore "tumour associated" rather 
than tumour specific. This may take the form of 
over-expression of an antigen normally present on the 
tissue eg. epidermal growth factor receptor (EGFR)(2®^ ) 
or it may be an aberrant expression eg. EMA. Specific 
antibody binding may not, however, be essential to 
produce a positive image as radiolabelled MAb may 
accumulate in tumour tissue which does not express the 
target antigen. This may explain the positive
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localisation of human tumours reported by Epenetos 
using a non-specific MAb (-^3). biodistribution of
radiolabelled antibodies varies following 
administration to patients. This may depend on the 
specificity of the antibody administered, although 
monoclonal antibodies raised to the same target antigen 
may have similar^2®**) or markedly different 
biodistributions( ) ,  or it may vary with the 
radiolabel being used(-*-2^). Independant of these 
factors there is commonly uptake of radiolabelled 
antibody in the liver, spleen, bone marrow and the 
testicles. The reason for this distribution in normal 
tissues which do not express the target antigen is a 
major problem in immunoscintigraphy and was discussed 
in Section 4.1.
An additional problem in the use of radiolabelled 
MAb's for the localisation of cancers is the secretion 
of antigen from the tumour into the circulation. High 
circulating levels of secreted tumour associated 
antigens have been shown in animal models to 
correspond with a high level of formation and removal 
of circulating immune complex and a reduced uptake of 
radiolabelled MAb in the tumour (2^4)# jn the patient 
studies by Goldenberg, however, satisfactory images 
were obtained of colorectal cancer using anti-CEA even 
when circulating CEA levels were greatly elevated (^7)# 
These positive images may have been produced by dual 
isotope subtraction artefacts (-1-22) or the uptake of 
soluble immune complexes by the tumour tissue.
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Antigen access to tumour tissue
Larger tumours are easier to localise by external 
imaging because they accumulate more radioactivity than 
small tumours. The uptake of radioactivity per gram, 
however, decreases as the size of the tumour increases 
(264)^ This is probably related to a failure of the 
blood supply to match the growth of the tumour (2^9)#
The access of radiolabelled antibodies to large tumours 
is therefore poor and non uniform and the site of 
biopsy of tumour tissue may result in discrepancies 
in the reported tumour to normal tissue ratios.
Although the vascularity of a tumour may be poor the 
capillaries are more porous than in normal tissues and 
therefore the access for large molecules to surface 
antigens on the tumour cells is facilitated (2^^). This 
extravasation is important because antibody fragments 
F (ab') and F(ab')2 show greater accumulation in tumour 
than do whole antibody despite their more rapid 
clearance from the blood
The immunoreactivity of an antibody is a measure of 
its binding with a specific antigen. This does not 
reflect on the ability of the antibody to localise 
tumour deposits. It does, however, allow the effect of 
certain manipulations eg. conjugation with DTPA, to be 
assessed.
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The radiolabel
As mentioned in the Section 1.3.iii) the two most
frequently used radiolabels in patient studies are ^31j
and -^^ In. With both isotopes the labelling procedures
employed may lead to alterations in the
immunoreactivity of the antibody, the extent of which
depends on the method being used and the nature of the
antibody itself. The biodistribution is also affected
by the radiolabel. Labelling of the same antibody with
125j and In has been carried out in mice with
colonic carcinoma xenografts. At 48 hours after
injection the blood levels of activity are similar but
the activity in the tumour, liver and spleen are
111significantly higher with 1J,1In. Whether this is a 
reflection of tissue dehalogenation or other factors 
remains to be resolved These findings have,
however, been supported by other authors (230,265,266)^
Antibodies may be labelled with -^^In and a stable 
pharmaceutical produced. They do however, require the 
monoclonal antibody to be conjugated with a metal 
chelating agent such as DTPA or EDTA. As the chelate : 
MAb ratio increases the immunoreactivity of the 
antibody decreases. The optimum ratio may well depend 
on the particular Mab being used. Most authors, 
however, report good immunoreactivities with a 1:1 or 
2:1 DTPA to MAb ratio. With conjugates prepared at 
these ratios, ^*^In labelling to specific activities of 
approximately 150 Megabequerels per milligram (MBq / 
mg) can be achieved.
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The nature of the chelate itself appears to have 
an important effect on the biodistribution of the 
radiolabelled antibody and newly designed chelates have 
been shown to reduce the uptake of radiolabel in the 
liver (282,291)^ This may be due to a reduction in the 
amount of *^^In being lost from the labelled antibody 
and binding to circulating transferrin or to a reduced 
immunogenicity of the labelled antibody.
Imaging techniques
The imaging techniques which are commonly used, 
and applications which have been attempted are outlined 
in Section 1.3.iii.b). Whatever the method employed, 
satisfactory imaging is dependent on the amount of 
radiolabel which accumulates in the tumour as compared 
with that in the normal tissues. Any factor which 
affects the labelling efficiency, purity or 
immunoreactivity of the labelled antibody or its 
access to tumour tissue will affect the image produced. 
Similarly factors which increase background activity 
will reduce the "signal to noise ratio" and obscure the 
image. Possible mechanisms for reducing non specific 
uptake were discussed in Chapter 4. A problem commonly 
encountered with the imaging of colorectal cancers is 
that primary tumours may be obscured by uptake in the 
bony pelvis and hepatic metastases by uptake in normal 
liver.
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Determination of the absolute uptake of 
radioactivity in the tumour from resected specimens is 
essential for progress to be made in imaging although 
few studies have reported this data. This information 
is also required to allow methods of reducing the 
background activity to be assessed.
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5.2. THE LOCALISATION OF COLORECTAL CANCERS BY
IMMUNOSCINTIGRAPHY WITH 11:LIn LABELLED ICR2 
i) Introduction
The localisation of colorectal cancers by anti-CEA
antibodies has been widely reported over the last 
decade (97,99,100,102,104-106,133,292-297)^ These
studies have shown a wide variation in sensitivities 
for the detection of primary colorectal cancer ranging 
from 30% (^96) to iQ0% (106,293) . The detection of 
primary tumours by immunoscintigraphy may be of limited 
clinical value as other forms of investigation can 
successfully localise these tumours. Imaging for 
metastatic deposits which are not satisfactorily 
localised by conventional investigations have generally 
produced poorer results (104,106,292)^
In an attempt to improve the results of the 
immunoscintigraphy of colorectal cancers MAb's to other 
target antigens have been investigated including 
791/T36 raised to a human osteosarcoma (HI), 17-1A and 
19-9 raised to colorectal cancer cell lines (115,116)^ 
B72.3 raised to a breast cancer membrane extract (298) 
and YPC2/12.1 raised to a colorectal cancer extract 
(■*■17). imaging with MAb's to these tumour associated 
antigens has not, however, shown any clinical advantage 
over anti-CEA.
In Chapter 2 it was demonstrated that the majority 
of colorectal cancers and their metastases express both 
CEA and EMA, whilst normal colon expresses CEA but
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rarely EMA. EMA is expressed more widely than CEA in
non-gastrointestinal tissues (201,202) kut a
better differential expression between colonic cancers
and normal colon on immunohistochemistry. MAb's to EMA
have not previously been investigated for a role in the
imaging of colorectal cancer. The anti-EMA MAb ICR2
labelled with ■*■*•*• In has therefore been evaluated for
the imaging of patients with colorectal cancer.
In addition to obtaining imaging information several
areas have been investigated where potential may exist
for improving the results obtained with
immunoscintigraphy. Firstly the stability and
111immunoreactivity of the ■LJ--LIn chelated antibody is
known to vary with several factors including the
chelate used and the number of chelate molecules
substituted (Section 1). The stability and
illimmunoreactivity of x In-ICR2 with changes in 
chelate : MAb ratio, pH and with storage has been 
investigated in order to optimise its preparation 
(Appendices 5.1.-5.3.)..
Another major problem in immunoscintigraphy is the 
formation of circulating immune complex with secreted 
tumour associated antigens resulting in a decreased 
uptake of labelled antibody in the tumour (Discussed in 
Chapter 6). Previous patient studies have assessed the 
effect of administering unlabelled antibody prior to 
labelled antibody on the images obtained. However the 
tumour uptake of radioactivity, levels of circulating 
immune complex and labelled antibody biodistribution
155.
were not quantified (242,243)^ To ciarify the
usefulness of unlabelled antibody administration a
group of patients in the present study have therefore
been administered unlabelled antibody prior to -^^In-
ICR2 administration and the effect measured on imaging
illas well as the biodistribution of xxxIn-ICR2.
An additional problem with immunoscintigraphy is the
background uptake of activity (Sections 1.3.iii.a and
5.1.). With •*-‘*--*-In this may be due in part to unstable 
illbinding of 1XiIn to the antibody molecule at areas
other than the DTPA binding site. In vivo any ■*■•*■•*■ In
which is not stably bound to the antibody molecule will
become bound to circulating transferrin and be removed
from the circulation by organs expressing receptors for
transferrin. Although the administration of a chelating
agent to the labelled antibody has been advocated for
the removal of this non specifically bound ^ I n  (^3)
little evidence exists for its efficacy. In Section
4.3., however, it was demonstrated that DTPA may be
used to reduce the hepatocyte uptake of In-ICR2 by
its application to the injectate. Whether a similar
reduction in non specific uptake may be achieved in
patients has been investigated in the present study by
illadding DTPA to the In-ICR2 prepared for patient
administration and the effect on the images produced
illand the biodistribution of xx In-ICR2 has been 
assessed. The results of these studies have been 
divided into imaging, presented in this chapter and 
biodistribution which is presented in chapter 6.
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Patients and methods
All patients entering this study gave fully
ill
informed consent for the administration of xxxIn-ICR2. 
The study was approved by the University College 
Hospital Ethics Committee and Department of Health 
approval was granted for the administration of the 
antibody.
Twenty-two patients with suspected colorectal 
cancer were studied (Table 5.1.). Nine were males and 
13 females with a median age of 66 years (range 51-83). 
In twenty patients the diagnosis of colorectal 
cancer was based on barium enema or colonoscopy with 
pre-operative histological diagnosis being obtained in 
8. Two patients were suspected of having recurrence of 
cancer following abdomino-perineal resection of the 
rectum, one 8 months following resection of a Dukes C 
lesion and the other 3 years following resection of a 
Dukes B lesion.
Of the three patients found on subsequent laparotomy 
to have liver metastases one was correctly diagnosed on 
pre-operative liver ultrasonography and none by 99mTc 
tin colloid liver scanning.
Of 20 patients with the diagnosis of primary 
colorectal cancers 19 underwent surgical exploration 
and resection. The remaining patient, a 79 year old 
female with a large dysplastic tubular adenoma of the 
rectum (No.20, D.F.) refused surgery and underwent a 
course of cytoreductive laser therapy.
Table 5.1. Patient details
No. Init. Age Sex Diagnosis Site Diff Dukes Operation
1. M.D. 60 M Ca R/S Mod B Lt. Hemi
2. M.B. 83 F Ca R/S Mod B Lt. Hemi
3. R.S. 53 M ?recur _ _ _ Laparotomy
4. R.N. 66 M Ca Hep flex Mod B Rt. Hemi
5. D.N. 51 M Ca Hep flex Mod B Rt. Hemi
6. J.L. 71 M Ca Rectum Mod c* Ant resection
7. J.H. 79 F Ca Trans. Signet B Lt. Hemi
8. B.T. 58 F Ca Rect Mod B Ant resection
9. J.P. 59 M Ca Sigmoid Mod B Lt. Hemi
10. K.H. 65 F ?recur _ _ _ No
11. M.J. 67 F Ca Sigmoid Mod C Lt. Hemi
12. B.B. 54 F Ca Rectum Mod C Ant resection
13. V.D. 74 F Ca Sigmoid Mod B Lt. Hemi
14. F.H. 76 F Ca Sigmoid Mod B Lt Hemi
15. B.S. 60 F Ca Sigmoid Mod c* Lt. Hemi
16. R.D. 64 M Lipoma Sigmoid _ _ Lt. Hemi
17. J.P. 76 F Ca Spl.flex Mod B Lt. Hemi
18. E.B. 73 F Adenoma Caecum — _ Rt Hemi
19. D.N. 73 F Ca Sigmoid Well C Lt Hemi
20. D.F. 79 F Adenoma Rectum _ _ Laser
21. G.X. 67 M Ca R/S Mod c* Ant resection
22. J.B. 56 M Ca Sigmoid Mod B Ant resection
* with liver metastases
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Pathological examination of the resected specimens 
confirmed colorectal cancer in 17 patients (7 rectum or 
rectosigmoid, 6 sigmoid, three at the flexures and one 
in the transverse colon). Of these one was well 
differentiated, one signet ring and the remainder 
moderately differentiated. Two patients undergoing 
surgery were found to have benign colonic tumours, one 
a large pedunculated lipoma in the sigmoid colon 
(No.16 R.D.) and the other a dysplastic tubulovillous 
adenoma in the caecum (No.18 E.B.). Of the two patients 
presenting with symptoms suggestive of recurrence 
one underwent laparotomy and was found to have dense 
inflammatory adhesions but no evidence of recurrent 
cancer and the others symptoms resolved and is being 
followed up in the out-patient clinic.
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Preparation and administration of ^^In-ICR2
The production and purification of ICR2 is described 
in Section 1.6. and its conjugation with DTPA, 
labelling with 111In, immunoreactivity and in vitro 
stability in Appendices 5.1-5.4.
To test for possible hypersensitivity a skin test 
was carried out on all patients prior to administration 
of labelled antibody. This consisted of the 
subcutaneous injection of 20ug of unlabelled ICR2 on 
the flexor aspect of the patients forearm with the skin 
test site being inspected after 20 minutes for evidence 
of an inflammatory response. If no skin reaction was 
noted the labelled antibody was administered 
intravenously in 50mls of normal saline over one 
minute.
Patients were divided into three groups by the 
nature of the administered activity. Ten patients 
recieved lmg of 111In-ICR2 alone (Group A), labelled as 
described in Appendix 5.4. A further 6 patients had 
their injectate reacted with DTPA (Group B and Appendix
5.4.). The final group of 6 patients also had DTPA 
added to their injectate but in addition had 5mg of 
unlabelled antibody administered intravenously in 
lOOmls of normal saline over the 30 minutes prior to 
administration of labelled antibody (Group C and 
Appendix 5.4.).
Following the administration of the antibody 
patients were monitored for a hypersensitivity reaction
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by recordings of temperature, pulse and blood pressure 
hourly for 12 hours. Full blood count (FBC), urea and 
electrolytes (U&E's) and liver function tests(LFT's) 
were compared before antibody administration and at 
frequent intervals over the subsequent two weeks.
External imaging
A dynamic study was carried out for the 30 minutes 
following injection of In-ICR2 followed by static
imaging. For the dynamic study the camera was placed 
anterior to the prone patient with the liver and heart 
included in the field of view and 20 x 3 second frames 
followed by 30 x 60 second frames were recorded by 
computer (Nodecrest, U.K.).
Static images of the anterior and posterior 
abdomen, anterior pelvis and pelvic outlet were 
acquired at 30 minutes, 24, 48 and 72 hours post 
injection using a 37 tube digitrac gamma camera 
(Siemens) fitted with a medium energy collimator.
300k counts in a 128 x 128 matrix were stored on the 
computer.
Interpretation of images
The static images were interpreted by a clinician 
with knowledge of the patients clinical and 
radiological findings (Observer A) and independently by 
an experienced nuclear medicine clinician who had no 
clinical details of the patients studied (Observer B). 
The image interpretations in this manner were
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considered to represent a subjective and an objective 
assessment respectively and were compared.
Tumour uptake of activity and antigen expression
The uptake of radio-activity in the tumours and that
in normal colon was measured in biopsies of the
resected specimen. These were accurately weighed by
placing them in individually weighed test tubes
(Luckham, Sussex, U.K.) which were then re-weighed
prior to measuring their radioactivity in a gamma well
counter (LKB Compugamma). This allowed the uptake of
activity in tumour to that of normal colon (T/NC ratio)
to be calculated per gram of tissue. The absolute
uptake of activity was calculated using a standard.
This was prepared by taking a known percentage (by
illweight) of the injected XJ"LIn-IGR2 and diluting it to 
500mls in a flask using normal saline. After thorough 
mixing a 2 ml aliquot of this solution was then sampled 
and counted in a gamma well counter (LKB Compugamma) at 
the time of analysis of the resected tissue. The amount 
of activity in the standard was calculated as a 
percentage of the activity injected thus allowing the 
percentage of the injected dose per gram (% I.D./g) of 
tumour tissue to be calculated.
Specimens of cancer from all patients undergoing 
resection were also examined immunohistochemically for 
EMA expression by the indirect immunoperoxidase method 
outlined in Chapter 2, while in those patients with 
suspected recurrences sections were obtained from
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paraffin blocks of the original tumour. Nodal 
metastases were also examined for EMA expression. 
Tumours were graded for antigen expression on a scale 
of 1-4 by the method of Ellis (^44)(Section 2.2.ii).
Human response to rat antibody
Serum samples were collected at random from patients
illfollowing administration of J"LXIn-ICR2 and analysed for 
a human response to the administration of rat antibody. 
The samples were stored at -20°C until assayed and then 
thawed, mixed and centrifuged to remove debris before 
use.
Procedure
96 well PVC plates (Dynatech, Bellingshut, Sussex) 
were coated with the F(ab')2 fraction of ICR2. These 
were prepared by adding 2mg of pepsin (Sigma,U.K.) to 
lOOmg of ICR2 in a dialysis sac (Medicell Ltd). This 
was then placed in 0.05M acetate buffer at pH 4 and 
dialysis was continued until 1/3 of the optical density 
of the ICR2/ pepsin solution was present in the 
dialysis solution. The reaction was terminated by 
dialysis at 6°C against PBS containing 0.5M saline. The 
F(ab')2 fragments were purified by gel filtration (ACA 
34) using 0.5M PBS as eluant. The F(ab')2 coated plates 
were blocked with PBS-EDTA-coating 0.5% BSA and stored 
overnight at 4°C. Dilutions of the serum samples were 
prepared in separate 96 well plates that contained 
180ul of PBS-BSA in the first well and 120ul of the
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same buffer in the remaining wells. Duplicate 60ul
samples of each serum were added to the initial wells
and then diluted serially ten times. After washing the
ICR2 F(ab')2 coated plates with PBS/BSA the serum
dilutions were applied and incubated for one hour. The
plates were then washed to remove any unbound antibody
and 50ul of ^25j labelled rabbit anti-human
immunoglobulin was applied. After a further incubation
period of one hour the plates were washed x 5 and the
wells cut and counted individually in a gamma well
counter (Innotron Hydragamma) . The -*-25 j bound to the
F(ab')2 fraction on the wells was plotted for each
specimen against the serum dilutions. With each patient
illserum samples taken prior to xxxIn-ICR2 administration 
were compared with those taken after antibody 
administration by plotting the bound activity against 
serum dilutions.
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5.2.iii Results
5.2.±±±.a) The interpretation of images
The imaging results are presented in this chapter 
and the analysis of In-1CR2 biodistribution in 
Chapter 6.
The results are presented in Table 5.2.. In all 
scans a high degree of background activity was found 
in the liver, spleen, kidneys, bone marrow and 
testicles.
Of the 22 patients administered ^In-ICR2 imaging
was carried out pre-operatively in 20. These 20
patients included two patients with suspected
recurrences and 3 with benign colonic tumours (lipoma
in one and tubulo-villous adenoma in two). The
remaining 15 patients had primary colorectal cancers.
Localised uptake in the region of the primary tumour
was found in 12 of the 15 patients (Sensitivity for
tumour detection 80% : Observer A). Figure 5.1
illdemonstrates the uptake of XXAIn-ICR2 in a cancer of 
the rectosigmoid junction (arrowed) most obvious in the 
anterior pelvic view at 48 hours after administration 
(No.l M.D.) and Figure 5.2. a cancer of the 
sigmoid colon (arrowed) which is apparent at both 48 
and 72 hours (No.13 V.D.). For comparison Figure 5.3. 
demonstrates a normal scan from the patient with a 
lipoma of the sigmoid colon (No.16 R.D.). Negative 
scanning of a primary tumour was more common in the 
transverse colon or the flexures but this did not
Table 5.2. Results of immunoscintigraphy
No. Init. Diag Site Dukes Observer A Observer B
1. M.D. Ca R/S B Tr +ve Tr+ve
2. M.B. Ca R/S B Incomplete scanning
3. R.S. recurr? __ __ F +ve Tr-ve
4. R.N. Ca Trans B Tr+ve Tr+ve
5. D.N. Ca Trans B Tr+ve F -ve
6. J.L. Ca Rectum c* Tr+ve Tr+ve
7. J.H. Ca Trans B F -ve F-ve
8. B.T. Ca Rect B Tr+ve F -ve
9. J.P. Ca Sigmoid B Incomplete scanning
10. K.H. recurr? __ __ F +ve F +ve
11. M.J. Ca Sigmoid C Tr+ve Tr+ve
12. B.B. Ca Rectum C Tr+ve TR+ve
13. Y.D. Ca Sigmoid c Tr+ve Tr+ve
14. F.H. Ca Sigmoid B F -ve Tr+ve
15. B.S. Ca R/S c* Tr+ve F -ve
16. R.D. Lipoma Sigmoid __ Tr-ve Tr-ve
17. J.P. Ca Spl flex B F -ve F -ve
18. E.B. Adenoma Caecum — F +ve F +ve
19. D.O.N. Ca Sigmoid C Tr+ve Tr+ve
20. D.F. Adenoma Rectum __ F +ve Tr-ve
21. XG. Ca R/S c* Tr+ve Tr+ve
22. J.B. Ca Sigmoid B Tr+ve F -ve
Figure 5.1. (No.l,M.D.)
The uptake of ^  ^In-ICR2 by a colorectal cancer at the rectosigmoid junction. 
Localised uptake can be seen (arrowed) in the pelvic outlet views at 24 (a) and 
48 (c) hours following administration corresponding to that in the anterior 
pelvic views at similar time periods ( b and d).
Figure 5.2. (No. 13 , V.D.)
Localisation of a sigmoid colon cancer with 11 ^In-ICR2. No tumour uptake is 
seen at 24 hours (a) but it becomes apparent in views of the anterior pelvis at 48 
(b) and 72 (c) hours after administration. Gamma camera imaging of the 
resected specimen demonstrates the site of the cancer (d).
Figure 5.3. (No. 16, R.D.)
11 lln-ICR2 scan of a patient with a lipoma of the sigmoid colon demonstrating 
normal blood pool activity, urinary excretion and testis/ scrotal uptake in the 
anterior abdomen (a) and pelvic outlet views (b) at 30 minutes and in the same 
views at 24 hours (c and d).
Anterior abdominal scan of a patient suspected of recurrent colorectal cancer at 
24 hours after * ^In-IC R 2 administration showing multiple focal areas of 
localisation.
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achieve significance (2 of 3 vs 2 of 12, with yates 
correction, n.s.).
In the two patients with suspected recurrences 
localised uptake was found with both. One patient 
(No.3, R.S.) had multiple foci of uptake seen on an 
anterior abdominal scan (Figure 5.4.) which was found 
on subsequent laparotomy to correspond to dense fibrous 
adhesions and not recurrent tumour. The other patient 
suspected of recurrent disease (No.10, K.H.) showed 
symptomatic improvement and no surgery was carried out.
Three patients were subsequently found to have 
benign tumours. Of these two had large adenomas and 
false positive scans (Nos.18, E.B. and 20, D.F.) and 
one a true negative scan (No.16, R.D.). The overall 
specificity in the detection of either primary or 
recurrent cancer on subjective assessment is 20%.
The imaging of metastatic deposits
The results on the localisation of primary tumours 
are in marked contrast to those with metastases. Of the 
six patients with nodal metastatic deposits 
(Nos.6,11,12,15,19 and 21), three had accompanying 
liver metastases (6,15 and 21) involving both liver 
lobes. Nodal metastases produced positive images pre- 
operatively in only one patient (No.11 M.J., Figure 
5.5.). None of the hepatic metastases, present in three 
patients, produced positive images.
Figure 5.5. (No. 11,M.J.)
Abdominal scan of the only patient in whom nodal metastases were localised 
pre-operatively demonstrating a normal anterior pelvic blood pool view (a) 
compared with the 24 hour after administration view demonstrating both the 
primaiy tumour and the nodal metastases (b) (arrowed). Gamma camera imaging 
of the resected specimen (c) confirmed a hot primary tumour and regional node 
metastases.
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Scan reporting without patient details
Of the 15 patients with primary colorectal cancers 9 
were correctly identified producing a sensitivity of 
60%. Two of the three patients with benign tumours had 
true negative scans (Nos. 16 and 20) as did one of the 
two patients with suspected recurrence (No. 3) 
resulting in a specificity of 60%. As in the subjective 
reporting in only one of the 6 patients with lymph node 
metastases were these detected pre-operatively. Of the 
20 patients in whom scanning was completed the results 
of the subjective assessment correlated with the 
independent assessment in 13 (65%) and disagreed in 7 
(35%).
The effect of DTPA and cold MAb administration
The effect of adding DTPA to the injectate and of 
administering cold MAb to the patient prior to labelled 
MAb was measured by comparing the sensitivity of 
primary cancer detection in control, DTPA and cold MAb 
groups. No significant differences were found between 
the groups on either subjective (control 5/6, DTPA 
alone 4/6, cold MAb 3/3) or objective assessment 
(control 3/6, DTPA 4/6, cold MAb 2/3) as may be 
expected from the small number of patients in each 
group. Similarly no differences were noted between the 
groups in the background uptake of radioactivity 
present on the scans either by subjective or objective 
reporting. The effect of these manipulations on tumour 
and normal organ uptake is decribed in Ghapter 6.
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b) Tumour uptake of activity and antigen expression
The absolute uptake of activity in the tumours as 
measured from gamma well counting of specimens and the 
prepared standard ranged from 0.0016% I.D./g to 0.016 % 
I.D./g., with a mean ratio in tumour to that of normal 
colon of 2.1 (+/- S.D. 0.915) : 1. No significant 
differences were found in the tumour/normal colon 
ratios or % I.D./g between the control patients and 
those in whom chelate was reacted with the injectate or 
cold antibody was administered (Table 5.3.)
The mean T/NC ratio for the three patients with 
false negative scanning was not significantly different 
from that in whom scanning was positive.
Of the 17 patients with primary colorectal cancer 
all but one tumour was found to express EMA on 
immunohistochemistry (Table 5.4.). This lack of EMA 
expression correlated with the negative imaging of a 
transverse colon carcinoma. Six patients had lymph node 
metastases on H & E microscopy all of which expressed 
EMA. On one of these six patients scanning pre- 
operatively localised both the primary tumour and nodal 
metastases, further confirmed by the imaging of the 
resected specimen (Figure 5.5.). Both patients 
investigated for recurrent colorectal cancer expressed 
EMA in their original primary tumours. The colonic 
lipoma showed no evidence of EMA expression (No.16 
R.D.). EMA expression was found in the two tubulo- 
villous adenomas (No.18 E.B. and No.20 D.F.)
Table 5.3. Tumour uptake of m in-ICR2
Patient group
Control DTPA Cold MAb
T/NC ratio 2.1+/-0.91 : 1 2.4+/-0.79: 1 2.4+/-0.56:1
% I.D./g 6.1+/-3.8 10.5+/-4.7 9.7+/-2.04
All values are mean +/- standard deviation
Table 5.4. Scanning, tumour activity and antigen expression
No. Init. Diag Site Dukes EMA
grade
T/NC % I.D./g 
(xl0“3)
Scan
1. M.D. Ca R/S B 2 3.2 6.5 Tr+ve
2. M.B. Ca R/S B 3 3.4 1.6 Incomplete
3. R.S. recurr? _ _ NA NA F +ve
4. R.N. Ca Hep flex B F 1.0 2.4 Tr+ve
5. D.N. Ca Hep flex B 2 1.8 4.3 Tr+ve
6. J.L. Ca Rectum C 2 2.0 6.2 Tr+ve
7. J.H. Ca Trans B -ve 1.2 12.0 F -ve
8. B.T. Ca Rectum B 3 2.1 10.0 Tr+ve
9. J.P. Ca Sigmoid B 3 NA NA Incomplete
10. K.H. recurr? _ _ NA NA NA F +ve
11. M.J. Ca Sigmoid C 1 3.5 8.4 Tr+ve
12. B.B. Ca Rectum C 1 NA NA Tr+ve
13. V.D. Ca Sigmoid B 2 1.6 16.0 Tr+ve
14. F.H. Ca Sigmoid B 2 2.3 NA F -ve
15. B.S. Ca Sigmoid B 1 NA NA Tr+ve
16. R.D. Lipoma Sigmoid _ -ve 1.6 6.5 Tr-ve
17. J.P. Ca Spl Flex B 1 2.3 7.2 F -ve
18. E.B. Adenoma Rectum __ Focal 1.4 6.0 F +ve
19. D.O.N. Ca Sigmoid C 3 1.9 9.0 Tr+ve
20. D.F. Adenoma Caecum _ 3 NA NA F +ve
21. G.X. Ca R/S c 3 3.0 r4oo Tr +ve
22. J.B. Ca Sigmoid B 2 2.3 12.0 Tr+ve
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corresponding to areas of tissue showing severe 
dysplasia. Both of these tumours produced positive 
images pre-operatively. In table 5.5. the EMA 
expression of the tumours graded by the method of Ellis 
is compared to the T/NC ratios of the excised tumours. 
Patients whose resected tumours showed no EMA 
expression or focal staining alone had lower T/NC 
ratios than those expressing EMA (1.30 +/- S.D.0.26 vs 
2.45 +/- S.D.0.65, p=0.005)(Table 5.5.).
Safety of ^^In-ICR2 and anti-rat response
No reactions were noted to the intradermal 
injection of ICR2 and no acute anaphylactic reactions 
occurred in any of the patients as a result of the 
injection of the rat antibody. Similarly recordings of 
patients temperature, pulse and blood pressure 
following administration showed no obvious 
abnormalities nor did follow up measurement of FBC,
U & E's and LFT's. One patient (No.15 B.S.) who had 
recieved unlabelled MAb did, however, develop a 
transient period of generalised malaise associated with 
urticarial weals around the elbows at 5 days following 
antibody administration. This resolved spontaneously 
without treatment in 4 8 hours.
The response to rat antibody administration was 
measured in 42 serum samples from 12 patients. The 
majority of these samples were from the first 7 days 
following antibody administration (Figure 5.6).and none 
of these samples showed any evidence of an immune
Table 5.5. EMA expression and tumour uptake of radioactivity
Grading of antigen expression 
-ve or focal I II III IV
T/NC ratio
1.0 2.3 3.2 3.4
1.2 3.5 1.8 2.1
1.4 2.0 1.9
1.6 2.3 3.0
1.6
2.3
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response to rat antibody. All three samples analysed 
from the second week after antibody administration, 
however, showed evidence of a response as demonstrated 
in Figure 5.7.
Bo
un
d 
cpm
 
(I
12
5)
-b
kg
d 
x 
10
00
 
N
um
be
r 
of 
sa
m
pl
es
 
an
al
ys
ed
Figure 5.6. Human response to rat MAb
15 n
Days following administration 
Figure 5.7. Example of human anti-rat response
6
5
2 w eeks
4
3
Pre
2
4 days1
0
0 2 4 6 8 1 0 1 2
Serum dilutions (commence 1 : 4)
169.
5.2.iv. Discussion
Epithelial membrane antigen is expressed by a wide 
variety of normal tissues (201,202)  ^ Despite this, 
immunoscintigraphy of colorectal cancers has been 
achieved in the present study due to the differential 
expression of EMA between colorectal cancers and normal 
adjacent colon (201,207,248)#
ill
The sensitivity of ■L-LJ*In-ICR2 imaging for the
detection of primary colorectal cancers was 80% when
assessed with a knowledge of the clinical details,
which is considerably better than some previous reports
with this disease using both anti-CEA 
(100,104,105,292,295,296) ancj against other
tumour associated antigens (115“H 7 ) e some studies have 
been reported in which all primary cancers have been 
localised following radiolabelled antibody 
administration (106,293)# In these studies, however, it 
does not seem that the scans were interpreted blindly.
In the present study six of the 17 patients with 
colorectal cancer had metastatic deposits in the lymph 
nodes and three of these also had liver metastases. 
Imaging of these six patients localised only one 
metastatic site in the regional lymph nodes. These 
results are in keeping with other reports in which 
small tumour deposits fail to be localised. The 
inability to image small tumour deposits is due to the 
small absolute uptake of activity within the tumour 
tissue relative to background activity. *^^In is also 
rapidly taken up by normal liver and the majority of
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studies claiming satisfactory localisation of liver
metastases with 111In labelled antibodies are based on
the finding of areas of lower radioactivity within the
liver substance (^96) or areas of lower radioactivity
on a blood pool view which later show accumulation of
radioactivity (■'■0®). This provides little advantage
over conventional liver imaging with technetium
illcolloids or by ultrasonography. The uptake of ■LAXln 
labelled monoclonal antibodies by normal tissues 
including the liver is discussed in Section 4.1. and 
possible strategies for reducing this uptake in the 
introduction to the present chapter (Section 5.2.1). Of 
interest regarding the general distribution of the 
radiolabelled antibody was the rapid uptake by the 
testis. This has previously been noted on antibody 
imaging with anti-CEA and attributed to the presence of 
CEA in the testis (2^9)# This does not, however, 
explain the uptake in the present study as EMA is not 
expressed on the testis (J.P.Sloane, unpublished 
observations).
Although previous studies have suggested that an 
increased number of metastatic tumour sites may be 
localised by the pre-administration of unlabelled 
antibody this has not been confirmed in the present 
study(2^2'2^2). The previous studies have been 
largely based on patients with melanoma who had a large 
number of metastatic sites detectable by other means.
In these patients the administration of cold MAb has
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been shown to be associated with the detection of an 
increased number of metastatic sites. These studies 
have not been accompanied, however, with any measure of 
the effect on tumour uptake of the radiolabelled 
MAb by administering cold MAb. The significance of 
these results must, therefore, remain open to question.
Similarly the role of adding chelating agents to the 
injectate has been suggested empirically as a method of
111
removing any non specifically bound XA-LIn. Although 
this again produced no significant difference to the 
sensitivity of cancer detection the biodistribution 
data presented in Chapter 6 allows its use to be 
evaluated.
The specificity of tumour localisation has been 
demonstrated in the present study by two independent 
analyses. Firstly a positive localisation on external 
imaging was only seen with primary tumours when the 
tumour expressed the target antigen (which included the 
adenomatous polyps) while the single non antigen 
expressing primary cancer did not produce a positive 
scan. Secondly a correlation was found between the 
antigen expression of the resected tumours as graded by 
immunohistochemistry and the tumour to normal colon 
ratios found on gamma well counting of biopsies, those 
tumours showing a high grade of antigen expression 
tending to have higher uptake ratios. Other alternative 
methods which have been used to prove the specificity 
of radiolabelled MAb uptake include double labelling
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techniques in which specific and non specific 
antibodies are administered with different 
radionuclides having different energies of gamma 
emissions allowing their separation and flow cytometric 
analysis The accuracy of the former is dependent
on the biodistribution of the antibodies being 
unaffected by the radiolabel, which is unlikely 
(230,265,266)  ^ with the latter the connective tissue 
elements of the excised tumour may lead to considerable 
errors^^) . Neither technique was therefore felt 
likely to provide additional information.
The T/NC ratio found in the present study of 2.1 
('+/- S. D. 0.91) : 1 is similar to that quoted for the 
uptake of some MAb's by colorectal cancer (113,114,117) 
but significantly lower than that recently reported 
using an antibody to CEA (^0®). This difference in 
uptake may explain the difference between the 
sensitivity of tumour detection by scanning in the 
latter study (100%) and that of the present study 
(80%).
The low "signal to noise ratio" caused by the high 
background activity and low uptake of radiolabelled MAb 
in cancers results in poor definition of the tumours on 
scanning. Attempts to improve this ratio have centred 
on clearing the activity in the blood pool after 
allowing time for localisation of the antibody. This 
has been attempted by the use of a second antibody to 
produce clearance by the reticuloendothelial system 
(133)^ computerised subtraction of a second circulating
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radioisotope (122-124,131,132) or t^e use Q  ^
streptavidin-biotin complex (300-302)^
Two patients in the present study had large 
tubulovillous adenomas which expressed EMA in areas of 
dysplasia and produced positive scans. The association 
between EMA expression of polyps and their degree of 
dysplasia was noted in Section 2.2. and may represent a 
stage in the adenoma to carcinoma sequence. Although 
the detection of these two benign tumours reduces the 
specificity of the radiolabelled MAb for cancer 
detection it may obviously be advantageous were 
scanning to localise dysplastic benign as well as 
malignant lesions.
As with other studies on the use of radiolabelled
ill
antibodies ■LXXIn-ICR2 administration produced no 
harmful side effects to the patients. The finding of a 
primary response to rat antibody in the second week 
after administration, however, is of major importance. 
Many studies have observed the human response to mouse 
antibody administration and have correlated this with a 
reduced quality of immunoscintigraphy scans on repeated 
radiolabelled antibody administration (303-304)  ^ Little 
information, however, is available on whether rat 
antibody is equally as effective at sensitising humans 
and further studies will be required to clarify the 
situation.
CHAPTER 6
THE BIODISTRIBUTION OF THE INDIUM LABELLED MONOCLONAL 
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6.1. INTRODUCTION
Many studies over the last 10 years have 
demonstrated the localisation of radiolabelled tumour 
associated monoclonal antibodies in colorectal cancers 
and their imaging by a gamma camera(97-106). Tke 
majority of studies have reported the results of 
imaging but given no information on the biodistribution 
of the labelled antibody. As the complexity of the 
process between radiolabeled antibody administration 
and the immunoscintigraphy of cancers has been 
identified (Chapter 5), the necessity for detailed 
biodistribution studies has become apparent. To this 
end some recent reports on patient studies with 
radiolabelled antibodies have concentrated on 
biodistribution rather than imaging (242,243)# These 
studies, however, have failed to explain the reason for 
the effective imaging that can be achieved despite the 
presence of high levels of circulating antigen and 
immune complexes. Although it has been suggested that 
increasing the dose of antibody administered may 
improve tumour imaging (184,305-308) £ew studies have 
directly explored this mechanism and most have been 
based principally on the quality of the images 
produced(242'24^).
A major problem in immunoscintigraphy is the non
illspecific uptake of A-LAIn labelled MAb's as discussed in 
Chapter 4. It was concluded from the study on 
isolated hepatocytes and the antigen expressing
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tumour cell line that DTPA may have a role to play in
reducing the liver uptake of radioactivity found in
patient studies using ^^In labelled MAb's. It was also
suggested that the mechanism for this effect may be the
111removal of weakly bound ■LJ"LIn from the MAb molecule and 
its stable extracellular binding with DTPA.
In this study the biodistribution of ^^•*‘In-ICR2 is 
examined in patients with colorectal cancer whose 
external imaging was discussed in Chapter 5 and the 
effect of administering unlabelled antibody and 
of treating the injectate with DTPA is investigated.
The rate of urinary excretion and blood clearance of 
radioactivity and the specific organ uptake including 
the liver, spleen and bone marrow were determined as 
well as that of the excised tumours. The organ uptake 
of radioactivity was calculated by computer 
(Nodecrest, U.K.) by drawing a "region of interest" 
(ROI) around the organ being measured on the static 
gamma camera images. Because of the inaccuracies in 
this technique due to the scattering and absorption of 
radioactivity by normal tissues a phantom was used to 
calculate the percentage of the injected dose 
accumulating in the liver.
The level of antigen in the circulation prior to 
radiolabelled MAb administration was also measured as 
was the amount of immune complex forming after 
administration.
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6.2. Materials and methods
In chapter 5 the results were described of external 
illimaging with In-ICR2 in patients with known or 
suspected colorectal cancer. The technique was able to 
localise both primary and metastatic colorectal cancers 
but had a low specificity if the imaging of antigen 
expressing dysplastic polyps was considered to be a 
false positive result. It was also shown that a high 
tumour to normal colon differential uptake of 
radioactivity was dependent on the antigen expression 
of the tumours (Table 5.5.) and that an anti-rat 
antibody response may occur during the second week 
after administration. The results of imaging were not 
significantly different when DTPA was added to the 
radiolabelled antibody or if additionally unlabelled 
antibody was administered prior to labelled antibody. 
Furthermore no significant differences were found 
between these patient groups in the % I.D./g in tumour 
tissue or the T/NC uptake ratio (Table 5.3.)
In this study the biodistribution of In-ICR2 was
analysed in the 22 patients whose imaging was described 
in Chapter 5. This consisted of a control group of 10 
patients (Group A) to whom lmg of labelled antibody 
alone was administered, a second group (Group B) of 6
ill
patients whose injectate (lmg of ■LJ"LIn-ICR2) was 
reacted with DTPA as outlined in Appendix 5.4 and a 
third group of 6 patients (Group C) who also had DTPA 
added to their injectate prior to gel chromatography 
but who additionaly had an infusion of 5mg of
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unlabelled antibody administered in lOOmls of normal 
saline over the one hour prior to labelled antibody 
administration. The nature of the injectate for each 
patient is shown in Table 6.1.. The number of patients 
on whom each variable was studied is shown in the 
corresponding tables as it was not always possible to 
study each variable on all patients.
6.2.a) Blood clearance, urinary excretion and tissue 
uptake
The clearance of activity from the blood was 
calculated by collecting 10ml samples of peripheral 
venous blood in heparinised bottles at lOmin, 30 min, 
24, 48 and 72 hours following injection, which were 
centrifuged at 3000 rpm for 5 minutes and the activity 
in paired 2ml aliquots of plasma calculated as a 
percentage of the activity in the 10 minute sample.
For each patient a standard was prepared to allow 
the percentage of the injected dose in the other 
samples to be calculated. At the time of administration 
of ■*,^ In-ICR2 a weighed aliquot of the injectate was 
removed, diluted to 500mls in normal saline containing 
0.04 molar HC1 and a 2ml aliquot of this solution thus 
contained a known percentage of the I.D.. The counting 
of this 2ml standard in a gamma well counter along with 
the sample being measured allowed the % I.D. to be 
calculated. The preparation of this standard is more 
fully described in Chapter 5, page 160.
Table 6.1. Patients and their injectate.
Nature of the injectate 
No. Init. Diagnosis Site Hlln-ICR2 DTPA Cold MAb
1. M.D. Ca R/S + - -
2. M.B. Ca R/S + - -
3. R.S. recurr? _ + - -
4. R.N. Ca Hep flex + - -
5. D.N. Ca Hep flex + - -
6. J.L. Ca Rectum + - -
7. J.H. Ca Trans + - -
8. B.T. Ca Rectum + - -
9. J.P. Ca Sigmoid + - -
10. K.H. recurr? — + - -
11- M.J. Ca Sigmoid + + -
12. B.B. Ca Rectum + + -
13. V.D. Ca Sigmoid + + -
14. F.H. Ca Sigmoid + + -
15. B.S. Ca R/S + + -
16. R.D. Lipoma Sigmoid + + +
17. J.P. Ca Splen flex + + -
18. E.B. Adenoma Caecum + + +
19. D.O.N. Ca Sigmoid + + +
20. D.F. Adenoma Rectum + + +
21. GX Ca R/S + + +
22. J.B. Ca Sigmoid + + +
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The urinary excretion of activity was calculated 
for the first 12 hrs and two subsequent 24 hr periods 
following injection of the radiolabelled MAb. Bowel 
preparation prior to surgery prohibited urine 
collection beyond this period. Prior to administration 
of In-ICR2 patients were instructed to empty the
urinary bladder and this voided volume was discarded. 
Timed urine collections were then carried out at the 
end of which the urinary bladder was again emptied and 
the volume voided added to the last 24 hour collection. 
The urinary excretion was calculated as a percentage of 
the injected dose by relating the activity in 2mls of a 
thoroughly mixed urine sample to that of 2mls of the 
standard.
illThe uptake of xxxIn-ICR2 m  the colonic cancer 
tissue was determined following resection by 
counting weighed samples of tumour and normal colon in 
a gamma well counter, results being expressed as cpm/g. 
These were then calculated as a % I.D. by comparison 
with the standard counts and as a ratio of counts per 
gram in tumour to that of normal colon.
Organ uptake of radioactivity
Imaging data was used to calculate the In-ICR2
uptake in the liver, spleen, kidney and bone marrow. 
This was carried out using a phantom and region of 
interest (ROI) analysis for the liver and ROI analysis 
alone for the spleen, kidney and bone marrow. The 
latter involves the calculation of the % I.D. in the
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organ by comparing the counts obtained by imaging the 
injectate ^In-ICR2) with ROI analysis of the 
organs. This, however, is less accurate than the use of 
a phantom in a Temex trunk (see later) and ROI analysis 
as the phantom represents normal liver geometry, and 
the Temex the absorption and attenuation of normal 
human tissues.
Liver
Liver uptake was determined using an 
anthropomorphic liver phantom in a Temex trunk. The 
phantom consists of a hollow plastic container 
equivalent in size and shape to a human liver which may 
be filled with a radioactive solution. The Temex trunk 
is a rubber mould in the shape of the human trunk in 
which the liver phantom can be placed, and which has 
a density to radioactivity equivalent to that of human 
tissues. For each patient the phantom was filled with a 
known percentage of the injected dose of ^^^In-ICR2 . 
Anterior and posterior images of the patients liver and 
the Temex trunk containing the liver phantom were 
acquired for 300k counts in a 128 x 128 matrix and 
region of interest analysis used to calculate the 
geometric mean of the patients liver and the liver 
phantom activity as cps with decay correction to 
injection time.
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Uptake in liver liver cps* x C.F. x 100
as % I.D. =___ ___________________________
phantom cps* x % I.D. in phantom
* : Geometric mean and decay corrected
C.F. : Attenuation correction factor to compensate
for differences between patient and phantom 
antero-posterior diameter(Appendix 6.1.).
Spleen, kidney and bone marrow
Region of interest analysis was used on anterior 
and posterior abdominal images to obtain the geometric 
mean of the uptake of radioactivity (cps), decay 
corrected to the time of injection. Comparing this with
the injected cps calculated from imaging of the
injectate in its syringe allowed the % I.D. in these
organs to be calculated. The injected cps was
calculated by placing the injectate in its syringe on 
the collimator of the gamma camera and using ROI 
analysis to assess the counts emitted. The 
counts injected were calculated by subtracting 
this figure from the counts left in the 
syringe after injection.
Organ uptake organ cps x C.F. x 100
as % I.D. _______________________
injected cps 
The attenuation correction factor used in this 
calculation is different from that used for 
the liver and is described in Appendix 6.2.
Because of the small amount of radioactivity 
accumulating in the spleen, kidney and bone marrow
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resulting in a low % I.D., data was also compared 
between patient groups for these organs as the counts 
obtained over these organs over a 5 minute period per 
MBq of labelled activity injected. Counts were obtained 
from organ regions of interest on the posterior 
abdominal images as these most clearly delineated the 
organs. The regions of interest were based on the 
spleen, left kidney and the fourth lumbar vertebra.
Circulating EMA. levels
The circulating EMA level was calculated prior to 
labelled MAb administration and compared with imaging 
results, immune complex formation and tumour uptake of 
radioactivity. This was carried out in 15 of the 22 
patients using the methodology outlined in Chapter 
3, page 108.
Measurement of circulating immune complexes
When a solute passes down a chromatography gel its 
molecules diffuse both into and out of the gel matrix 
(stationary phase). Seperation on gel filtration 
depends on the different ability of various sample 
molecules to enter pores in the stationary phase. Very 
large molecules never enter the gel matrix and move 
rapidly through the column whereas small molecules 
enter the gel pores and move more slowly through the 
column. High performance liquid chromatography (HPLC) 
is therefore an accurate method of seperating molecules 
in order of decreasing molecular size and has been used 
for detecting labelled antibody and immune complex in
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patient serum.
Analysis of serum samples by HPLC was carried out 
using a Zorbax GF250 size exclusion column which was 
run with 0.25M PBS pH 6.8. Serum samples were spun 
on a microcentrifuge (Hawksley, U.K.) to remove any 
clot or debris prior to 20ul aliquots being injected 
into the port of the HPLC. The molecular weight of 
eluted fractions was calculated against a commercially 
available standards package (Pharmacia, Upsalla,
Sweden).
Serum samples were analysed both prior to and
following 111In-ICR2 administration. "Cold" serum was
reacted with 12^I-ICR2 at a concentration of
0.3ug labelled antibody per ml of serum, an amount
equivalent to the distribution within plasma following
the administration of lmg of labelled antibody to a
patient with a plasma volume of 3 litres. The level
of immune complex formed in this sample was then
used as a control for each patient against which the
ill"hot" samples following ■LXXIn-ICR2 administration were 
compared. 125 j wag usecj rather than Hlln-ICR2 for this 
purpose because of its longer half life allowing an 
aliquot to be stored and used on several occasions. 
"Hot" serum samples, taken following Hlln-ICR2 
administration, were analysed directly without 
additional radiolabelling being required.
Aliquots of 20ul of serum which had either been 
reacted with 12^I-ICR2 or sampled following Hlln-ICR2 
administration were eluted through the HPLC column with
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PBS (0.25M, pH 6.8). The protein peak was charted by 
its U.V. absorption at 320nm and 0.5ml aliquots were 
collected and counted in a gamma counter (LKB 
Compugamma 1282, LKB Instrument, Stockholm)
Titration of unlabelled antibody
To investigate the possible effects on immune 
complex formation of administering unlabelled antibody 
prior to injection of the radiolabelled antibody plasma 
samples were taken from three patients and mixed with 
unlabelled ICR2 MAb to give a 1:1, 3:1, 10:1 and 100:1 
ratio of unlabelled ICR2 to the subsequently added 
125I-ICR2. Following the addition of 125I-ICR2 the 
samples were incubated for one hour then analysed by 
HPLC. Aliquots of 0.5ml were again collected from the 
column and counted in a well counter (LKB Compugamma)
HPLC analysis of patient sera
HPLC analysis of serum was carried out on 16 of
the 22 patients studied with In-ICR2. Samples taken
prior to antibody administration were reacted with
-*-2^I-ICR2 as were samples analysed following
administration of unlabelled ICR2. Further serum
analysis was carried out in patients at 10 and 30
illminutes following ICR2-InXJ-A administration as well as 
at 24 and 48 hours. The activity present as high 
molecular weight complex was calculated by integration 
of the area under the activity versus eluted volume 
curve.
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6.3. RESULTS
6.3.a) Blood clearance, urinary excretion and tissue 
uptake of activity. 
Blood clearance
The clearance of activity from the circulation is 
shown as a percentage of the circulating activity at 10 
minutes after injection in Figure 6.1.. The effective 
half life of circulating activity was 39 hours for the 
control group, 33 hours for Group B(DTPA alone) and 27 
hours for Group C(DTPA and cold MAb). The rate of blood 
clearance in Groups B and C was more rapid than for 
Group A, this being statistically significant for DTPA 
at 48 hours (p=0.005) and for the cold MAB at both 24 
hours (p=0.034) and 48hrs (p=0.0000)(Table 6.2.and 
Appendix 6.3.).
Urinary excretion of activity
The mean urinary excretion of activity in group A 
(controls) was 16.2% of the injected dose in the first 
12 hours, 3.2% for the next 24 hrs and 2.1% for the 
subsequent 24hrs (Table 6.3., Figure 6.2.a, Appendix
6.3.). Treatment of •*'In-ICR2 with DTPA reduced the 
mean urinary excretion of activity by 82% in the first 
12 hour period following injection (16.2+/-S.D.6.94 vs 
2.9 +/-S.D.1.8, p=0.007). No significant differences in 
excretion of activity were noted over the subsequent 48 
hours. The administration of cold MAB in addition to 
DTPA had no significant effect on the urinary excretion 
of activity.
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Figure 6.1. Blood clearance of activity
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Table 6.2. Blood clearance of activity
Time after administration
Patient group 10 min 30 min 24hrs 48hrs 72hrs
Controls (n=9) 100 95+1-6 61+1-1 44+/-3 24+/-7
DTPA alone(n=5) 100 96+/-2 59+/-8 35+/-6* 26+/-4
Cold MAb(n=6) 100 90+/-5 53+7-5+ 34+/_4++ 19+/-3
Activity is shown as a percentage of that at 10 minutes following injection. 
All results are mean +/- standard deviation.
Statistical comparison with controls * p = 0.005,+ p = 0.034,++ p = 0.000
Table 6.3. Urinary excretion of activity
Time after administration 
Patient group lstl2h rs next24hrs next24hrs
Controls(n=6) 16.2+/-6.9 3.2+/-0.9 2.1+/-1.0
DTPA alone(n=4) 2.9+/-1.8* 2.4+/-0.5 2.5+/-0.3
Cold MAb(n=6) 4.1+/-1.6+ 2.1+/-1.3 2.0+/-0.8
Mean % I.D.+/- S.D.
Statistical comparison with controls * p = 0.007,+ p = 0.012 
Cold MAb vs DTPA alone, n.s.
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The nature of the activity in the urine was 
analysed in a random selection of specimens using HPLC 
and was found in all cases to be in a single low 
molecular weight form. An example is shown in Figure
6.2.b. with the HPLC of the same patients serum 
superimposed for comparison of the molecular weights 
(high M.Wt. to left of page).
Tissue uptake of activity
The uptake of activity by tumour and normal colon 
have been described in Chapter 5 (5.2.iii.b., page 166)
Organ uptake of ^^In-ICR2 
Liver
The uptake of activity in the liver in the initial 
30 minutes calculated from the dynamic imaging is shown 
compared with blood pool activity in Figure 6.3.
This was measured by taking sequential ROI's of both 
the liver and an area overlying the heart representing 
blood activity. After the initial phase the blood 
activity gradually declines whereas that of the liver 
continues to rise suggesting an active uptake 
mechanism. Comparing this early uptake between the 
control, DTPA and cold MAB groups demonstrates a wide 
range in the rate of uptake between patients and no 
significant differences between the groups (Figure 6.3. 
and Appendix 6.4.). By 48 hours 20-30% of the I.D. has 
accumulated in the liver as calculated using the 
phantom. This was significantly higher in the DTPA
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Figure 6.3.
The activity-time curve for the liver is shown for the first 30 minutes 
following ***In-ICR2 administration and compared with blood pool 
activity using a region of interest centered on the heart. The 
background level of activity is also shown.
Heart
Liver
Background
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group than the control group at 45 minutes (p=0.049),
24 (p=0.029) and 48 hours (p=0.002). The administration 
of unlabelled antibody produced a significant reduction 
in the uptake of activity in the liver at 48 hours when 
compared to the group with DTPA alone (32% vs 26%, 
p<0.05)(Table 6.4., Figure 6.4., Appendix 6.5.).
Spleen
Within the first 48 hours following administration 
2-3% of the injected dose accumulated in the spleen 
(2.44+/-S.D.1.4, control group). There was no 
significant difference in the % I.D. in the spleen 
between the patient groups at 45 minutes or 24 hours 
although by 48 hours the uptake was significantly 
greater for both the DTPA group (p=0.05) and cold MAB 
group (p=0.048) (Table 6.5., Appendix 6.6.) However, 
using the ROI cts / 5 min/ MBq evaluation, significant 
differences were noted between the control and the DTPA 
group at 45 minutes (p=0.05) and between controls and 
the cold MAB group at 45 minutes (p=0.000), 24 hours 
(p=0.000) and 48 hours (p=0.000)(Table 6.6., Figure
6.5., Appendix 6.7.)
Renal and marrow uptake of radioactivity
Approximately 2% of the injected dose accumulated 
in the kidney (left) by 45 minutes (2.04+/-S.D.0.49) 
and remained at a similar value for the subsequent 48 
hours. No significant differences were noted between 
the patient groups as regards the renal or bone marrow
Table 6.4. Liver uptake of ^^4n-ICR2
Time after administration 
Patient group 45 mins 24hrs 48hrs
Control(n=9) 18.1+/-3.2 20.7+/-3.5 21.9+/-4.6
DTPA alone(n=6) 22.2+1-2.6* 26.0+/-4.9** 31.8+/-3.7***
Cold MAb (n=6) 18.7+/-6.0 22.8+/-4.4 25.8+/-4.0+
Figures are the mean % injected dose +/- standard deviation.
Statistical comparison with controls * p = 0.049, ** p = 0.029, *** p = 0.002 
Cold MAb vs DTPA alone,+ p < 0.05
Table 6.5. Spleen uptake of ^^^In-ICR2 as % I.D.
Time after administration 
Patient group 45 mins 24hrs 48hrs
Control(n=8) 2.44+/-1.4 2.14+/-0.95 1.93+/-0.72
DTPA alone(n=5) 3.07+/-0.9 2.60+/-0.85 2.74+/-0.35*
Cold MAB(n=6) 3.00+/-0.7 2.97+/-0.65 2.83+/-0.66**
Figures are the mean +/- standard deviation. 
Statistical comparison with controls * p = 0.05, ** p = 0.048
Table 6.6. Spleen uptake as cts/5 min/MBq
Time after administration
Patient group 45mins 24 hours 48 hours
Control (n=8) 433+/-154 470+/-159 450+/-149
DTPA alone(n=5) 603+/-124+ 615+/-141 526+/-76
Cold MAb(n=6) 815+/-157* 859+/-110** 800+/-143***
Results are mean +/- standard deviation
Statistical comparison with controls + p =0.05, * , **, *** all p = 0.000
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uptake of activity.(Table 6.7., appendices 6.8.,
6.9., 6.10.)
HPLC analysis
The nature of the labelled antibody was analysed for 
both the -^25j ancj llljn labels and was found to elute 
as a single peak corresponding to a molecular weight of 
the standard of 150-160,000 (Figure 6.6.). When 
antibody with either label was combined with human 
serum from either cancer or normal patients two peaks 
eluted, the first comprising approximately 30% of total 
activity and the latter 70%. The former eluted with the 
void volume of the chromatography column and had a 
M.Wt. > 600,000. The latter corresponed to the 150- 
160,000 of IgG (Figure 6.7.).
The titration of unlabelled antibody
The results are shown for the progressive increase 
in cold antibody concentration in Figure 6.8.(a-d).
In all of the patients serum studied the activity 
forming the high molecular weight complex was reduced 
by progressive increases in cold antibody 
administration. In the sample shown a decrease was 
achieved in the percentage of the radiolabelled 
activity forming immune complex from 37.6% at a 1:1 
ratio of cold to labelled MAb to 26.3% at a 10:1 ratio.
Table 6.7. Renal uptake of activity
Patient group
Time after administration 
45min 24hrs
4
48hrs
Control (n=10) 434+/-107 475+/-116 423+/-102
DTPA alone (n=5) 436+/-138 470+/-165 422+/-140
Cold MAb(n=6) 523+/-120 600+/-116 586+/-87
Results are mean counts/5 min/ MBq injected activity +/- standard deviation
Table 6.8. Immune complex formation
Patient group 
No cold MAb Cold MAb
Pre MAb admin 32+ /-2 33+ /-5
Post cold MAb 30+ /-2
Post n i In-ICR2
10m in 34+/-6 30+/-6
30min 31+/-6 28+/-6
24hrs 28+/-8 23+/-6
The results shown are the % of circulating activity present in the high 
molecular weight form. All mean +/- S.D..
Figure 6.6.: HPLC of injectate
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Serum analysis from imaging study patients
HPLC analysis of serum was carried out on 16 of
the 22 patients studied with 111In-ICR2. Prior to
•*-1^In-ICR2 administration 31.5 (+/- S.D. 3.60) of the
activity was associated with the high molecular weight
complex. Following patient administration the
activity associated with the high molecular weight peak
decreased gradually with time.(Table 6.8. and Figure
6.9.) Five of the 6 patients given a 5mg dose of
111unlabelled antibody prior to *LJ-J*In-ICR2 administration 
had analysis of the high molecular weight complex after 
this step.(Figure 6.10.) Cold antibody administration 
reduced the mean level of high molecular weight complex 
from 34.2% (+/-S.D.4.66) to 30.2% (+/-S.D.1.92).
Circulating EMA levels
The mean EMA level measured in 15 of the patients in
the present study of 544 (+/-S.D.340) ng/ml was not
statistically different from 830 (+/-S.D.1462) and
714 (+/-S.D.609) for the colorectal cancer and control
groups respectively, studied in Chapter 3. Three of the
15 patients had levels greater than 1000 ng/ml, of
which one had extensive liver metastases in both lobes
of the liver, and another had two synchronous cancers.
Only one patient had a level less than lOOng/ml. This
patient had a small tumour which failed to image with 
ill In-ICR2 although the antigen was expressed by the 
tumour when examined on immunocytochemistry.
Figure 6.9. Clearance of immune complex
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Since the % I.D. taken up in the tumours and the 
tumour to normal colon uptake ratios were not 
significantly different between the patient groups the 
EMA levels on all patients were pooled and 
compared with other measurements.
There was no significant difference in the blood
clearance of activity within the first 48 hours of
111In-ICR2 administration between patients with low
(n=9, < 500ng/ml) or those with high (n=6, >500ng/ml)
circulating EMA levels (Figure 6.11.). A positive
correlation was, however, found between the EMA level 
illprior to AAJTn-ICR2 administration and the amount of 
immune complex subsequently forming in the circulation 
(n=ll, r = 0.61, p <0.05) and the % of the injected 
dose taken up by the tumour (n=9, r=0.65, p= 0.05 
(Table 6.9., Figures 6.12. and 6.13.).
No significant correlation was found between the 
circulating EMA level and the uptake of activity by 
either the liver or spleen (Table 6.9.).
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Figure 6.11.: [EMA] and blood activity
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Figure 6.12.: [EMA] and immune complex formation
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Figure 6.13.: [EMA] and tumour uptake
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Table 6.9. Circulating antigen
No. Initial [EMA]
ng/ml
% high mol wt 
complex*
Tumour
%I.D./g**
Liver 
% I.D.
Spleen 
% I.D.
1. M.D. 220 NA 6.5 25 NA
2. M.B. 420 27 1.6 NA NA
3. R.S. NA NA NA 23 NA
4. R.N. 300 31 2.4 19 2.0
5. D.N. 470 NA 4.3 18 3.7
6. J.L. 490 29 6.2 20 1.9
7. J.H. 480 NA 12.0 17 1.6
8. B.T. 640 31 10.0 16 1.1
9. J.P. 1150 33 NA 22 1.5
10. K.H. 720 NA NA 26 3.2
11. M.J. NA NA 8.4 29 2.9
12. B.B. 170 30 NA 23 2.6
13. V.D. 650 33 16.0 25 2.8
14. F.H. 60 28 NA 25 3.8
15. B.S. 1030 30 NA 34 2.3
16. R.D. 360 27 6.5 20 2.6
17. J.P. 1150 33 7.2 25 1.2
18. E.B. NA 34 6.0 19 3.3
19. D.O.N. NA 27 9.0 26 2.2
20. D.F. NA 35 NA 27 2.4
21. G.X. NA 40 8.1 16 3.8
22. J.B. NA 35 12.0 24 3.5
* In samples taken prior to both cold and hot antibody administration.
** % I.D. x 10‘3/g
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6.4. DISCUSSION
The patients studied in Chapter 5 (external imaging)
were divided into three groups depending on whether
illthey received lmg of xxxIn-ICR2 alone, had their
injectate incubated with DTPA or were given, in
addition, cold MAb prior to radiolabelled MAb
administration. The purpose of these manipulations was
to increase the tumour to normal colon ratio of uptake
by reducing the administration of free ^^^In (DTPA
group) or by competitively inhibiting immune complex
formation (cold MAb group) in order to improve the
quality of images produced. Both the scan appearances
and the tumour to normal colon ratios achieved,
however, were not significantly different between the
groups. In this chapter the effect was analysed of DTPA
and cold MAb administration on the biodistribution of 
ill In-ICR2 in these groups of patients.
111A role for xIn chelating agents for the scavenging
ill illof any free In present with an xxxIn labelled
antibody preparation has been suggested on an empirical
basis (2^3). pew animal studies have been carried out
to investigate this problem and none which are directly
relevant to the clinical situation. In 1986 Goodwin
reported on the effect of the intraperitoneal
injection of EDTA (5mg) commencing immediately after
the administration of ^^^In-DTPA-MAb to mice(^®^). This
resulted in an increased urinary excretion of activity
whereas in the present study the urinary excretion of
activity was reduced in the patient group recieving
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DTPA. This difference may be explained by the chelate 
being administered to the animal in Goodwin's study 
rather than to the labelled antibody prior to 
chromatography as in the present study which separated 
the chelated activity from the labelled antibody and 
allowed its removal prior to administration. The effect 
of administering 0.2mls of 30mmol DTPA 15 minutes 
before or 1 hour after administration of the labelled 
antibody on the normal biodistribution of ^^^In-MAb in 
mice has also been investigated in a further study with 
no effect being found on the percentage of the injected 
dose taken up by the liver (^83)^ The effect on 
biodistribution of the addition of chelate to the 
injectate prior to administration has not previously 
been investigated in patient studies.
In Chapter 4 a model of isolated rat hepatocytes and 
a tumour cell line established that the chelating agent 
DTPA reduced the uptake of activity from ^^In-MAb, a 
reduction in hepatocyte uptake of 40% being acheived by 
incubating the labelled MAb with a 0.5mM [DTPA] for 15 
minutes prior to administration. This occurred without 
a significant reduction in uptake of activity by the 
tumour cell line. In the patient studies the labelled 
MAb was similarly incubated with 0.5mM [DTPA] for 15 
minutes although prior to administration unbound 
activity was seperated and removed by gel 
chromatography.
The reduction in the early urinary excretion (first 
12 hours after administration) found in the groups
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receiving DTPA would suggest that a reduced amount of
activity which is not firmly adherent to the antibody
molecule has been administered, this activity normally
being excreted in the urine. This would support the
suggestion that the effects are mediated by the removal
illof non specifically bound XJ-J-In from the MAb by the 
chelate.
The clearance of activity from the circulation was
more rapid in the chelate group than with controls.
Because of the removal of non specifically bound ^^In
from the injectate in this group a smaller percentage
1 1 1of circulating activity will be in In-transferrin
illform rather than stable In-DTPA-MAb. The difference 
in the rates of clearance of radioactivity from the 
circulation may therefore reflect the relative rates 
of removal of labelled antibody by the
reticuloendothelial system and ^^^In-Tf by the sites of 
transferrin receptors.
Contrary to the result expected from the studies 
carried out in Chapter 4 the liver uptake as a 
percentage of the injected dose was significantly 
increased following DTPA administration to the 
injectate. As this group of patients will have less 
free activity in the circulation this would suggest 
that the uptake in the liver is related to the 
radiolabelled antibody and not the low molecular weight 
complex which is excreted in the urine.
The clinical findings did not correspond with the 
substantial reduction in the hepatocyte uptake seen in
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the experimental situation (Chapter 4). This may 
reflect unavoidable differences in methodology. In the 
tissue culture studies both the chelate and the 11'LIn- 
MAb to which it had been added were subsequently 
incubated with the cells. In patient studies, however, 
gel chromatography was carried out after application of 
DTPA to the labelled antibody as explained previously. 
The presence of the chelate in the medium surrounding 
the cells may be required to produce a significant 
reduction in the cell uptake of radioactivity. This is 
likely to be the case if a constant dissociation of
In from the antibody bound chelate is occurring, a 
phenomenon which has been described as "chelate 
leak"(^^). An additional factor making a comparison 
difficult is that the method for measuring the liver 
uptake of activity in patient studies gives the total 
uptake of activity. The presence of blood pool activity 
in addition to cellular uptake of activity may result 
in the differences in cellular uptake being disguised 
if blood pool activity is high.
The uptake of activity by the spleen was also 
significantly greater in those patients in whom DTPA 
was administered. This would suggest that this effect, 
as with the liver, is related to a reduction in the 
urinary excretion of activity rather than an increased 
uptake per se.
The significance of circulating antigen levels and 
the formation of immune complex on the quality and 
effectiveness of radiolabelled antibody imaging has not
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been investigated adequately in human studies. Earlier 
reports suggested satisfactory imaging could be 
obtained with anti-CEA in the presence of high 
circulating levels of the antigen(^). Many antibodies 
presently used for immunoscintigraphy are directed 
against secreted tumour associated antigens 
(235,309-312) ancj m a n y  studies have demonstrated that a 
large proportion of injected radiolabelled antibody 
forms immune complexes in the circulation 
(100,261,313,314)  ^ Tke ^ g g  dependent effects on
biodistribution and improved tumour targetting reported 
with the use of higher antibody dosages (305-307,315) 
may be related to the formation of immune complexes 
with the radiolabelled MAb. This relationship between 
tumour antigen, circulating antigen, immune complex 
formation and tumour uptake of activity appears to be 
complex. In animal xenografts Martin demonstrated an 
increased CEA secretory rate and serum CEA with 
increasing size of the tumour with the tumour CEA 
content and secretory rate per gram remaining 
constant( ) .  in contrast Philben reported no 
difference in circulating CEA levels with tumour size 
and CEA content again using a mouse xenograft model 
(317) whiist in human studies a poor correlation 
between tumour CEA content and the level of plasma CEA 
was reported by Wagener^^®).
It would appear that the correlation between tumour 
antigen expression and the circulating level is 
variable even for a particular antigen and may
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therefore depend on the epitope being measured.
An apparent contradiction also exists when considering 
the association between the level of circulating 
antigen and the tumour uptake of radioactivity 
following radiolabelled MAb administration. In the 
present study high levels of circulating EMA were shown 
to be associated with increased immune complex 
formation and increased uptake of radioactivity in the 
tumour. This has previously been reported in some 
studies investigating tumour CEA expression (317,319) 
but contradicts the findings of Hagan (264) 
high levels of circulating antigen were associated with 
increased levels of circulating immune complex but 
reduced tumour uptake of radioactivity. The latter 
study also demonstrated a high liver uptake of activity 
which was explained by the clearance of increased 
immune complex by the reticuloendothelial system. These 
differences in biodistribution may be explained by 
variation in the immunogenicity of the immune complex 
formed and hence the likelyhood of its clearance by the 
RES. Why tumours with high antigen content, secretion 
and circulating levels should image satisfactorily in 
the presence of high levels of immune complex may be 
explained if the images produced are related to a 
sequestration of complex in the tumour or an exchange 
of radiolabelled MAb between the circulating immune 
complex and the tumour bound antigen.
The rationale behind the administration of cold MAb 
prior to labelled MAb injection may at first appear
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logical although the interactions involved are poorly 
understood and have scarcely been investigated.
Cold MAb will bind with circulating antigen and reduce 
the immune complex formed with radiolabelled MAb 
allowing more of the labelled antibody to be available 
for binding with the target antigen on the tumour 
tissue. On this rationale Carrasquillo and his 
colleagues (?43) pre-administered varied doses of cold 
MAb to patients with melanoma prior to administration 
of radiolabelled MAb and reported improvements in the 
quality of pictures obtained when higher dosages of 
cold MAb were administered. This observation was not, 
however, supported by any objective evidence that a 
higher percentage of the injected radioactivity was 
present in the tumour tissue or that the background 
uptake of radioactivity was reduced. Caution is 
required to ensure that the cold antibody is not only 
preventing immune complex formation with the 
radiolabelled antibody but blocking its binding to the 
target antigen on tumour tissue.
The HPLC analysis on cold serum in the present study 
suggested that immune complex formation could indeed be 
inhibited with the addition of cold MAb and the 
specificity of the antibody / antigen reaction was 
demonstrated by the inability of a isotype matched 
antibody to effect its formation (Personal 
communication, J Babich, Institute of Cancer 
Research, Sutton , Surrey). The dose of cold MAb 
administered in the patient studies (5mg) was an
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arbitrary choice which was considered likely to produce 
a significant and analysable effect on biodistribution 
without swamping the antigen expression of the tumours. 
In contrast to the results of Carrasquillo (^43) these 
patients showed no obvious improvement in the quality 
of their scans. In addition no significant difference 
was found in the tumour to normal colon ratio in these 
patients when compared to those of controls.
With a 5mg dose of cold antibody a mean reduction of 
only 4% in the amount of circulating immune complex was 
achieved and no significant difference in the rate of 
blood clearance of activity was established. The 
reduction of RES uptake of radioactivity which would 
have been expected due to the receptor mediated removal 
of immune complex was supported by a significant 
reduction in the liver uptake of activity at 48hrs 
although surprisingly the spleen uptake of 
radioactivity has increased rather than decreased. This 
may suggest that rather than avoiding the formation of 
circulating immune complex and hence RES uptake of 
radioactivity that the cold MAb has in fact "primed" 
the RES system to clear immune complex.
In conclusion the analysis of biodistribution in
these patients would suggest that tumour uptake of
radioactivity is increased by high levels of
circulating immune complex and that this is directly
related to the level of circulating antigen. Although
DTPA treatment of the injectate reduces the amount of 
111free AAAIn in vivo and hence the urinary excretion of
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activity this is not reflected by an improvement in 
scan quality or in a reduction in the uptake of 
radioactivity by the liver. Cold MAb administration 
prior to radiolabelled MAb has been shown to produce a 
reduction in the level of circulating immune complex 
although large doses would be required to prevent its 
formation. The reduction in immune complex produced in 
the present study was not, however, associated with an 
increased uptake of activity in tumour tissue or tumour 
to normal colon ratio.
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7.1. s PATIENT STUDIES ON INTRA-OPERATIVE 
RADIOIMMUNOLOCALISATION 
a) Introduction
In Chapter 1 (Section 1.3.iii.a) the use was 
described of a gamma radiation detecting probe(GDP) for 
the intra-operative(I/O) radioimmunolocalisation(RIL) 
of colorectal cancer deposits following their uptake of 
radiolabelled antibodies.
The feasability of this technique was originally 
described by Aitken and his colleagues in 1984 (147) 
who used a CEA secreting xenograft and an 131j labelled 
anti-CEA antibody to demonstrate that elevated counts 
could be recorded over the tumour with the gamma 
detecting probe. Having established the technique with 
the CEA secreting xenograft Aitken carried out I/O 
probing in a patient with a colorectal cancer following
1 O 1
the administration of •LJAi labelled anti-CEA. 
Unfortunately the counts detected over the tumour were 
low as was the tumour to normal colon (T/NC) ratio.
A series of patients with both primary and recurrent 
colorectal cancers was then investigated using 13 
labelled anti-CEA . In this study higher T/NC ratios 
were obtained with a mean T/NC ratio of 3.97:1 in 
primary and 4.18:1 in recurrent cancers. These figures 
were not compared, however, with the actual uptake as 
measured by the gamma well counting of biopsies and 
no clinical benefit to these patients was 
established (143).
It was apparent from these preliminary studies that 
the results were limited by a high background 
radioactivity and low T/NC ratio of counts. 0'Dwyer 
attempted to overcome these problems by the use of the 
MAb 17-1A, an alternative target antigen expressed by 
colorectal cancers. In addition the use of F(ab')2 
fragments was explored in an attempt to overcome the 
problem of Fc receptor mediated clearance of 
radiolabelled antibody and an alternative radiolabel, 
1251, (jue to its long half life(60 days) which allows 
time for the clearance of background radioactivity 
prior to probing. Despite these modifications the mean 
T/NC ratio obtained with the probe in this study was 
only 3.4:1 with whole antibody and 2.3:1 with 
fragments, values which were significantly less than 
those found from gamma well counting of biopsies. 
Despite these problems results obtained using the GDP 
contributed to the intra-operative management in three 
of the 18 patients studied (149). similarly use of the 
GDP altered the management in 6 of the 31 patients 
studied by Sickle-Santanello and colleagues using 125j 
labelled MAb B72.3 (1^®), which recognises the Tag 72 
antigen. Other recent reports on I/O probing using 125j 
labelled B72.3 have shown that the intra-operative 
findings may be correlated with the results obtained by 
gamma well counting of excised tissue (320) ancj ^hat 
the same technique may be applicable to other cancers 
(321)# Furthermore the use of I/O probing following 
administration of 1^I-B72.3 has been shown to localise
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colorectal cancer deposits not detectable by other
means including barium studies, CT scanning and
exploratory laparotomy (^22)#
The best results obtained so far with I/O RIL have
employed the MAb B72.3 which recognises the target
antigen Tag 72. This antigen is expressed by the
majority of adenocarcinomas and by a variety of normal
tissues, particularly the breast. The similarity of the
distribution of this target antigen with EMA would
suggested that ICR2 may be suitable for the I/O RIL of
colorectal cancers.
The radionuclides ^lj ancj 125j have been used in
previous clinical studies. Because of its favourable
energy of gamma emissions, lack of beta emissions and
illsuitable half life, -L-LJ'In, a radionuclide frequently 
used for external immunoscintigraphy but not previously 
investigated for I/O radioimmunolocalisation has been 
selected for antibody labelling in this study.
The two main types of radiation detector available 
for intra-operative use have been investigated in both 
the clinical and experimental evaluation of I/O RIL. 
These probes, which have been described in Section 
1.3.iii.b), utilise crystals of either Nal or CdTe.
The clinical study carried out in part 1 of this 
chapter investigates patients with suspected primary or 
recurrent colorectal cancer.
204.
Patients, materials and methods
Sixteen of the patients with primary colorectal
tumours on whom external imaging had been carried out
illfollowing the administration of xxxIn-ICR2 (see Chapter 
5) were investigated using the GDP at the time of 
surgery . The clinical details of the patients and the 
findings on external imaging are shown in Table 7.1.
The radiolabelled antibody was given 3-6 days prior to 
surgery and was prepared and administered as described 
in Appendix 5.4.
Intra-operative probes
Two types of radiation detector were used for the
intra-operative detection of gamma emissions following
the administration of -*-^In-ICR2. A Nal(Tl)
scintillation detector with a crystal (Harshaw) 26mm
diameter and 20mm thick connected to a photomultiplier
tube (PMT, EMI) and collimator designed in-house for
illthe intra-operative detection of xxxIn was used in 11 
patients with colorectal cancer (Figure 7.1.). 
Subsequently a CdTe semiconductor probe designed for 
surgical use was used in a further five patients 
(Radiation Monitoring Devices, Watertown,
Massachusetts. Figure 7.2.)
Intra-operative counting
At the time of surgical resection, counting was 
carried out with the gamma detecting probe in a sterile 
instrument drape. After opening the abdomen but prior
Table 7.1. Patient details and results of external imaging
No. Init. Age Sex Diagnosis Site Dukes Imaging
1. M.D. 60 M Ca R/S B +
2. M.B. 83 F Ca R/S B N.A.
5. D.N. 51 M Ca Hep flex B +
6. J.L. 71 M Ca Rectum C +
7. J.H. 79 F Ca Trans B -
8. B.T. 58 F Ca Rectum B +
11. M.J. 67 F Ca Sigmoid C +
12. B.B. 54 F Ca Rectum C +
13. V.D. 74 F Ca Sigmoid B +
14. F.H. 76 F Ca Sigmoid B -
16. R.D. 64 M Lipoma Sigmoid - -
17. J.P. 76 F Ca Splen flex B -
18. E.B. 73 F Adenoma Caecum - +
19. D.O.N. 73 F Ca Sigmoid C +
21. G.X 67 M Ca R/S C +
22. J.B. 56 M Ca Sigmoid B +
R/S : rectosigmoid 
Hep flex : hepatic flexure 
Splen flex : splenic flexure 
Trans : transverse colon
Figure 7.1. Sodium Iodide (Nal) probe
The Na I probe is shown connected to a multichannel analyser via a power 
supply and signal amplifier.
Figure 7.2. : The Cadmium Telluride (CdTe probe)
The CdTe probe is shown with interchangeable collimators and ratemeter.
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to mobilising the tumour, counts were taken for twenty- 
seconds and repeated three times on the right and left 
sides and anterior to the tumour. The probe was held 
stationary, flush with the tumour and at right angles 
to the surface. The twenty second count period could be 
preset automatically with both detector systems and the 
number of gamma emissions recorded over this period 
displayed numerically.
Two seperate sites were used for the counting of 
normal colon, three counts being recorded at both sites 
for a period of twenty seconds. Having mobilised the 
primary tumour on its mesentery this was palpated for 
the presence of enlarged lymph nodes suspicious of 
containing metastatic tumour. Any nodes palpated were 
counted with the gamma detecting probe, again 
triplicate counts being taken over a twenty second 
period. Lastly the liver was probed with triplicate 20 
second counts being recorded over the right and left 
lobes.
Probing the resected specimen
In order to quantify the effect that background and 
specific organ uptake had on the measurements obtained 
by intra-operative probing, the specimen of tumour and 
normal colon was again probed after it had been removed 
from the patient.
Immediately after resecting the specimen it was 
washed to remove blood and any remaining bowel contents 
then orientated anatomically on a flat surface. The
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sites at which the tumour was scanned intra-operatively 
were then located and re-counted for three 20 second 
periods.
In four patients the resected specimens were probed 
at identical sites with both the Nal and CdTe probes. 
Triplicate counts over a twenty second period were 
taken using each detector to allow the results obtained 
to be compared directly.
Comparison of probe results with other data
The results obtained on intra-operative probing were 
expressed as the ratio of the mean counts obtained over 
the tumour to the mean counts measured over normal 
colon (T/NC ratio). Similarly the counts obtained over 
the tumour and the normal colon for the resected 
specimen were expressed as a ratio of the mean counts 
(T/NC ratio). These results were compared, for each 
patient, with the ratio of uptake calculated from the 
counts obtained per gram of resected tissue by weighing 
and gamma well counting biopsies from both the tumour 
and the normal colon. A comparison was also carried out 
between the intra-operative T/NC ratios and the %
I.D./g in tumour tissue calculated using a standard as 
described in Chapter 5 (5.2.iii.b, pl60) . Finally the 
T/NC ratios obtained were compared with the antigen 
expression of the resected tumours as measured by 
immunocytochemistry. Statistical comparisons were made 
by the students t test.
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Results
To allow the tumour to normal colon (T/NC) uptake 
ratios for both the Nal and CdTe probes to be grouped 
together for comparison with other data the results 
were compared between the two groups of patients. No 
significant differences were found in the T/NC ratios 
found at operation, on the resected specimen or on the 
gamma well counting of biopsies. In addition when the 
same resected specimens were probed with both the CdTe 
and Nal probe the counts obtained with the latter were 
significantly higher than with the former (151+/-S.D.60 
against 1215+/-S.D.602, p=0.03) but the T/NC ratios 
were not significantly different (Table 7.2, 7.3.,
7.4.) T/NC ratios for both probes was therefore 
considered together for comparison with other data.
Of the 16 patients studied 14 had primary colorectal 
cancers, two with liver metastases and two had benign 
colonic tumours, a large sigmoid lipoma in one patient 
and a large dysplastic tubulovillous adenoma of the 
caecum in the other. The intra-operative T/NC ratio was 
greater than 1.5:1 in 9 of the 14 patients with cancer 
(64%), in whom the mean ratio was 1.83 (+/-S.D.0.21) :
1 (Table 7.2.). The two patients with benign tumours 
showed no preferential localisation of activity with 
T/NC ratios of 0.96:1 and 1.06:1.
A poor correlation was found between intra-operative 
tumour to normal colon ratio of counts and those 
obtained by gamma well counting, although patients with 
high intra-operative ratios tended to have higher well
Table 7.2. Results of intra-operative probing
No. Init. Probe
I/O
T/NC ratios 
Specimen Well count
% I.D. /g 
x 10-3
1. M.D. Nal 1.66 4.50 3.2 6.5
2. M.B. Nal 1.98 5.13 3.4 1.6
5. D.N. Nal NA 1.23 1.0 NA
6. J.L. Nal 1.64 4.00 2.0 6.2
7. J.H. Nal 1.81 2.73 1.2 12.0
8. B.T. Nal 1.66 4.45 2.1 10.0
11. M.J. Nal 2.13 5.87 NA NA
12. B.B. Nal 2.00 6.82 3.5 8.4
13. V.D. Nal 0.90 4.22 1.6 16.0
14. F.H. CdTe 1.00 6.25 2.3 NA
16. R.D. CdTe 0.91 3.40 1.6 6.5
17. J.P. CdTe 1.32 4.90 2.3 7.2
18. E.B. CdTe 1.06 2.70 1.4 6.0
19. D.O.N. CdTe 2.06 3.35 1.9 9.0
21. X.G. Nal 1.57 5.15 3.0 8.1
22. J.B. Nal 1.07 5.69 2.3 12.0
T/NC ratios : Ratio of mean counts from tumour to that of normal colon 
I/O : intra-operative
Table 7.3. Comparison of T/NC ratios in probe groups
T/NC ratio by probe utilised
Nalprobe(n=10) CdTe probe(n=5) Difference
Well counting 2.33+/-0.90:1 1.9+/-0.41 :1 n.s.
I/O probing 1.64+/-0.39:1 1.27+/-0.47: 1 n.s.
Excised specimen 4.53+/-1.54:1 4.12+/-1.44: 1 n.s
Table 7.4. Dual probing of the same resected specimens
CdTe probe(cpm) Nal probe(cpm)
Specimen No. Tumour Colon T/NC* Tumour Colon T/NC*
1 150 24 6.3 1176 180 6.5
2 78 22 3.5 603 237 2.5
3 225 43 5.2 2040 420 4.9
4 162 15 10.8 1041 183 5.7
Probe counts are the mean values of at least three determinations 
* Paired t test, p=0.302, n.s.
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counting ratios. This is shown diagramatically in
Figure 7.3. Of the four patients who had I/O probing
illcarried out at six days after xxxIn-ICR2 administration 
two showed no preferential uptake (T/NC of 0.90:1 and 
1.00:1) whereas only one of the 12 patients probed at 
three days showed no preferential uptake (1.07:1). This 
difference did not, however, achieve significance.
In all patients a higher T/NC ratio was obtained on 
probing the resected specimens than that found intra- 
operatively with a mean T/NC for the resected specimen 
of 4.44 (+/-S.D.1.37) : 1 against 1.51 (+/-S.D.0.44) :
1 for intra-operative probing (p=0.000). The mean T/NC 
ratio found on probing the resected specimen of 
4.44 (+/-S.D.1.37) was also higher than that found on 
weighing and gamma well counting of biopsies of tumour 
and normal colon from the resected specimen. The 
resected specimen tumour to normal colon ratios found 
on probing correlated well with the T/NC ratio 
calculated by weighing and gamma well counting of 
biopsies of tumour and normal colon from the resected 
specimens (Figure 7.4.) (r = 0.8, p<0.001).
In all patients studied the counts obtained on 
probing over the liver were significantly greater than 
those obtained over either the tumours or the normal 
colon (all p<0.05). The mean probe counts over the 
liver to that of tumour was 2.48 (+/-S.D.1.10) : 1 and 
to that of normal colon was 3.83 (+/-S.D.0.98) : 1. Of 
the two patients in the present study with liver 
metastases one was probed directly over the site of a
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liver metastasis and in the other the site of the 
metastasis was not accessible . The mean count over the 
metastasis was less than that over the normal liver but 
not significantly so (5100+/-S.D.430 vs 5920+/-S.D.483)
Intra-operative probing of a regional lymph node was 
carried out in 7 patients who had an easily palpable 
node in the mesentery. None of the probed nodes had 
clinically obvious tumour involvement and all were less 
than 1cm in diameter. Two of the seven nodes probed 
were subsequently shown on histological examination to 
contain metastatic tumour. The two lymph nodes 
containing tumour had a significantly higher uptake of 
radioactivity relative to normal colon than the five 
which did not (1.71+/-S.D.0.06:1 against 0.84+/- 
S.D.0.33:1, p < 0.05) .
The antigen expression of the resected specimens 
measured by immunohistochemistry using the indirect 
immunoperoxidase method demonstrated EMA expression in 
12 of the 16 resected tumours and in all regional lymph 
nodes involved by metastatic deposits. The remaining 
four resected specimens showed either no EMA expression 
or a focal pattern of staining alone. The T/NC ratios 
found on gamma well counting of biopsies were 
significantly higher with those tumours which expressed 
the target antigen than those which did not or showed 
focal staining alone (2.45+/-S.D.0.65 : 1 against 
1.30+/-S.D.0.26 : 1, p=0.005). The correlation between 
antigen expression and T/NC uptake ratios was 
demonstrated in Table 5.5..
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Discussion
In this study 85% of the patients with colorectal 
cancer had elevated counts obtained over primary cancer 
compared to that of normal colon as measured by in vivo 
probing following administration of 111In-ICR2 and in 
65% of patients the T/NC ratio was greater than 1.5:1. 
In a similar study carried out by Sickle-Santanello and 
colleagues intra-operative probing resulted in a T/NC 
ratio of greater than 1.5:1 in 83% of the patients 
studied using the B72.3 MAb raised to the tumour 
associated antigen Tag-72 and labelled with 125j(150)^ 
This similarity in the proportion of cancers showing 
uptake of the radiolabelled MAb may be explained by the 
antigen having a similar distribution to that 
recognised by ICR2 and a similar reactivity with 
colorectal cancers (J.P. Sloane, unpublished 
observation, 248, 323, 324^ In tj10 present study,
however, false negative results on probing could not be
explained by a lack of antigen expression on the
cancers as suggested in the study by Sickle-Santanello,
as the three tumours showing no preferential uptake
expressed EMA (all grade II) on immunohistochemistry.
The time between administration of ^^In-ICR2 and
intra-operative probing may be important as a tendency
was noted for low T/NC ratios to occur more often at 6
rather than three days. From the studies reported in
Chapter 5 the time which was optimal for external
imaging was found to be 48-72 hrs after administration 
111of A-L In-ICR2 at which time satisfactory counts were
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obtained and the blood activity had cleared. A wide
range has been reported for the optimum time period for
illcolon cancer localisation with -LJ"LIn labelled MAb 
(102,105,294) an(j this may vary with the dose of
antibody or radioactivity administered, the nature of 
the antibody and the particular epitope of the antigen 
being targeted.
A possible explanation for cancers which express the 
target antigen on immunohistochemistry not showing 
specific uptake on probing is that the labelled 
antibody clears from the tumour tissue due to the 
turnover of the membrane antigen. This possibility is 
supported by comparing the results of the external 
imaging study with that of the intra-operative probing, 
two of the three patients showing no preferential 
uptake on probing at six days (T/NC ratio approximately 
1) having previously had positive tumour images on 
external scanning at 24 and 48 hours after 
administration.
Metastatic tumour deposits were found on 
histological examination in two of the 7 regional lymph 
nodes which were probed intra-operatively. The lymph 
nodes which were involved with metastatic tumour had a 
significantly higher node to normal colon ratio than 
those which did not contain metastases. These nodal 
metastases were less than 1 cm in diameter which is 
smaller than the tumour deposits reported as being 
detectable by external immunoscintigraphy 
(105,315,325,326)  ^ Although these metastases were
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within the field of surgical resection and hence their 
detection did not affect the clinical management for 
that particular patient this finding is of significance 
since it indicates that tumour deposits which would not 
be detected by other means can be localised by this 
technique. As the antigen expression of metastatic and 
recurrent deposits corresponds to that of the primary 
cancer (^4) ^he uptake of ^^In-ICR2 in tumour tissue 
demonstrated in the present study is that which would 
be found in patients undergoing second look laparotomy 
for suspected recurrent colorectal cancer. It is in 
this group of patients that intra-operative 
radioimmunolocalisation has shown greatest clinical 
benefit <149' 150' 322).
The uptake of -^^In-MAb in normal liver tissue was 
found to be greater than for liver metastases and it 
may be concluded that 111In labelled MAb's are not 
likely to have a role in the detection of tumour 
deposits in the liver. The mechanism of uptake of 
radioactivity by the liver following administration of
111
xxxIn-MAb was discussed in Chapter 4 and accumulation 
in the liver appears to be independent of the MAb used 
or the antigen targeted. The uptake may be related to 
instability of the ^^^In-DTPA-MAb complex as newly 
developed 111In chelating agents give a reduced uptake 
of activity by normal liver tissue. Whether this 
reduction in background will be sufficient to allow 
the detection of liver metastases by intra-operative
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probing remains to be established (286, 291, 327) More 
favourable results for detecting liver metastases 
intra-operatively have been obtained following the 
administration of MAbs labelled with radionuclides of 
Iodine. Because of the rapid dehalogenation in liver 
tissue the radioactivity taken up by normal tissue 
clears rapidly and allows a positive differential in 
counts to be obtained between tumour and normal 
liver
In addition to undergoing rapid dehalogenation and 
clearance from normal liver substance, 125j j^g 
advantage of a long half-life of 60 days thus allowing 
background activity to clear from the liver and other 
organs prior to intra-operative probing. This effect 
may explain the higher T/NC ratios found in studies 
using 125j than those found in the present study with 
111In..(149' 150' 321' 322). While higher ratios may be 
achieved due to clearance of background radioactivity 
fewer counts will be obtained over both tumour and 
normal colon due to radioactive decay and 
dehalogenation so that the statistical significance of 
the ratio of counts will be reduced. The importance of 
applying nuclear counting statistics to the 
interpretation of intra-operative probe counting is 
discussed and described in part b) of this chapter.
An alternative radionuclide which may be suitable 
for intra-operative radioimmunolocalisation is " mTc. 
This radionuclide has a short half life of 6 hours 
which would allow a larger dose to be administered and
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higher count rates to be obtained over the tumour 
tissue as long as adequate tumour uptake of the 
radiolabelled antibody occurs prior to intraoperative 
probing and decay of the radionuclide.
The use of ^^mTc has been suggested for labelling 
MAbs although no studies on intra-operative RIL with 
this radionuclide have as yet been carried out. A major 
advantage to its use is that the energy of gamma 
emissions would allow both pre-operative external 
imaging and intra-operative probing to be carried out 
on the same patients with a single administration of 
99mTc labelled MAb. The localisation of the 99mTc 
labelled MAb to the tumour deposits would, however, 
require to be rapid due to the six hour half life of 
the radionuclide.
Alternative approaches which have been investigated 
for improving external immunoscintigraphy have been 
directed at reducing the background uptake of 
radioactivity and these may also have a role to play in 
intra-operative probing. For example the radiolabelled 
MAb may be cleared from the circulation once tumour 
localisation has occured by administering a liposomally 
bound antibody directed against the first which forms a 
circulating complex which is cleared by the 
reticuloendothelial system (I33).
Another technique which has recently been 
investigated makes use of the exceptionally high 
affinity of strepavidin for biotin (300-302)^ In ^bis 
procedure MAb conjugated to streptavidin is
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administered and then the non tumour bound activity is 
allowed to clear prior to administration of 
radiolabelled biotin. This technique may result in 
lower background radioactivities and higher T/NC ratios 
and would be particularly suitable for radionuclides 
such as 99mTc with a good energy of emissions but whose 
short half life may otherwise prohibit their use as a 
radiolabel for MAbs.
The Nal probe used in the present study was adapted 
from other clinical applications . Its large size and 
the weight of its lead shielding made it difficult to 
use at operation. It also needs a high voltage for its 
operation and required to be connected to the mains 
power supply. A further disadvantage to its clinical 
use is that the Nal crystal is sensitive to variations 
in temperature producing difficulty for the cleaning 
and sterilisation of the probe.
The CdTe probe has advantages in several of these 
areas. It is small, light and manoeuvrable and 
therefore easy to us at the time of operation. It also 
works with a rechargeable 12 volt power supply 
increasing its safety of use and making it completely 
portable. The probe does, however, require to be 
sterilised by ethylene oxide.
In addition to these practical considerations as to 
which probe may be most easily used at the time of 
operation the sensitivity of the detectors and the 
ability of the collimation (the shielding around the 
aperture) to avoid uptake of scattered radioactivity
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are important to the results obtained.
In the direct comparison of the two probes on the 
same resected specimens the counts obtained with the 
Nal probe were significantly higher than those with the
CdTe probe although the T/NC ratios were not
significantly different. The small number of specimens 
examined, however, did not allow the probes to be 
adequately compared and the question of which probe is 
best suited to the detection of small tumour deposits
with ^--^In-MAb was therefore addressed in the
following section using a phantom model.
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7.2. THE LIMITATIONS OF INTRA-OPERATIVE 
RADIOIMMUNOLOCALISATION
7.2.a) Introduction
The preceding clinical study on the intra-operative 
use of the gamma detecting probe showed that the 
majority of primary tumours and some lymph node 
metastases less than 1cm diameter could be localised 
following the injection of ^^^In-ICR2. As in previous 
studies on intra-operative RIL no clinical benefit was 
established for patients with primary colorectal 
cancers although the results provide an indication to 
the likely use of the radiolabelled MAb in patients 
with suspected recurrent disease, (149,150,322 )^
Some of the possibilities for improving the results 
of intra-operative probing have been suggested at the 
end of the preceding section. Although these may lead 
to improved clinical results no studies have considered 
the limitations of intra-operative
radioimmunolocalisation or considered the necessity for 
statistical analysis to the probe counting data. To 
investigate the theoretical limitations of I/O RIL a 
model has been constructed in which a "tumour" lies 
within a radioactive "background", the levels of 
radioactivity in both corresponding to those found in 
patient studies. This system has been used to evaluate 
both the Nal and CdTe probes used in the clinical 
study. By varying the size of the "tumours" and the 
ratio of radioactivity between "tumour" and 
"background" the minimum tumour size detectable with
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these GDP's could then be established for a given range 
of tumour to normal tissue ratios and counting times.
7.2.b) Materials and Methods 
Biodistribution data
The model was based on data available from studies 
on patients with cancer to whom ^^In labelled 
monoclonal antibodies have been administered. The 
percentage uptake of radioactivity by tumour tissue was 
obtained from the few studies which have provided this 
data, including the present study, and was taken as 
being 0.001% I.D./g, (113,130,243,305,)# ^he other
parameters chosen for the model are based on those 
generally used or which have been found in clinical 
studies namely an injected dose of lOOMBq (2.7mCi) of
illJ”L1In and tumour to background ratios from 2:1 (present 
study, 101/H3) to 8:1 (106) • Tbe background activity 
was calculated from the present clinical study based on 
the injected activity, uptake in tumour tissue per gram 
and the tumour to normal colon and tumour to blood 
ratios calculated in 10 of the patients in the 
preceding clinical study. (Table 7.5.)
The model of the intra-abdominal tumour.
1) "Tumours"
The hollow containers used in this study to 
represent tumour deposits are shown in Figure 7.5..
The smaller tumour sizes were represented by test 
tubes in which the liquid was sealed using dental
Table 7.5. Phantom background calculation
No. Initials T/Blood T/N Col
2. M.B. 2.4 3.4
4. R.N. 0.8 1.0
5. D.N. 0.9 1.8
6. J.L. 1.9 2.0
7. J.H. 1.4 1.2
8. B.T. 0.7 2.1
11. MJ. 3.5 3.5
13. V.D. 1.4 1.6
14. F.H. 5.4 2.3
16. R.D. 1.6 1.6
Mean 2.00 2.05
S.D. 1.46 0.84
T/Blood and T/N C ol: ratio of counts per gram for tumour to blood and 
tumour to normal colon.
Figure 7.5. Active solutions representing tumour deposits
The sealed solutions of 1 ^ I n  represent tumour volumes of 0.5-10mls as shown.
Figure 7.6. The abdominal phantom
The tank solution represents background activity and contains 15 litres of 
radioactive water at pH < 2.0.
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moulding wax and the larger sizes were formed from 
latex rubber (Mates Ltd.) These contained a solution of 
In Cl in water, the concentration of radioactivity 
present being altered for each tumour to background 
ratio examined. Prior to the containers being filled 
with the radioactive solution an aliquot was counted in 
a gamma well counter to ensure that the tumour to 
background ratio was within +/- 5% of that required.
2) Background activity
The tank used to represent the abdominal cavity is 
shown in Figure 7.6.. Its dimensions were 30 x 28 x 20 
cm and it was filled with radioactive solution to a 
depth of 17cm to give a volume of 15 litres. The 
radioactive solution was again comprised of 111InCl in 
water with the addition of sufficient concentrated HC1 
to give a final tank pH of less than 2. This pH was 
required to prevent aggregation of the InCl due to the 
formation of ^^In(0H)n. As with the tumour models the 
amount of radioactivity present in the tank was checked 
prior to commencing each probe study by removing a 1ml 
volume and counting it in a gamma well counter. By 
comparing this with the 1ml aliquot taken from the 
"tumours" the accuracy of the tumour to background 
ratio produced could be measured and altered 
accordingly if required.
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3) Gamma detecting probes and tumour positioning
The "tumours" were placed in the centre of the tank 
representing background activity by attaching them to 
the end of a perspex rod attached to a retort stand as 
shown in Figure 7.7.. The upper surface of the 
tumours was held exactly 1cm below the surface of the 
active background regardless of the tumour size. The 
probe under investigation was also supported by a 
retort stand (Figure 7.7.) and positioned exactly over 
the centre of the tumour deposit with the tip of the 
probe collimator touching, and perpendicular to, the 
surface of the active background.
The collimator is the shielding at the front of the 
crystal which surrounds the aperture, the shape and 
size of which influences the radioactivity detected by 
the crystal. With the Nal probe the collimator was 
fixed whereas the CdTe detector had two interchangeable 
collimators. Since this may affect the region from 
which counts are detected and hence the probes ability 
to differentiate tumour from background the CdTe probe 
was analysed with both the wide angle (w.a.) collimator 
which was virtually a protective cap to the crystal 
with very little shielding and the parallel hole (p.h.) 
collimator whose depth of shielding provided a long and 
narrow aperture.
The energy windows for counting were set at 120- 
300keV for both probes allowing the two gamma emissions 
(171 and 245 keV) of ^^In to be counted.
Figure 7.7. Positioning of the probe and tumour
The probe was placed perpendicular to the tank solution with the collimator in 
contact with the surface. Tumours were situated with their upper surface 1cm 
below the liquid surface.
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4) Counting and statistical analysis
The CdTe probe (RMD) is supplied with a 
counter/timer device and can be preset to count for a 
fixed period. The Nal scintillation detector was used 
with a multichannel analyser also set to count for a 
fixed period (Figure 7.1.). For all tumour sizes and 
all uptake ratios counting with both probes was carried 
out for both 20 and 100 seconds and repeated three 
times. Counting over the tumour was carried out with 
the probe positioned as previously described whereas 
counts over background were taken at a site remote from 
the tumour which was chosen to be 10cm. The shorter 
count time was selected as being a practical time 
period for counting over one site at the time of 
operation and the longer counting period was included 
to allow the importance of counting time to be 
analysed. The threshold of counts that can be taken as 
a reliable measure of tumour detection was based on 
simple statistical principles outlined in Appendix 
7.1.. Differences between the counts obtained over the 
tumour to that of the background activity were measured 
by the number of standard deviations between the mean 
counts obtained over the tumour to those obtained over 
background. Three standard deviations of the difference 
in mean counts was taken as a level of detectability 
for the tumour (Appendix 7.1.). Because the time 
involved in carrying out each part of this study was 
significant in relation to the half life of ^^^In(2.8 
days) all counts recorded were corrected for
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radioactive decay to the time at which the first 
measurements were taken.
7.2.c) Results
The results of the statistical analysis is shown in 
Tables 7.6.-7.12. and the data on which they were 
calculated in Appendices 7.2.-7.12.. The mean counts 
for both tumour and background have been calculated for 
each tumour size (marked on the left of the table) at 
each tumour to background ratio (top of tables) and the 
number of standard deviations of the difference in 
counts calculated (data in the centre of the tables).
By defining a difference between tumour and 
background of 3 S.D's. as a threshold of detectability 
(outlined in bold in Tables 7.6.-7.11), with a 2:1 
tumour /background ratio and a 20 second count none of 
the tumours were detectable with the CdTe probe whereas 
only the 10ml was detectable with the Nal probe. With a 
counting period of 100 seconds at this ratio the 10 ml 
tumour could be detected with the CdTe probe (p.h.) 
(Table 7.11.) and those of 5 and lOmls with the Nal 
probe. (Table 7.7.).
When the tumour to background ratio was increased to 
4:1 then a counting period of 20 seconds allowed the 
detection of tumours of 1.5mls and greater with the Nal 
probe (Table 7.6.) and only those of lOmls with the 
CdTe probe using either collimator (Table 7.8. and 
7.10.). Extending the counting period to 100 seconds at 
4:1 ratio improved the tumour detection with both
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probes, allowing all tumours to be detected with the 
Nal probe (Table 7.6.) , those above 5mls with the CdTe 
probe fitted with the wide angle (w.a.) collimator 
(Table 7.9.) and those above 1ml with the parallel hole 
(p.h.) collimator. A similar improvement with extended 
counting time was seen with a 6:1 ratio of uptake, 
tumours of 1.5mls and above and 5mls and above being 
detected with the Nal and CdTe (both collimators) 
probes at 20 second counts (Tables 7.6., 7.8., 7.10) 
whereas all sizes could be detected at 100 seconds with 
the Nal probe (Table 7.7.) and those of 1ml and above 
with the CdTe(either collimator)(Table 7.9. and 7.11). 
At an 8:1 tumour to background ratio both probes could 
detect tumours of 1ml and above when counting for 
twenty seconds (Table 7.6., 7.8. and 7.10) and all 
tumours (0.5cm and above) with a 100 second count 
(Tables 7.7., 7.9. and 7.11).
A summary of the tumour sizes detectable, based on 
three standard deviations as a threshold of 
detectability, is shown for the different probes, 
uptake ratios and counting times in Table 7.12.
Table 7.6. Nal probe : 20 second count time
Tumour size(mls) Tumour to background ratio 
2:1 4:1 6:1 8:1
0.5 -0.72 -0.17 2.42 1.38
1.0 -0.94 2.88 2.29 5.42
1.5 0.16 3.27 3.68 7.92
2.0 0.37 0.38 5.15 10.82
5.0 2.37 8.00 12.19 14.78
10.0 3.81 9.09 16.78 18.71
Table 7.7. N a l probe : 100 second count time
Tumour size (mis) Tumour to background ratio 
2:1 4:1 6:1 8:1
0.5 -1.12 5.44 4.47 6.26
1.0 2.63 4.39 5.75 11.16
1.5 1.30 6.80 11.53 15.24
2.0 -0.45 4.37 13.16 23.49
5.0 3.32 15.44 24.66 31.28
10.0 8.53 20.79 35.76 47.17
Table 7.8. CdTe probe (w.a.) : 20 second counts
Tumour size (mis) Tumour to background ratio 
2:1 4:1 6:1 8:1
0.5 0.17 0.39 -0.31 2.86
1.0 -0.80 1.13 -1.62 3.00
1.5 -2.33 1.98 1.82 4.09
2.0 -0.89 0.15 1.72 5.70
5.0 1.37 2.82 6.49 6.20
10.0 2.13 6.19 9.56 15.55
Table 7.9. Cd Te probe ( w.a.): 100 second counts
Tumour size (mis) Tumour to background ratio 
2:1 4:1 6:1 8:1
0.5 -1.11 -0.93 -2.15 5.24
1.0 -1.66 1.82 3.24 4.35
1.5 -2.84 1.15 4.33 7.25
2.0 -0.04 1.51 3.19 9.71
5.0 2.16 7.86 13.10 17.77
10.0 2.50 10.54 21.59 33.13
Table 7.10. CdTe probe (p.c.): 20 second count
Tumour size (mis) Tumour to background ratio
2:1 4:1 6:1 8:1
0.5 0.51 -1.57 1.15 1.19
1.0 1.91 1.67 0.58 3.95
1.5 2.03 2.24 0.57 1.94
2.0 1.23 1.81 2.58 4.80
5.0 2.50 2.67 4.72 4.41
10.0 1.42 4.29 5.42 8.57
Table 7.11. CdTe probe (p.c.) : 100 second count
Tumour size (mis) Tumour to background ratio
2:1 4:1 6:1 8:1
0.5 -1.10 1.29 2.31 4.04
1.0 1.52 4.01 4.52 3.28
1.5 1.36 4.04 1.86 6.29
2.0 -0.55 4.27 6.18 8.74
5.0 1.83 6.28 11.53 11.35
10.0 3.17 7.64 13.42 19.08
Table 7.12. Minimum tumour sizes detectable
Probe Nal CdTe (w.a.) CdTe(p.h.)
Count time (secs) 20 100 20 100 20 100
2:1 10.0 5.0 none none 10
Ratio 4:1 1.5 0.5 10.0 5.0 10.0 1.0
6:1 1.5 0.5 5.0 1.0 5.0 1.0
8:1 1.0 0.5 1.0 0.5 1.0 0.5
The minimum tumour sizes detectable are shown(mls) based on a level of 
detectability of 3 S.D.'s.. Figures are for 20 second and 100 second counting 
periods, w .a.: wide angle collimator, p.h.: parallel hole collimator.
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7.2.d) Discussion
This is the first study to be carried out to 
investigate the potential and limitations of intra­
operative gamma detecting probes for the localisation 
of tumour deposits following the administration of 
111In labelled monoclonal antibodies.
The results suggest that intra-operative probing may 
be able to detect tumour deposits as small as 1.5ml at 
a tumour to background ratio of 4si (Nal probe) and one 
ml at an 8:1 ratio (both probes) with a counting period 
of 20 seconds. This size of tumour deposit could easily 
be overlooked by the surgeon at the time of laparotomy 
and its detection may significantly alter the prognosis 
for the patient involved.
The accuracy of the present model is dependent on 
the premises on which it is based and in particular on 
the %I.D. taken up in the tumour tissue. This figure is 
based on the findings of the present study with In 
labelled ICR2 in patients with colorectal cancer and is 
in agreement with other studies using In labelled 
MAb's (113,130,243,305)# ^any studies on MAb's used in 
colorectal cancer patients have not, however, quoted 
the tumour uptake as %I.D./g or the differential ratio. 
These labelled antibodies may, therefore, provide 
better or worse results than those determined from the 
present study.
Another factor of prime importance in evaluating the 
clinical correlation of the present model is that
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in patients the primary, metastatic or recurrent 
tumours do not lie within an even background of 
activity but may occur in relation to non tumour sites 
of high uptake of labelled antibody, such as the liver, 
spleen and bone marrow.
The liver may be responsible for uptake of 30-40% 
(125) 0£ the injected dose of ^-^In labelled antibody 
and this would therefore produce considerably higher 
background activity when probing in its vicinity. 
Similarly the pelvis and retroperitoneal tissues are 
common sites of recurrent colorectal cancer and intra­
operative probing in this area will be influenced by 
the high uptake of activity in the bony pelvis and 
lumbar vertebrae. Consequently the results obtained in 
vivo may be considerably worse than those calculated 
from the present model.
Of the two probe types analysed the Nal 
scintillation detector was able to detect smaller 
tumours at lower tumour to background ratios than the 
CdTe probe at either of the counting times 
investigated. This is due to the higher number of 
counts being recorded over both the tumour and the 
background with the Nal probe resulting in improved 
counting statistics and a greater statistical 
significance to the differences between the mean 
counts. The number of counts detected for any 
individual probe will depend on the intrinsic 
properties of the detecting material (Nal or CdTe), the
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size and shape of the crystal used and the collimation
of the probe itself. Although both of the probes used
1 1 1in the present study were suitable for detecting ■LXXIn 
some improvement might be achieved by increasing the 
crystal thickness and hence the sensitivity of the CdTe 
probe, thereby improving the detectability of small 
tumours at low tumour to background ratios.
A novel approach to the problem of background 
activity has been investigated by Hickernell and 
colleagues using a probe with two concentric detectors. 
By this means the area of suspected tumour may be 
counted simultaneously with an adjacent area of normal 
tissue and the results subsequently compared. By using 
a computer simulation of the surgical staging of 
metastases this dual detecting probe was shown to 
perform better than a single detector probe (328)# A 
clinical evaluation of the probe is awaited.
The statistical analysis of the tumour and 
background counts used in the present study points to 
the way ahead for future clinical studies on intra­
operative probing. The system presently used is based 
on an arbitrary cut off level of 1.5 for suspected 
tumour to background counts (149,150)^ Although this 
system is easily applied in a clinical situation the 
significance of this ratio will depend on the actual 
number of counts on which it is based. Hence a ratio of 
1.5 based on counts of 1500 and 1000 has an entirely 
different statistical significance to a ratio
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of 1.5 based on counts of 15 and 10. The system 
developed for the interpretation of tumour 
detectability in the phantom model could be applied in 
the clinical situation. This would require the number 
of standard deviations to be calculated between the 
mean tumour and background counts and would allow the 
significance of this difference in counts to be 
calculated. Taking a confidence limit of two standard 
deviations between the counts would result in a 95% 
certainty that the difference in counts is significant 
and with three standard deviations there would be less 
than a 1% chance that the difference in counts is due 
to random error (329-331  ^Appendix 7.1.).
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Appendix 3.1.: Serum EMA levels
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EMA levels by patient group (ng/ml)
No. Controls Breast Ca. Colon Ca.
1 105 760 990
2 430 500 270
3 560 1030 240
4 240 1550 280
5 110 1230 210
6 100 760 390
7 610 1240 1100
8 700 620 310
9 350 3000 845
10 400 1010 455
11 830 560 640
12 550 550 1600
13 650 790 140
14 570 250 440
15 720 250 380
16 470 880 750
17 210 460 470
18 220 1120 470
19 1830 1560 710
20 365 290 480
21 630 740 9920
22 780 440 650
23 635 300 680
24 152 1000 1150
25 510 1110 670
26 1000 1000 58
27 1950 890 750
28 1820 650 495
29 108 960 1350
30 980 470 420
31 280 650 410
32 920 800
33 1750 1320
34 400 830
35 1000 260
36 540 700
37 720 550
38 470 600
39 630 2010
40 440 320
41 930 200
42 540 337
43 560 990
44 3680 16430
45 1500
46 410
47 470
48 630
49 210
50 540
51 750
52 2390
53 1150
Other Cancers
580
580
185
220
67400
9720
120
1720
5360
Appendix 4.1. Folin-Lowry protein assay
The cells from the uptake experiments were kept at -20°C until the protein 
assay was carried out. After thawing at room temperature each samples was 
sonicated for 30 seconds (Soniprep 150, Fisons) to produce an even cell 
suspension and 0.5mls of each sample mixed with an equal volume of 0.5M 
sodium hydroxide. After a mixing period of one hour, to each sample was added 
5mls of 2% sodium carbonate solution containing (1ml for every 50mls) sodium 
and pottasium tartrate (2% solution) and copper sulphate(l% solution). This was 
mixed thoroughly and after exactly 10 minutes 250ul of Folin and Ciocalteau's 
reagent (2.2M)(diluted 5mls in 8mls of water) was added to each tube.
As a standard solutions of bovine serum albumin(BSA) containing protein 
concentrations of 0.05,0.10,0.15,0.20,0.25 and 0.30mg /ml were prepared and 
treated in the same manner.
After leaving for one hour to allow colour development all samples were 
read on a u.v., spectrophotometer (Unicam SP1800) at 500nm. A standard curve 
was then produced from the dilutions of BSA and the protein concentrations of 
the other samples read from the standard curve.
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Appendix 4.2. Baseline uptake of -^^4n-ICR2
1) MCF7 tumour cells
Cpm/plate Protein conc. 
(mg/ml)
cpm/mg Applied 
(cpm x 105)
Uptake 
(% applied/mg)
244,632 0.23 1,063,617 31.0 34.3
292,810 0.29 1,009,698 31.4 32.2
255,377 0.24 1,064,070 28.2 37.7
2) Hepatocytes
Cpm/plate Protein conc. 
(mg/ml)
cpm/mg Applied 
(cpm xlO^)
Uptake 
(% applied/mg)
23,589 0.20 117,945 26.4 4.47
21,387 0.20 106,935 31.8 3.36
19,242 0.20 96,210 29.6 3.25
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Appendix 4.3. Temperature and cell uptake of H4n-ICR2
1) MCF7 cells at 37°C
Applied cpm Bound cpm Uptake as % applied cpm
528,497 50,585 9.57
495,359 54,546 11.00
582,752 56,550 9.70
2) Hepatocytes at 37°C
Applied cpm Bound cpm Uptake as % applied cpm
561,149 3048 0.54
573,149 1880 0.33
552,876 2429 0.44
3) MCF7 cells at 4°C
Applied cpm Bound cpm Uptake as % applied cpm
635,032 38,360 6.04
679,836 25,904 3.81
655,709 30,608 4.60
4) Hepatocytes at 4°C
Applied cpm Bound cpm Uptake as % applied cpm
622,927 1673 0.27
618,020 1912 0.31
699,811 1894 0.27
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Appendix 4.4. Preparation of Transferrin (Tf)
Iron precipitates without a chelator at neutral pH so the iron saturated 
transferrin was prepared at acidic pH. A 90% iron saturated solution of 
Transferrin was prepared by the reaction of 20mg of Transferrin in 0.5mls of 
molar Tris /  HC1 pH 8.5 with 0.4uM of ferrous ammonium sulphate in 0.1M HC1 
(previously bubbled with N2). A few grains of sodium bicarbonate were then
added to ensure an alkaline pH. After 30 minutes the solution was then made up 
to 1ml with PBS and dialysed against RPMI1640 medium (Gibco.U.K.) for two 
hours. A final concentration of 2 g/1 was achieved by the application of the 
transferrin solution to the culture medium of the cells.
Appendix 4.5. Tf and the hepatocyte uptake of ^^4n-IGR2
Cell group Applied 
(cpm x 10^)
Cell uptake 
(cpm/plate)
% applied counts
Control 3.81 300 0.078
Control 3.09 331 0.107
Control 3.77 445 0.118
Tf 3.34 362 0.108
Tf 3.84 392 0.102
Tf 3.89 297 0.076
ApoTf 3.95 438 0.110
ApoTf 3.65 223 0.061
ApoTf 3.77 429 0.114
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Appendix 4.6. Effect of apoTf on cell uptake of radioactivity
1) MCF7
Cell group Counts applied 
(cpm x 1()6)
Uptake per plate 
(cpm x 10^)
% applied counts
Control 2.45 285 11.7
Control 2.47 277 11.2
Control 2.45 336 13.7
ApoTf 2.36 243 10.3
ApoTf 2.32 271 11.6
ApoTf 2.46 313 12.7
2) Hepatocytes
Cell group Counts applied 
(cpm x 10 )^
Uptake per plate 
(cpm x 10^)
% applied counts
Control 2.37 5.63 0.24
Control 2.43 5.46 0.23
Control 2.44 6.65 0.27
ApoTf 2.37 5.76 0.24
ApoTf 2.39 6.27 0.26
ApoTf 2.46 4.48 0.18
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Appendix 4.7. The effect of DTPA co-administration
1) MCF7
Cell group Applied 
(cpm x 105)
Uptake/ plate 
(cpm x 10^)
(%)
applied
Protein
(mg/ml)
Uptake/mg 
(cpm x 10-3)
Control 5.11 15.3 3.0 3.7 4.12
Control 5.53 17.7 3.2 3.7 4.78
Control 5.60 16.6 3.0 3.7 4.47
DTPA 5.57 12.6 2.9 3.7 4.47
DTPA 5.61 20.0 3.6 3.7 5.41
DTPA 5.61 10.0 1.8 3.5 2.94
2) Hepatocytes
Cell group Applied 
(cpm x 105)
Uptake/ plate 
(cpm x 10 )^
(%)
applied
Protein conc. 
(mg/ml)
Uptake/mg 
(cpm x 1GP)
Control 4.07 6.02 1.48 3.7 1.63
Control 5.37 7.96 1.48 3.7 2.15
Control 5.68 7.47 1.31 3.7 2.02
DTPA 5.72 4.48 0.78 3.7 1.21
DTPA 5.56 4.41 0.79 3.7 1.19
DTPA 5.85 3.24 0.55 3.5 0.92
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Appendix 4.8. Cell incubation with DTPA
1) MCF7's
Cell group Applied 
(cpm x 105)
Uptake/plate 
(cpm x 10-3)
Uptake
(%)
Protein
(mg/ml)
Uptake
cpm/mg
control 5.11 15.23 3.0 3.7 4116
control 5.53 17.71 3.2 3.7 4787
control 5.60 16.56 2.9 3.7 4475
DTPA 5.20 17.10 3.3 3.7 4622
DTPA 5.50 12.21 2.2 3.7 3301
DTPA 5.40 14.02 2.6 3.7 3788
2) Hepatocytes
Cell group Applied 
(cpm x 105)
Uptake/plate 
(cpm x 10 )^
Uptake
(%)
Protein
(mg/ml)
Uptake
(cpm/mg)
control 4.07 6.02 1.48 3.7 1627
control 5.37 7.96 1.48 3.7 2152
control 5.68 7.47 1.31 3.5 2020
DTPA 5.64 4.52 0.80 3.7 1223
DTPA 5.64 5.32 0.94 3.7 1439
DTPA 5.72 4.89 0.85 3.7 1322
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Appendix 4.9. : Dose response of DTPA
1) MCF7’s
[DTPA] Applied 
(cpm x 10^)
Uptake
(%)
Uptake/plate 
(cpm x 103)
Prot.
(mg/ml)
cpm x 103 
per mg
0 3.10 7.89 244.63 0.23 1063.62
0 3.14 9.32 292.81 0.29 1009.69
0 2.82 9.05 255.37 0.24 1064.07
lOOuM 3.04 9.07 275.95 0.26 1061.36
lOOuM 3.01 6.22 187.33 0.21 892.05
lOOuM 2.86 8.16 233.57 0.26 898.34
ImM 3.24 9.94 322.08 0.26 1238.76
ImM 3.04 10.92 332.12 0.34 976.83
ImM 2.12 13.35 283.13 0.26 1088.97
lOmM 2.88 7.80 229.79 0.24 957.45
lOmM 3.14 8.63 270.87 0.28 967.41
lOmM 3.16 9.32 294.63 0.28 1052.27
2) Hepatocytes
[DTPA] Applied 
(cpm x 10^)
Uptake
(%)
Uptake/plate 
(cpm x 103)
Protein
(mg/ml)
cpm x 103 
per mg
0 3.16 0.75 23.59 0.20 117.94
0 3.18 0.67 21.39 0.20 106.93
0 2.96 0.65 19.24 0.20 96.21
lOOuM 2.92 0.73 21.21 0.21 100.99
lOOuM 2.49 0.74 18.56 0.22 84.37
lOOuM 2.54 0.68 17.04 0.20 85.18
ImM 3.22 0.13 4.33 0.20 21.66
ImM 2.40 0.13 3.27 0.16 20.45
ImM 3.23 0.13 4.34 0.20 21.69
lOmM 3.19 0.14 4.46 0.22 20.25
lOmM 2.93 0.13 3.89 0.22 17.69
lOmM 3.10 0.11 3.48 0.21 16.56
Appendix 4.10. DTPA incubation period and cell uptake
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1) MCF7's
Cell group Applied 
(cpm x 105)
Uptake
(%)
Uptake/plate 
(cpm x 10^)
Prot. conc. 
(mg/ml)
cpm x 10^/mg
control 5.30 4.8 25.29 0.36 70.26
control 4.62 7.8 36.25 0.43 81.99
control 4.96 6.0 29.59 0.34 87.04
5 mins 4.77 5.4 26.05 0.28 93.03
5 mins 4.80 4.5 21.87 0.28 78.11
5 mins 4.49 7.4 33.53 0.36 93.13
15 mins 4.55 5.7 25.76 0.32 86.50
15 mins 4.57 5.1 23.51 0.32 73.47
15 mins 4.47 5.0 22.89 0.20 81.78
30 mins 4.89 6.1 29.89 0.31 96.44
30 mins 4.93 6.6 32.52 0.36 90.33
30 mins 4.74 5.1 24.43 0.28 87.24
60 mins 5.22 4.0 20.82 0.28 74.36
60 mins 4.62 4.5 20.94 0.29 72.21
60 mins 3.20 7.2 23.16 0.28 81.25
2) Hepatocytes
Cell group Applied 
(cpm x 105)
Uptake
(%)
Uptake/plate 
(cpm x 10^)
Prot. conc. 
(mg/ml)
cpm x 10^/mg
control 5.30 1.13 6.02 0.92 6.54
control 5.09 1.27 6.48 1.03 6.29
control 5.35 1.57 8.43 0.94 8.97
5 mins 4.69 1.02 4.32 0.94 4.60
5 mins 4.66 1.02 4.76 0.91 5.23
5 mins 4.92 0.88 4.36 0.88 4.96
15 mins 4.51 0.83 3.73 0.78 4.78
15 mins 4.30 0.78 3.36 0.96 3.50
15 mins 4.73 0.83 3.92 0.96 4.08
30 mins 4.87 0.98 4.76 1.03 4.62
30 mins 4.67 0.80 3.75 0.91 4.12
30 mins 4.71 0.57 2.68 0.93 2.88
60 mins 4.79 1.16 5.55 0.99 5.60
60 mins 4.55 0.61 2.80 0.81 3.45
60 mins 4.53 0.73 3.32 1.03 3.22
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Appendix 4.11. Cell uptake of ^ I n  and m in-DTPA
1) MCF7’s : Free x l l In
Applied 
(cpm x 105)
Uptake
cpm/plate
Uptake
(%)
Protein
mg/ml
Uptake/mg
(cpm)
1.84 1258 0.68 0.40 3140
1.85 622 0.34 0.21 2962
1.87 1102 0.59 0.42 2624
2) MCF7 : Free ^ I n  /  co-admin DTPA
Applied 
(cpm x 10 )^
Uptake
cpm/plate
Uptake
(%)
Protein
mg/ml
Uptake/mg
(cpm)
1.84 780 0.42 0.37 2108
1.84 480 0.27 0.35 1371
1.88 580 0.31 0.35 1657
3) Hepatocytes : Free ^ I n
Applied Uptake Uptake Protein Uptake/mg
(cpm x 105) cpm/plate (%) mg/ml (cpm)
1.82 1522 0.83 0.75 2029
2.03 1568 0.77 0.74 2119
1.87 938 0.51 0.45 2084
4) Hepatocytes : Free l ^ I n  / co-admin DTPA
Applied Uptake Uptake Protein Uptake/mg
(cpm x 105) cpm/plate (%) mg/ml (cpm)
1.84 800 0.43 0.56 1428
1.83 718 0.39 0.75 957
1.86 874 0.47 0.82 1065
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5) MCFV's: m In-DTPA
Applied 
(cpm x 10*)
Uptake
cpm/plate
Uptake
(%)
Protein
mg/ml
Uptake/mg
(cpm)
1.90 498 0.26 0.46 1083
1.95 432 0.22 0.43 1005
1.99 638 0.32 0.38 1679
6) MCF 7 : m In-DTPA / co-admin DTPA
Applied Uptake
(cpm x 105) cpm/plate
Uptake
(%)
Protein
mg/ml
Uptake/mg
(cpm)
1.87 548 0.29 0.38 1442
1.91 630 0.33 0.43 1465
1.86 660 0.35 0.38 2750
7) Hepatocytes : ^ In -D T P A
Applied Uptake Uptake Protein Uptake/mg
(cpm x 105) cpm/plate (%) mg/ml (cpm)
1.80 290 0.16 0.74 392
1.83 494 0.27 0.72 686
1.86 382 0.20 0.48 796
8) H epatocytes : n-DTPA  /  co-adm in D T PA
Applied 
(cpm x 105)
Uptake
cpm/plate
Uptake
(%)
Protein
mg/ml
Uptake/mg
(cpm)
1.92 478 0.25 0.62 771
1.81 502 0.27 0.69 727
1.91 464 0.24 0.66 642
270.
Appendix 4.12. A comparison of chelators
Cell group Applied
(cpm x 1()6)
Uptake/plate 
(cpm x 10 )^
Uptake
(%)
Protein
(mg/ml)
cpm/mg 
(x l (P)
MCF7 ctr 1.32 73.88 5.6 0.175 211.09
MCF7 ctr 1.36 42.47 3.1 0.115 184.66
MCF7 ctr 1.44 50.94 3.5 0.135 188.65
MCF7 ctr 1.39 31.11 2.2 0.115 135.26
MCF7EDTA 1.44 67.95 4.7 0.180 188.74
MCF7EDTA 1.28 53.36 4.2 0.120 222.35
MCF7EDTA 1.30 32.43 2.5 0.110 147.40
MCF7EDTA 1.27 14.95 1.2 0.065 114.97
MCF7 DTPA 1.28 61.38 4.8 0.085 361.06
MCF7 DTPA 1.29 30.39 2.4 0.100 151.96
MCF7 DTPA 1.30 68.14 5.3 0.140 243.35
MCF7 DTPA 1.36 45.34 3.3 0.075 302.28
MCF7 ccDTPA 1.34 66.62 5.0 0.145 229.72
MCF7 ccDTPA 1.38 28.67 2.1 0.120 119.47
MCF7 ccDTPA 1.50 89.09 5.9 0.195 228.43
MCF7 ccDTPA 1.33 26.93 2.0 0.085 158.42
MCF7 CP040 1.27 34.51 2.7 0.085 203.00
MCF7 CP040 1.23 23.16 1.9 0.060 192.97
MCF7 CP040 1.26 82.30 6.5 0.085 484.13
MCF7 CP040 1.15 37.17 3.2 0.075 247.83
Heps ctr 1.38 66.40 4.8 0.320 103.74
Heps ctr 1.34 52.78 3.9 0.375 70.37
Heps ctr 1.37 73.24 5.3 0.310 118.13
Heps ctr 1.32 58.10 4.4 0.355 81.82
Heps EDTA 1.28 61.76 4.6 0.375 84.40
Heps EDTA 1.36 63.30 4.6 0.375 84.40
Heps EDTA 1.35 59.24 4.4 0.475 62.35
Heps EDTA 1.44 57.53 4.0 0.505 56.96
Heps DTPA 1.33 53.60 4.0 0.445 60.23
Heps DTPA 1.41 46.88 3.3 0.475 49.35
Heps DTPA 1.37 43.04 3.1 0.445 48.36
Heps DTPA 1.27 45.99 3.6 0.385 59.73
Heps ccDTPA 1.40 50.71 3.6 0.385 65.86
Heps ccDTPA 1.52 58.68 3.9 0.330 88.91
Heps ccDTPA 1.20 37.84 3.1 0.390 48.51
Heps ccDTPA 1.50 59.84 4.0 0.335 89.31
Heps CP040 1.53 129.15 8.4 0.400 161.43
Heps CP040 1.48 143.66 9.7 0.400 179.58
Heps CP 040 1.61 139.62 8.7 0.415 168.22
Heps CP040 1.66 152.82 9.2 0.415 184.11
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Appendix 4.13. The effect of pooled rat IgG
Cell group Applied 
(cpm x 10^)
Uptake/plate 
(cpm x 10 )^
Uptake
(%)
Protein
(mg/ml)
cpm/mg 
(x HP)
MCF7 ctr 9.7 70.56 7.3 0.42 168.00
MCF7 ctr 10.0 73.32 7.3 0.37 198.17
MCF7 ctr 9.8 75.32 7.7 0.47 160.26
MCF7 x 10 9.7 71.27 7.3 0.40 285.08
MCF7 x 10 10.1 74.51 7.4 0.50 149.00
MCF7 x 10 10.3 80.97 7.9 0.43 188.30
MCF7 x 50 10.9 84.09 7.7 0.37 227.26
MCF7 x 50 9.6 66.58 6.6 0.42 158.53
MCF7 x 50 10.1 76.95 7.6 0.45 171.00
MCF7 x 100 10.2 77.78 7.6 0.42 185.20
MCF7 x 100 10.4 85.14 8.2 0.45 189.20
MCF7 x 100 10.0 86.12 8.6 0.42 205.04
MCF7 x 1000 9.4 57.68 6.1 0.40 144.20
MCF7 x 1000 9.4 63.75 6.5 0.50 127.50
MCF7 x 1000 9.8 63.56 6.5 0.43 147.82
Heps ctr 9.1 2.93 0.32 0.53 5.52
Heps ctr 9.0 3.59 0.40 0.64 5.61
Heps ctr 9.2 4.98 0.54 0.57 8.74
Heps x 10 9.7 6.33 0.64 0.51 12.41
Heps x 10 9.8 6.36 0.65 0.57 11.15
Heps x 10 9.6 6.31 0.66 0.64 9.85
Heps x 50 10.2 5.27 0.52 0.72 7.32
Heps x 50 10.3 4.52 0.44 0.69 6.55
Heps x 50 9.9 5.31 0.54 0.66 8.04
Heps x 100 10.4 4.77 0.46 0.72 6.63
Heps x 100 10.2 6.55 0.64 0.72 9.10
Heps x 100 14.0 6.71 0.48 0.58 11.58
Heps x 1000 8.0 4.00 0.50 0.61 6.56
Heps x 1000 6.1 3.39 0.56 0.61 5.56
Heps x 1000 10.2 4.41 0.43 0.61 7.22
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Appendix 5.1. Method of conjugation of ICR2
Antibody was stored in the preservative sodium azide (0.01% w/v). This was 
removed prior to conjugation by dialysing (Dialysis membrane PJC/400/050/L, 
Medicell International Ltd.) against Hepes buffer (0.05M, pH 7.5) for 48 hours with 
changes of dialysate 12 hourly. The antibody was then concentrated to 
10-20mg/ml using a protein concentrator No. A25(Amicon Corp. Lexington. Mass., 
U.S.A.). The amount of DTPA required for reaction with the antibody was then 
calculated using the following formula,
DTPA (mg) = MWtDTPA x C.R. x mg MAb 
MWtMAb
where C.R. is the conjugation ratio required. A solution of DTPA was prepared in 
the inorganic solvent dimethylsulfoxide (DMSO)(Sigma) at 1 mg DTPA per ml of 
DMSO, the procedure requiring vigorous mixing. The concentrated antibody was 
then added to the amount of ccDTPA/DMSO as calculated from the above formula 
and vortexed for one minute. Unwanted DTPA in the reaction mixture was then 
removed by dialysis against Hepes buffer pH 7.5 0.05M for 48 hours. Following 
dialysis the conjugated antibody was further purified by gel chromatography 
using a 50 x 2 cm column of G25 Sephadex pretreated with 2mls of human serum 
albumin in Hepes buffer at pH 7.5 to block non specific protein binding on the 
Sephadex. The conjugated antibody was applied and eluted with Hepes buffer pH
7.5. Fractions of 2ml were collected using an LKB ultrorak and the protein content 
of each fraction was determined from the U.V. absorption at 282nm using a Cecil 
CE272 linear U.V. spectrophotometer.
273.
Appendix 5.2. Labelling and in vitro stability of m in-IC R 2
A wide range of labelling efficiencies and specific activities have been 
reported for 1H In labelled MAb's which may be related to the antibodies 
themselves or their methods of conjugation or labelling. The stability of the 
radiopharmaceutical is likely to have an important bearing on the results of its 
clinical use. Prior to clinical use some preliminary studies were carried out on the 
effect of labelling pH and storage on the stability of l^In-ICR2 and on the effect 
of DTPA conjugation on its immunoreactivity.
Indium chloride is supplied in 0.04M HC1 because at neutral pH it hydrolyses 
in water to form insoluble complexes of In(OH)n. There are two possible 
approaches to prevent hydrolysis occurring during the labelling procedure.
Firstly the reaction with MAb-DTPA can be carried out at acid pH possibly leading 
to damage to the antibody or alternatively the InCl can be reacted with sodium 
acetate at pH 6-7 to produce the weakly bound indium acetate. The effect of pH on 
labelling efficiency was assessed for ICR2 at pH 3.5, 7.5 and 8.95.
Effect of pH on labelling efficiency
1) Labelling at pH 3.5
200ug of ICR2-DTPA was mixed with 15MBq of InCl in 0.04 M HC1 for 20mins. 
A BioRad 20 x 1 cm chromatography column was filled with Sephadex G 25 which 
had been swollen in 0.01 M glycine buffer overnight at pH 3.5. The column was 
eluted with lOmls glycine, 2mls of 1% HSA to block any protein binding sites then 
washed with a further
lOmls of glycine buffer pH 3.5. Labelled antibody was applied to the column, 
eluted with lOmls glycine and 1 ml fractions collected and counted in a gamma 
well counter.
2) Labelling at pH 7.5
The same amount of antibody was labelled with the same activity as in the 
previous experiment (200ug ICR2 with 15MBq InCl). The indium chloride in 0.04M 
HC1 was reacted with an equal volume of molar sodium acetate prior to adding the 
antibody to this mixture for twenty minutes. The sephadex G25 was swollen 
overnight in Hepes buffer (0.05M, pH 7.5) and the column prepared as before but 
with Hepes buffer at pH 7.5 replacing glycine. 1ml fractions were collected and 
counted.
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3) Labelling at pH 8.95
The procedure as outlined above was repeated but using a 
carbonate/bicarbonate buffer at pH 8.95. The activity of column fractions within 
the protein peak were summated to give the labelled activity. Eluting non protein 
bound activity and that remaining on the column was assessed by gamma well 
counting. The labelling efficiency was expressed as a ratio of antibody bound 
activity to total applied activity.
Results
Buffer pH Activity in 
protein peak
Activity in 
column
Labelling
efficiency
Glycine 3.5 10.6 4.3 71%
Hepes 7.5 13.6 1.3 91%
Bicarb 8.95 13.8 1.2 92%
Figures are mean of three determinations
The preliminary experiments on labelling pH suggested that a 
satisfactory labelling efficiency may be achieved at a physiological pH. The 
stability of the labelled antibody with alterations in the pH at which it is stored 
was then investigated.
Procedure
lOOug of ICR2 was labelled with U lln  via ccDTPA as previously described 
using a glycine buffer at pH 3.5 or Hepes buffer at pH 7.5. Aliquots were taken 1,2  
and 7 days from the time of labelling, stored at this pH and then subjected to gel 
chromatography using a PD 10 column (bed volume 9.1ml, bed height 5cm). 
Sephadex G 25 was swollen in normal saline containing methiolate as preservative 
(0. lg/1) and the non ionic detergent Berol 048. Aliquots of ^^In-ICR2 were eluted 
with 0.5ml volumes of TBS (0.15M, pH7.4) and 0.5ml fractions collected and 
counted. The activity associated with the protein peak was calculated as a 
percentage of total activity eluting.
Results : % protein bound activity
Buffer Glycine pH 3.5 Hepes pH 7.5
Days after labelling
Day 1 98% 93%
Day 2 92% 95%
Day 7 87% 66%
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These results suggested that 1 * ^ In-ICR2 labelled at either pH was stable over 
a 48 hour period. Due to the short half life of 1 ^ In  (2.8 days) antibody labelled 
with this isotope is used shortly after the labelling procedure and the pH of 
storage is therefore not likely to be a major factor. On injection of the labelled 
antibody into a patient, however, a rapid change in pH will occur with antibody 
labelled at pH 3.5. The stability of ^  ^ In-ICR2 with changes in pH of storage were 
therefore investigated.
Procedure
The protein bound activity was compared in samples labelled and stored at pH 
3.5,. those labelled and stored at pH 7.5 and those labelled at pH 3.5 and stored at pH
7.5. Two samples of 200ug of ICR2 were labelled at pH 3.5 or pH 7.5 as outlined 
above. After labelling, an aliquot of the sample labelled at pH 3.5 was passed 
through a PD 10 column of Sephadex G 25 which had been equilibrated with TBS at 
pH 7.5. Fractions of 0.5ml were collected from the protein peak. The three samples 
were then compared for protein bound activity by repeating the column 
chromatography after storage for 1 hour and for 1 week.
Results
All three samples had >90% protein bound activity when re-run after 1 hour 
whereas the sample labelled at pH 3.5 but stored at pH 7.5 showed only 13% of 
initial radioactivity was protein bound after one week compared with 88% in the 
control samples kept in Glycine buffer at pH 3.5 or Hepes buffer at pH 7.5.
Overall conclusions
For patient studies ICR2 would be labelled with  ^^ In  at a physiological pH of 
7.5 in Hepes buffer. The problem of ^^In forming insoluble indium hydroxide 
was overcome by the addition of 1M sodium acetate to the InCl/HCl solution prior 
to labelling. Storage and pH changes after labelling were avoided.
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Appendix 5.3. The immunoreactivity of ICR2
To preserve the immunoreactivity of the antibody it is necessary to 
determine the effect of the conjugation with DTPA on antibody 
immunoreactivity. To assess this a competition radioimmunoassay was carried 
out using 96 well PVC plates (Dynatech Ltd.) coated with MID/2, a monoclonal 
anti-idiotypic antibody directed against the combining site of ICR2 (Dean et al, 
unpublished data.) Serial dilutions of the DTPA conjugate were assessed for the 
ability to inhibit the binding of labelled ICR2 to the MID/2 coated plates. The 
results showed that while the immunoreactivity of the 1:1 conjugate was 98% of 
unconjugated antibody , the 2:1 conjugate was reduced to 65% of the 
unconjugated ICR2. (C. Dean et al, Institute of Cancer Research, Sutton, Surrey, 
personal communication) A 1:1 conjugation ratio of ICR2 to ccDTPA was therefore 
selected for patient studies.
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Appendix 5.4. Antibody labelling for patient administration
For patient studies all procedures were carried out using aseptic technique in 
a laminar flow hood. Antibody for administration was assessed for sterility , 
pyrogenicity and freedom from viruses. All materials and reagents were 
autoclaved and tested for sterility.
Procedure
Sealed vials containing at reference date 2mCi of i^InC lin0.2m lsof 0.04M 
HC1 were obtained from Amersham U.K.. The vials were assayed for their 
radioactivity on the day of labelling in a gamma well counter (Vintner U.K.). The 
vials were then opened in the sterile hood and 0.2mls of 1M sodium acetate added 
to achieve a pH of 6-7. One mg of antibody was then added which had been 
conjugated to DTPA at a ratio of 1:1 and the mixture left to stand for 20 minutes 
with occassional agitation. A 20 x 1cm column (Bio-Rad) was filled to a bed height 
of 17cm with G25 Sephadex which had been swollen overnight in Hepes buffer 
and sterilised in a liquids autoclave. The column was then eluted with lOmls of 
Hepes buffer pH 7.5 (0.05M) followed by 2mls of 1% human serum albumin to 
block protein binding. Further elution with 20mls of Hepes buffer removed any 
excess unbound human albumin from the column. Labelled antibody was added 
to the column after the 20 minute incubation period and eluted through the 
column with exactly lOmls of Hepes buffer. One ml fractions were collected in 
sterile tubes (Sterilin U.K.) and assayed individually in a well counter. Using this 
method the protein peak eluted from the column in fractions 4-6 which were 
pooled and assayed for their protein bound activity by thin layer 
chromatography as described by Carrasquillo and c o l l e a g u e s ^ : ? ) .  The pooled 
fractions of labelled antibody were then filtered through a 0.22um filter 
(Millipore, France) into a sterile universal container (Sterilin, U.K.) to which 20 
mis of normal saline were added. The labelled antibody was then once again 
assayed for radioactivity in a gamma well counter. Following preparation of the 
injectate aliquots were removed for the preparation of a liver phantom and a 
standard for each patient (Chapter 6).
The labelling procedure was the same for patients in the DTPA group 
except that after the antibody had been incubated for 20 minutes with indium 
acetate an equal volume of 500uM DTPA was added to the mixture for 15 minutes 
prior to the gel chromatography.
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Appendix 6.1. Liver attenuation correction for patient size
An attenuation correction factor was derived to allow the counts 
detected over the patients liver to be correlated with those over the liver 
phantom (Temex trunk). It is based on the following mathematical model.
Ant
Post
Where
Ij = anterior detected liver counts per second decay corrected to 
time of injection.
I2 = posterior detected liver counts per second decay corrected to 
injection.
Io = actual liver counts per second decay corrected to injection 
time.
u = linear attenuation coefficient of tissue equivalent for * ^ In  
cm-1
Geometric mean (GM) =j l j  x I2 =Jl0 e^"u(^ l + ^2) = I0e ' ^ ( ^ l  + ^2) where 
X i + X 2 = Antero-posterior diameter of the patient.
To obtain the attenuation correction factor (f) by comparing the counts 
from the standard and the patient liver.
IT __ ioC-1/2uYT
IP i0e-!/2uYP 
Where
IT = geometric mean of activity detected from the standard
IP = geometric mean of activity detected from the patient
YT = AP diameter of the phantom
YP = AP diameter of the patient at the level of the xiphisterum.
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rr = e-l/2u(YT-YP) = f
IP
The correction factor was then computed for different patient AP 
diameters using the log of this formula in the form -l/2u(YT-YP) = Inf 
The measured value of u for Temex (tissue equivalent ) = 0.102 
AP diameter of the Temex trunk = 23 cms in midline at liver level. The 
patients AP diameter was measured at the xiphistemum.
Patient diameter(cms) Correction factor f
15 0.665
16 0.700
17 0.736
18 0.775
19 0.815
20 0.858
21 0.903
22 0.950
23 0.0
24 1.052
25 1.107
26 1.165
27 1.226
28 1.291
29 1.358
30 1.429
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Appendix 6.2. Attenuation correction for other organs
The attenuation correction for the spleen, kidney and bone marrow 
uptake of radioactivity was based on the following mathematical model.
Ant i,
Post
Transverse section of the patients body where 
I0 = organ cps at point y 
Ij = anterior detected organ cps at point y 
12 = posterior detected organ cps at point y 
u =  linear attenuation coefficient (0.102 cm"*)
II = I0e-U(x l) I2 = I0e'u(x 2)
The geometric mean of the counts = J  Ij x I2 = J I0^e_u(x l + x 2)
= Ioe-l/2u(X1 + X2)
This can be applied to all other points within the organ.
Geometric mean of organ cps(Ip) = I^ e ’^ u C X j+ X 2) where
IA = unattenuated organ cps
X1 + x2 = patient antero-posterior diameter at the level of the xiphistemum 
f  = e-l/2u(X1 + X2)
Dividing Ip by f  corrects for attenuation of 1^
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'p Ip
IA = -  = -
e-l/2u(X1 + X2) f
Errors in f  may occur due to
1) The approximate nature of the measurement of u
2) Attenuation over the full patient width is corrected for using u.
3) The patients antero-posterior diameter is measured at the level of the 
xiphistemum and may differ over the organ in question.
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Appendix 6.3. Urinary excretion and blood clearance data
Urinary excretion (% I.D.) Blood activity (% 10 min)
No. Initial
First
12hrs
Next
24hr
Next
24hrs lOmin 30min 24hrs 48hrs 72hrs
1. M.D. 20.1 3.3 3.7 100 92.4 56 44 10.3
2. M.B. NA NA NA NA NA NA NA NA
3. R.S. 21.3 3.4 1.9 100 105 67 43 NA
4. R.N. 7.5 3.0 2.0 100 91.4 57.1 45 23
5. D.N. 8.3 2.6 2.0 100 91 76 47 33
6. J.L. NA NA NA 100 106 56 42 25
7. J.H. 15.5 4.7 NA 100 96 60 46 30
8. B.T. 24 2.0 0.8 100 93 63 46 22
9. J.P. NA NA NA 100 91 56 NA NA
10. K.H. NA NA NA 100 91 56 38 26
11. MJ. 1.9 2.5 2.9 100 93 65 42 30
12. B.B. 1.1 2.2 2.4 100 95 57 34 25
13. V.D. NA NA NA 100 97 70 33 29
14. F.H. NA NA NA NA NA NA NA NA
15. B.S. 3.6 1.9 NA 100 97 51 26 20
16. R.D. 5.2 1.5 2.0 100 91 47 34 NA
17. J.P. 5.2 3.0 2.3 100 96 53 40 NA
18. E.B. 1.3 0.7 0.9 100 95 61 33 21
19. D.O.N. 3.74 1.9 NA 100 91 52 38 NA
20. D.F. 3.9 1.4 3.1 100 91 52 38 NA
21. G X 4.5 4.4 1.5 100 80 54 NA NA
22. J.B. 6.1 2.7 2.4 100 94 53 28 17.5
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Appendix 6.4. Dynamic liver uptake (first 30 mins)
Counts calculated from ROI analysis and expressed as cpm/ MBq injected 
dose.
Patient group Time after administration(mins)
Control (n=10)
DTPA alone (n=3)
Cold MAb (n=5)
5 10 15 20 25 30
692 706 738 729 725 746
308 325 309 NA NA NA
470 462 459 456 463 459
597 586 585 578 579 572
695 673 665 663 663 644
861 845 838 823 821 830
664 648 638 644 638 647
493 424 413 NA NA NA
627 653 635 NA NA NA
560 583 645 674 643 732
432 464 470 485 501 511
615 632 660 676 690 685
770 761 812 816 844 851
539 508 531 544 546 551
421 426 413 410 403 407
706 697 692 699 NA NA
463 439 436 434 430 432
1022 1040 1001 1004 1005 1020
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Appendix 6.5. Liver uptake of ^ ^4n-ICR2 (% I.D.)
No. Init. 45min
Time after injection
24hr 48hr Patient group
1. M.D. 22 25 30 Ctr
2. M.B. 20 NA NA Ctr
3. R.S. 20 23 23 Ctr
4. R.N. 17 19 21 Ctr
5. D.N. 18 18 19 Ctr
6. J.L. 22 20 20 Ctr
7. J.H. 15 17 19 Qr
8. B.T. 14 16 16 Ctr
9. J.P. 13 22 NA Qr
10. K.H. 20 26 27 Qr
11. M.J. 23 29 33 DTPA alone
12. B.B. 20 23 30 DTPA alone
13. V.D. NA 25 27 DTPA alone
14. F.H. 24 25 31 DTPA alone
15. B.S. 27 34 36 DTPA alone
16. R.D. 19 25 27 Cold MAb
17. J.P. 17 20 NA DTPA alone
18. E.B. 12 19 24 Cold MAb
19. D.O.N. 25 26 29 Cold MAb
20. D.F. 18 27 30 Cold MAb
21. G X 12 16 19 Cold MAb
22. J.B. 26 24 26 Cold MAb
Appendix 6.6. Spleen uptake of ^^4n-ICR2(% I.D.)
No. Init.
Time after injection 
45mins 24hours 48hours Patient group
1. M.D. NA NA NA Qr
2. M.B. NA NA NA Qr
3. R.S. NA NA NA Qr
4. R.N. NA 2.0 1.7 Qr
5. D.N. 4.6 3.7 3.1 Ctr
6. J.L. NA 1.9 1.7 Ctr
7. J.H. 1.9 1.6 1.7 Qr
8. B.T. 1.3 1.1 1.0 Ctr
9. J.P. 1.4 1.5 NA Ctr
10. K.H. 3.0 3.2 2.4 Ctr
11. M.J. NA 2.9 2.9 DTPA alone
12. B.B. 2.3 2.6 2.5 DTPA alone
13. V.D. NA 2.8 2.8 DTPA alone
14. F.H. 4.0 3.8 3.2 DTPA alone
15. B.S. 2.9 2.3 2.3 DTPA alone
16. R.D. 2.7 2.6 2.4 Cold MAB
17. J.P. NA 1.2 NA DTPA alone
18. E.B. 3.3 3.3 2.5 Cold MAb
19. D.O.N. 2.4 2.2 2.8 Cold MAb
20. D.F. 2.5 2.4 2.1 Cold MAb
21. G X 2.8 3.8 3.9 Cold MAb
22. J.B. 4.3 3.5 3.3 Cold MAb
Appendix 6.7. Spleen uptake (cts/5 min/MBq)
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No. Init.
Time after injection 
45mins 24hours 48hours Patient group
1. M.D. 340 389 396 Contol
2. M.B. 335 NA NA Control
3. R.S. 376 428 383 Control
4. R.N. 385 486 455 Control
5. D.N. 764 685 676 Control
6. J.L. 442 320 298 Control
7. J.H. 432 378 431 Control
8. B.T. 322 302 290 Control
9. J.P. 287 467 NA Control
10. K.H. 645 768 671 Control
11. MJ. 456 453 436 DTPA
12. B.B. 497 538 479 DTPA
13. V.D. NA 510 516 DTPA
14. F.H. 690 659 630 DTPA
15. B.S. 625 700 570 DTPA
16. R.D. 671 676 610 Cold
17. J.P. 747 830 NA DTPA
18. E.B. 706 782 752 Cold
19. D.O.N. 648 888 730 Cold
20. D.F. 939 965 823 Cold
21. GX 922 950 1037 Cold
22. J.B. 1004 895 851 Cold
Appendix 6.8. Renal uptake of ^4n-ICR2(%  I.D.)
No. Init.
Time after injection 
45mins 24hours 48hours Patient group
1. M.D. NA NA NA Control
2. M.B. NA NA NA Control
3. R.S. NA NA NA Control
4. R.N. 2.5 3.2 2.8 Control
5. D.N. 1.5 1.7 1.9 Control
6. J.L. 2.2 2.2 1.8 Control
7. J.H. 1.6 1.3 1.6 Control
8. B.T. 2.4 2.0 1.5 Control
9. J.P. 2.5 2.7 NA Control
10. K.H. 1.5 1.6 1.3 Control
11. M.J. 1.4 1.9 1.4 DTPA
12. B.B. 1.7 2.5 2.3 DTPA
13. V.D. NA 1.9 1.9 DTPA
14. F.H. 3.2 3.9 2.9 DTPA
15. B.S. 2.5 2.6 2.4 DTPA
16. R.D. 2.1 2.8 2.8 Cold
17. J.P. 1.4 1.5 NA DTPA
18. E.B. 1.8 2.3 2.6 Cold
19. D.O.N. 2.4 2.9 2.1 Cold
20. D.F. 2.5 2.4 2.1 Cold
21. G X 1.6 2.1 2.0 Cold
22. J.B. 2.8 2.5 1.6 Cold
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Appendix 6.9. Renal uptake of m in-IC R 2
(cts / 5 min / MBq)
No. Init.
Time after injection 
45mins 24hours 48hours Patient group
1. M.D. 532 534 516 Control
2. M.B. 328 NA NA Control
3. R.S. 270 317 267 Control
4. R.N. 537 655 588 Control
5. D.N. 334 356 366 Control
6. J.L. 450 448 394 Control
7. J.H. 490 449 475 Control
8. B.T. 553 505 440 Control
9. J.P. 510 627 NA Control
10. K.H. 329 375 348 Control
11. M.J. 249 252 230 DTPA
12. B.B. 453 448 484 DTPA
13. V.D. NA 346 329 DTPA
14. F.H. 611 717 687 DTPA
15. B.S. 512 567 585 DTPA
16. R.D. 507 526 . 604 Cold
17. J.P. 357 481 NA DTPA
18. E.B. 376 494 524 Cold
19. D.O.N. 610 731 659 Cold
20. D.F. 655 699 647 Cold
21. GX 381 474 446 Cold
22. J.B. 614 684 640 Cold
Appendix 6.10. Marrow uptake of ^^4n-ICR2
(Cts/5min/MBq)
No. Init.
Time after injection 
45mins 24hours 48hours Patient group
1. M.D. 133 143 150 Control
2. M.B. NA NA NA Control
3. R.S. 101 115 163 Control
4. R.N. 121 135 136 Control
5. D.N. 129 142 141 Control
6. J.L. 214 189 186 Control
7. J.H. 229 219 220 Control
8. B.T. 187 165 169 Control
9. J.P. 222 165 169 Control
10. K.H. 135 136 150 Control
11. M.J. 111 96 108 DTPA
12. B.B. 141 135 157 DTPA
13. V.D. NA 165 169 DTPA
14. F.H. 161 167 160 DTPA
15. B.S. 178 217 191 DTPA
16. R.D. 114 128 118 Cold
17. J.P. NA NA NA DTPA
18. E.B. 126 124 135 Cold
19. D.O.N. 223 225 253 Cold
20. D.F. 178 207 222 Cold
21. G X 109 127 125 Cold
22. J.B. 152 137 166 Cold
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Appendix 6.11. Cold MAb and immune complex
No cold MAb
No. Initial Pre m In-ICR2
Post m In-ICR2 
lOmin 30min 24hrs 48hrs
7. J.H. NA 40 36 36 NA
9. J.P. 33 33 24 NA NA
11. M.J. NA 28 33 26 NA
12. B.B. 30 39 35 34 28
13. V.D. 33 NA NA NA NA
14. F.H. 28 NA NA NA NA
15. B.S. 30 28 25 18 NA
17. J.P. 33 NA NA NA NA
Cold MAb
Post m In-ICR2
No. Initial Pre m In-ICR2 Post cold lOmin 30m in 24hr 48hr
16. R.D. 27 NA 20 18 13 NA
18. E.B. 34 28 35 35 28 28
19. D.O.N. 27 29 30 29 22 17
20. D.F. 35 31 32 29 23 NA
21. G X 40 33 NA NA NA NA
22. J.B. 35 30 32 28 28 NA
The results shown are the % of the circulating activity present in 
high molecular weight form.
Appendix 7.1.: Statistical significance of data
Radioactive decay is a process of random disintegration of nuclei 
and as such is described mathematically by the statistics of Poisson 
processes. Random variations in disintegration rate give rise to a range 
of recorded values on successive measurement with a distribution about 
the mean value described by the Poisson distribution. An important
i
feature of this distribution is that the variance of the distribution, 6  is
equal to the mean, p of the distribution 6 1 -  p
and therefore that the standard deviation, 6  , is given by
Now, if a large number of readings are taken, then the mean value x is
a good approximation to p and so 6  2 ^  X , 6
Thus the standard deviation of a number x is approximately equal to the
square root of the mean. For readings of large values, typical in
radiation counting measurements, where the discrete distribution of
numbers approximates to a distribution of a continuous variable then
the Poisson distribution is virtually indistinguishable from the more
general Gaussian (or normal) distribution for the case where * p
For a Gaussian distribution it may be shown(329) that the propogation of
errors for a result computed from a number of readings is such that the
standard deviation of the sum or difference of two readings N1 and N2 ,
( Nt t Vl * . )  is given by £  ( n v 1  -=» N*
and the standard deviation 6  ( N) of a mean R  of a number of readings n
is given by 6  ( N ) a  J N/*
Thus , for the study described, the standard deviation of the mean 
tumour and background counts are respectively .______
6 ( T ) 9 j l z ,  ^ “ V  ^3
and the standard deviation 6  ( T -  &) ° f  the difference between mean 
tumour and mean background counts is such that
6(=F-e) ,j| + !
It can also be shown that the percentage error in the reading 
represented by the standard deviation is given by
Jn v ioo ^ - too 3
“  ■ X  i ■
This indicates a very important factor in radiation measurement 
techniques ; that as the counts obtained for a result are allowed to 
increase (by increasing counting time or use of a more sensitive 
detector) so the percentage uncertainty decreases and the statistical 
reliability of the result increases.
289.
i
The variance 6 is a parameter such that 68.3% of results fall 
within +/-6 of the true mean. Additionally 90% of results lie within 
+/-1.64 6 , 95% within+/-2 6 and99.7% within+/-3 6 .These are 
termed confidence levels and from this it can be stated that if a result 
lies beyond +/-3 6 from the mean, there is a chance of less than 1% 
that this is due to random error alone, and the difference can be 
considered to be statistically significant.
Thus if 3 s.d. (3 6 ) is used as a threshold of detectability then the 
difference in mean tumour and background counts must exceed this for 
the tumour to be deemed detectable
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Appendix 7.2.: CdTe probe, 2:1 ratio, w.a.collimator,
Size Decay 
(mis) factor^
Tumour 
mean^  S.D.3
Corrected
mean^
Background 
mean^  S.D.3
Corrected
meari^
Signif.5
20 second counts
0.5 1.023 2487 32.0 2544 2480 75.5 2537 0.17
1.0 1.029 2449 18.5 2520 2481 37.0 2553 -0.80
1.5 1.031 2382 25.9 2456 2474 53.6 2551 -2.33
2.0 1.037 2457 60.7 2548 2493 60.9 2585 -0.89
5.0 1.044 2503 11.4 2613 2448 118.3 2556 1.37
10.0 1.047 2489 32.9 2606 2405 65.3 2518 2.13
100 second counts
0.5 1.023 12381 119.6 12666 12481 171.2 12768 -1.11
1.0 1.029 12281 161.9 12637 12430 212.6 12790 -1.66
1.5 1.031 12135 62.2 12511 12388 92.3 12772 -2.84
2.0 1.037 12265 84.4 12719 12269 113.7 12723 -0.04
5.0 1.044 12268 74.8 12808 12078 93.9 12609 2.16
10.0 1.047 12409 123.8 12992 12188 74.5 12760 2.50
1 Correction for radioactive decay occuring during the period of the experiment
2 Mean counts corrected for room background activity
3 Standard deviation of the raw counts
4 Mean counts corrected for radioactive decay
5 Number of standard deviations between mean tumour and mean background
counts (by method outlined in Appendix 7.1.).
Appendix 7.3,.: CdTe probe , 2:1 ratio, p.h. collimator
Size Decay 
(mis) factor^
Tumour Corrected 
mean^  S.D.3 mean^
Background 
mean^  S.D.3
Corrected
mean^
Signif. 5
20 second counts
0.5 1.053 84.7 12.7 89.2 81.0 3.4 85.3 0.51
1.0 1.056 88.0 8.0 92.9 74.3 6.6 78.5 1.91
1.5 1.058 79.0 4.6 83.6 65.3 5.5 69.1 2.03
2.0 1.062 83.7 7.4 88.9 75.0 4.4 79.7 1.23
5.0 1.066 83.3 9.9 94.1 70.7 10.8 75.3 2.50
10.0 1.069 89.3 23.3 95.5 79.0 9.0 84.5 1.42
100 second counts
0.5 1.053 390.3 19.5 410.9 391.7 28.4 412.5 -0.10
1.0 1.056 416.3 8.1 439.6 392.0 41.6 413.9 1.52
1.5 1.058 401.7 4.6 425.0 380.3 27.3 402.4 1.36
2.0 1.062 394.0 23.1 418.4 402.7 27.3 427.7 -0.55
5.0 1.066 417.3 19.5 444.8 388.3 8.6 413.9 1.83
10.0 1.069 440.0 13.4 470.4 389.0 3.5 415.8 3.17
1-5 as in Appendix 7.2.
291.
Apppendix 7.4.: Nal probe, 2:1 ratio
Size Decay Tumour Corrected Background Corrected Signif.
(mis) factorl mean2 S.D.3 mean"* mean2 S.D.3 mean"*
20 second counts
0.5 1.100 684.3 31.3 752.7 699.0 13.5 768.9 -0.72
1.0 1.095 681.7 31.8 746.5 701.0 10.6 767.6 -0.94
1.5 1.092 703.0 19.7 767.7 699.7 35.9 764.0 0.16
2.0 1.089 683.3 18.5 744.1 675.7 7.8 735.8 0.37
5.0 1.083 743.3 32.5 804.9 693.3 50.5 750.9 2.37
10.0 1.080 772.3 33.3 834.1 691.3 37.8 746.6 3.81
100 second counts
0.5 1.100 3420 58.1 3762.7 3472.0 38.0 3819.2 -1.12
1.0 1.095 3500 28.7 3832.9 3380.0 46.0 3701.1 2.63
1.5 1.092 3497 71.6 3819.1 3437.6 22.9 3753.9 1.30
2.0 1.089 3492 47.1 3802.4 3512.3 21.0 3824.9 -0.45
5.0 1.083 3707 19.8 4014.3 3549.7 19.4 3844.3 3.32
10.0 1.080 3803 113.5 4107.2 3400.7 37.5 3672.7 8.53
1-5 as in Appendix 7.2.
Appendix 7.5. : CdTe 4 :1 ratio, w.a. collimator
Size
(mis)
Decay
factor*
Tumour 
mean2 S.D.3
Corrected
meari*
Backs
mean2
round
S.D.3
Corrected
mean"*
Signif.^
20 second counts
0.5 1.046 2661 65.0 2783.8 2645 17.4 2766.7 0.39
1.0 1.048 2690 16.8 2819.1 2643 43.1 2770.2 1.13
1.5 1.053 2618 53.5 2757.5 2700 21.9 2843.1 -1.98
2.0 1.056 2672 151.9 2821.9 2656 71.7 2815.3 0.15
5.0 1.058 2745 93.7 2904.9 2629 45.4 2782.2 2.82
10.0 1.061 2838 49.1 3010.8 2582 38.2 2739.9 6.19
100 second counts
0.5 1.046 13219 290.0 13827 13304 139.4 13916 -0.93
1.0 1.048 13416 120.4 14050 13239 71.5 13874 1.82
1.5 1.053 13393 154.4 14103 13288 120.9 13992 1.15
2.0 1.056 13243 105.3 13985 13106 175.3 13840 1.51
5.0 1.058 13864 26.0 14668 13139 166.3 13901 7.86
10.0 1.061 14075 135.7 14934 13102 66.6 13901 10.54
1-5 as in Appendix 7.2.
292.
Appendix 7.6.: CdTe probe, 4:1 ratio, p.h. collimator
Size
(mis)
Decay
factor*
Tumour 
mean^  S.D.3
Corrected
mean^
Background 
mean^  S.D. 3
Corrected
mean^
Signif. 5
20 second counts
0.5 1.023 84.7 6.3 85.59 95.7 12.9 97.87 1.57
1.0 1.026 99.3 12.7 101.92 86.3 12.2 88.58 1.67
1.5 1.029 101.0 4.0 103.93 83.7 17.0 86.09 2.24
2.0 1.033 109.0 14.0 112.60 94.3 12.8 97.45 1.81
5.0 1.037 103.3 8.1 107.16 82.7 6.1 85.73 2.67
10.0 1.039 119.0 13.2 123.64 84.3 8.4 87.62 4.29
100 second <counts
0.5 1.023 468.3 11.0 479.11 447.0 16.4 456.26 1.29
1.0 1.026 503.0 11.5 516.08 433.0 35.4 444.26 4.01
1.5 1.029 513.0 9.0 527.88 443.0 11.8 454.82 4.04
2.0 1.033 520.7 14.0 537.85 445.3 24.6 460.03 4.27
5.0 1.037 573.0 46.1 594.20 458.7 43.4 475.64 6.28
10.0 1.039 595.3 16.3 618.55 455.0 9.5 472.75 7.64
1-5 as in Appendix 7.2.
Appendix 7 .7 .: Na I probe, 4:1 ratio
Size
(mis)
Decay
factor*
Tumour 
mean^  S.D.3
Corrected
meari^
Background 
mean^  S.D-3
Corrected
mean^
Signif. *
20 second counts
0.5 1.242 658 20.3 790.3 639.3 8.1 794.1 -0.17
1.0 1.239 693 20.3 831.4 617.3 41.1 764.9 2.88
1.5 1.235 705 18.1 843.1 621.3 29.0 767.9 3.27
2.0 1.229 681 22.3 836.9 673.7 20.2 827.9 0.38
5.0 1.228 810 43.4 995.1 651.0 23.8 799.4 8.00
10.0 1.217 834 25.9 1015.4 673.0 12.1 792.3 9.09
100 second counts
0.5 1.242 3367 85.1 4182.2 3140 58.4 3900.0 5.44
1.0 1.239 3387 30.9 4196.1 3202 26.0 3967.3 4.39
1.5 1.235 3431 118.9 4237.3 3144 81.3 3883.3 6.80
2.0 1.229 3447 87.9 4237.2 3261 64.1 4008.2 4.37
5.0 1.228 3926 60.7 4820.7 3244 91.7 3984.5 15.44
10.0 1.217 4170 33.2 5074.9 3203 93.2 3935.4 20.79
1-5 as in Appendix 7.2.
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Appendix 7.8. : CdTe probe , 6:1 ratio, w.a. collimator
Size
(mis)
Decay
factorl
Tumour 
mean^  S.D. 3
Corrected
meari^
Backgri
mean^
ound
S.D.3
Corrected
meari^
Signif. ^
20 second counts
0.5 1.058 2757 76.9 2916.9 2775 52.6 2930.3 -0.31
1.0 1.056 2828 107.4 2986.4 2887 36.1 3058.9 -1.62
1.5 1.052 2908 48.4 3059.6 2831 47.6 2977.9 1.82
2.0 1.049 2894 28.8 3035.8 2820 44.3 2958.9 1.72
5.0 1.046 3081 60.6 3222.7 2803 47.6 2928.8 6.49
10.0 1.040 3299 22.0 3431.3 2874 87.8 2988.9 9.56
100 second counts
0.5 1.058 13741 77.8 14538 13942 128.8 14751 -2.15
1.0 1.056 14283 190.3 15083 13977 17.3 14760 3.24
1.5 1.052 14324 40.1 15069 13914 68.5 14638 4.33
2.0 1.049 14241 64.3 15967 13966 205.0 14650 3.19
5.0 1.046 15240 71.6 15941 14006 60.8 14619 13.10
10.0 1.040 16526 179.3 17187 14376 91.7 14619 21.59
1-5 as in Appendix 7.2.
Appendix 7.9.: CdTe probe, 6:1 ratio, p.h. collimator
Size
(mis)
Decay
factor*
Tumour 
mean^  S.D.3
Corrected
mean^
Background 
mean-2 S.D.3
Corrected
meari^
Signif.;
20 second counts
0.5 1.021 105.0 13.1 107.21 95.7 11.5 97.68 1.15
1.0 1.026 103.0 8.5 105.68 98.3 7.4 100.89 0.58
1.5 1.028 105.7 16.2 108.63 101.0 6.2 103.83 0.57
2.0 1.031 113.0 7.2 116.50 92.0 7.9 94.85 2.58
5.0 1.034 135.6 19.6 140.28 95.0 12.1 98.23 4.72
10.0 1.037 140.3 5.0 145.53 93.3 8.1 96.79 5.42
100 second counts
0.5 1.021 528.7 24.3 539.77 486.7 18.8 496.89 2.31
1.0 1.026 544.3 8.7 558.49 462.7 46.1 474.69 4.52
1.5 1.028 541.0 30.8 556.15 506.7 16.2 520.85 1.86
2.0 1.031 585.6 35.0 603.82 471.3 18.6 485.95 6.18
5.0 1.034 662.0 10.5 684.51 444.3 6.8 459.44 11.53
10.0 1.037 738.6 33.6 765.99 473.6 6.4 491.19 13.42
1-5 as in Appendix 7.2.
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Appendix 7.10.: Na I probe, 6:1 ratio
Size
(mis)
Decay
factor*
Tumour 
mean^  S.D.3
Corrected
mean4
Background 
mean^  S.D.3
Corrected
meari^
Signif. 5
20 second counts
0.5 1.073 808 34.3 866.6 754 22.6 809.4 2.42
1.0 1.075 815 24.8 876.5 739 43.3 822.0 2.29
1.5 1.080 826 21.2 892.4 745 22.3 804.9 3.68
2.0 1.083 862 25.4 933.9 748 24.4 809.7 5.15
5.0 1.086 1010 48.3 1097.6 729 41.6 791.7 12.19
10.0 1.089 1102 36.7 1200.4 707 24.8 770.3 16.78
100 seconds counts
0.5 1.073 3999 93.5 4291.6 3780 33.6 4055.9 4.47
1.0 1.075 4138 34.7 4448.3 3851 54.0 4140.5 5.75
1.5 1.080 4283 77.1 4626.4 3710 20.2 4007.5 11.53
2.0 1.080 4345 152.6 4705.9 3690 45.6 3996.9 13.16
5.0 1.086 5022 26.9 5453.9 3743 57.0 4064.9 24.66
10.0 1.089 5502 32.0 5991.3 3718 66.2 3934.6 35.76
1-5 as in Appendix 7.2.
Appendix 7.11. : CdTe probe, 8 :1  ratio, w.a. collimator
Size
(mis)
Decay
factor^
Tumour 
mean^  S.D.3
Corrected
mean^
Backgn
mean^
ound
S.D.3
Corrected
mean^
Signif.;
20 second counts
0.5 1.048 2961 36.2 3102.4 2837 60.8 2973.9 2.86
1.0 1.050 2971 13.1 3118.5 2841 55.5 2983.8 2.99
1.5 1.053 2933 141.7 3088.8 2759 34.0 2905.9 4.09
2.0 1.058 2962 11.1 3134.1 2721 53.8 2878.9 5.70
5.0 1.060 3070 54.3 3254.6 2804 49.4 2972.2 6.20
10.0 1.064 3303 74.4 3514.7 2633 20.3 2801.1 15.55
100 second counts
0.5 1.048 14692 58.9 15397 14190 179.4 14871 5.24
1.0 1.050 14697 111.7 15432 14280 64.1 14994 4.35
1.5 1.053 14745 58.3 15526 14052 5.0 14797 7.25
2.0 1.058 14673 130.3 15524 13754 64.6 14552 9.71
5.0 1.060 15650 112.1 16589 13936 51.2 14772 17.77
10.0 1.064 16709 29.0 17779 13487 17.0 14350 33.13
1-5 as in Appendix 7.2.
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Appendix 7.12.: CdTe probe, 8:1 ratio, p.h. collimator
Size Decay Tumour Corrected Background Corrected Signif. 5 
(mis) factor^ mean^  S.D.3 mean^  mean^  S.D.3 mean^
20 second counts
0.5 1.080 97 7.0 104.76 88.0 7.2 95.04 1.19
1.0 1.079 115 6.1 124.44 84.3 12.0 90.99 3.95
1.5 1.075 113 5.0 121.48 97.3 7.5 104.63 1.94
2.0 1.071 127 6.8 136.37 88.0 6.2 94.25 4.80
5.0 1.069 131 15.0 140.39 94.3 8.5 100.84 4.41
10.0 1.066 165 10.4 175.89 88.7 8.1 94.52 8.57
100 second counts
0.5 1.080 516 30.0 557.64 446 6.4 482.40 4.04
1.0 1.079 531 24.0 571.15 471 25.5 508.93 3.28
1.5 1.075 573 16.2 515.15 460 17.3 494.50 6.29
2.0 1.071 599 28.6 641.53 441 16.2 473.03 8.74
5.0 1.069 673 48.4 719.08 459 8.0 491.03 11.35
10.0 1.066 840 36.5 899.35 459 38.6 488.94 19.08
1-5 as in Appendix 7.2.
Appendix 7.13.: N al probe, 8:1 ratio
Size Decay Tumour Corrected Background Corrected Signif. 5 
(mis) factor! mean^  S.D.3 mean^  mean^  S.D.3 mean^
20 second counts
0.5 1.217 726 14.2 883.5 698 5.0 850.28 1.38
1.0 1.221 782 21.5 954.42 673 13.6 822.55 5.42
1.5 1.255 811 37.4 1017.81 654 3.8 821.61 7.92
2.0 1.264 845 14.4 1068.08 631 18.3 798.00 10.82
5.0 1.260 963 34.5 1212.9 657 23.1 827.40 14.78
10.0 1.270 1085 17.9 1378.8 682 13.4 866.78 18.71
100 second counts
0.5 1.217 3708 26.0 4512.6 3431 65.1 4175.5 6.26
1.0 1.221 3943 133.1 4814.4 3442 44.0 4202.7 11.16
1.5 1.255 4061 57.5 5096.9 3384 28.5 4246.5 15.24
2.0 1.264 4286 71.6 5417.9 3239 87.5 4094.9 23.49
5.0 1.260 4812 170.0 6063.1 3357 72.9 4230.7 31.28
10.0 1.270 5492 149.2 6974.8 3236 52.9 4109.7 47.14
1-5 as in Appendix 7.2.
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